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A significant release of catecholamines within the heart has been observed during
myocardial ischaemia. Ischaemia-induced catecholamine release can be markedly
inhibited by desipramine and other amine uptake blocking agents, allowing
investigation of the importance of such release for arrhythmia production. The
mechanism of this release appears to occur by a carrier-mediated efflux from
neurons, which is not operative under normal conditions. The aim of the project
has been to study this release process in chromaffin cells isolated from the bovine
adrenal medulla, which are recognised as a model system for studying the
sympathetic nervous system. Understanding this process of catecholamine release
may lead to new methods of protecting the heart against ischaemia-induced
arrhythmias.
Isolated chromaffin cells could be maintained in primary culture for up to 7 days
and retained all their normal secretory responses. Conditions designed to mimic
ischaemia, that is, anoxia or metabolic inhibition, resulted in a significant release
of catecholamines. This release was shown to be independent of extracellular
calcium but, in contrast to the release observed in ischaemic hearts, it was not
inhibited by uptake., blockers.
One of the main criteria for exocytosis is the co-release of other secretory
granule components. Polyacrylamide gel electrophoresis and Western blotting
techniques were utilised to examine this following metabolic inhibition.
Significant levels of the granule proteins chromogranin A, neuropeptide Y and ATP
were released following metabolic inhibition, indicative of an exocytotic
mechanism. Furthermore, there was no release of the cytosolic protein lactate
dehydrogenase, indicating that there was no breakdown of the cell membrane
during metabolic inhibition.
Over the first 10 minutes of metabolic inhibition there was a marked uptake of
22Na+ by the cells. It is suggested that this Na+ influx triggers the catecholamine
release by affecting the cytosolic Ca2+ concentration through a direct effect on
intracellular stores.
Intracellular Ca2+ mobilisation was measured using the calcium-sensitive
fluorescent probe Fura-2. It was found that cytosolic free calcium levels were
increased in response to metabolic inhibition.
(ii)
The conditions required to evoke carrier-mediated efflux were also examined.
Cytosolic levels of catecholamines could be artificially raised following treatment
with reserpine. Cytoplasmic catecholamine levels were measured following
permeabilisation with the detergent digitonin which renders the plasma
membrane leaky. Conditions designed to reverse the uptake carrier and cause
carrier-mediated efflux in the presence of raised cytoplasmic catecholamines,
such as removal of extracellular sodium, did not evoke any catecholamine
overflow. These studies suggest the chromaffin cell uptake-, carrier is not
reversible and may be gated in some way. This work has, therefore, raised
questions concerning the suitability of chromaffin cells as a conventional model
for sympathetic nerve terminals.
(iii)
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Ischaemic heart disease is the primary cause of death in the Western world today.
In England and Wales 30% of all deaths among men and 22% among women are the
result of ischaemic heart disease (Dwyer and Hetzel, 1980). Improved
understanding of how the heart is impaired during ischaemia and understanding of
the metabolic changes that occur is vital for the development of effective
prevention and treatment of the disease.
The heart is critically dependent on a constant supply of oxygen and substrate and
can only tolerate an oxygen debt for a few seconds before functional changes occur.
Anything that impedes oxygen availability will, therefore, have serious
consequences. Myocardial ischaemia has been defined as an imbalance between the
supply of oxygenated blood and the oxygen requirements of the myocardium
(Reimer and Jennings, 1986). The origins of this imbalance are almost always
the result of coronary artery disease, namely atherosclerosis. The formation of
atherosclerotic lesions is complex and not yet fully understood. The end result,
however, is the formation of plaques which occlude coronary arteries and have a
tendency to fissure and rupture. Disruption of an atherosclerotic plaque leads to
coronary thrombosis; that is, formation of a clot, which causes the occlusion.
Following coronary occlusion the area supplied by the occluded artery becomes
ischaemic since there is reduced blood flow to the myocardium and there is a rapid
loss of myocardial contractility.
1.1 Biochemical consequences of myocardial ischaemia,
The underlying mechanisms by which myocardial ischaemia leads to a loss of
contractile function within seconds have now been established. These include
acidosis, reduced sensitivity of contractile proteins to calcium, and intracellular
accumulation of inorganic phosphate and lipid, in the form of acyl CoA esters. Very
rapidly after the onset of ischaemia aerobic respiration declines and there is a
marked depletion of high energy phosphates (ATP and creatine phosphate).
Creatine phosphate content of the myocardium falls by over 80% within 2 to 3
min, with ATP content declining more slowly (Alpert, 1989). Initially, anaerobic
glycolysis is stimulated but this is subsequently inhibited by the development of
acidosis and the accumulation of citrate, NADH and lactate (formed from
pyruvate).
The generation of lactic acid and the conversion of oxygen to C02 are probably the
major causes for the early development of acidosis. The mechanism by which
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acidosis reduces contractility, however, is still unclear (Poole-Wilson, 1987).
Contraction is normally initiated by the rapid release of calcium from the
sarcoplasmic reticulum, this release itself being triggered by a rise in cytosolic
calcium. Acidosis is known to affect the transport of calcium across the
sarcolemma and the uptake of calcium by the sarcoplasmic reticulum. Cytosolic
calcium combines with specific receptor sites on the regulatory protein,
troponin, which ultimately leads to muscle tension and shortening. An increase in
intracellular H+ concentration may alter the interaction of calcium with troponin,
thus impairing the actin-myosin interaction. These processes would lead to a
reduction in contractility.
The second major consequence of acute myocardial ischaemia is an alteration in the
form of action potentials and the subsequent development of arrhythmias. This
change in action potential is a direct response to changes of pH and extracellular
potassium levels. Early in ischaemia there is a marked rise in extracellular
potassium due to increased efflux. This efflux is thought to be the consequence of
increased conductance, intracellular accumulation of permeant anions such as
lactate, and reduced activity of the Na+/K+ ATPase. The change in extracellular
potassium and the cellular acidosis are sufficient to account for alterations in the
action potential and other electrophysiological effects (Hirche et a/.,1980).
Initially this inhibition of cellular functions is reversible, but if ischaemia is of
sufficient severity and duration (longer than 15 to 20 min) the myocytes become
irreversibly damaged and undergo cellular necrosis, that is, the myocardium
becomes infarcted.
In conjunction with these metabolic changes within the first hour after the onset
of myocardial ischaemia there is a progressive release of noradrenaline from the
adrenergic nerve terminals of the myocardium (Abrahamsson et a/.,1984). This
overflow of noradrenaline has long been recognised as being of central importance
in the development of arrhythmias (Rona,1985). This locally-released
noradrenaline has a metabolic role in the activation of anaerobic glycolysis early
in ischaemia, but may also increase calcium influx to the myocyte, contributing to
the progression of ischaemic cell injury and death. It is this overflow of
noradrenaline along with the ischaemia-induced changes in myocyte function that
lead to the development of ventricular fibrillation . In this condition there is
chaotic electrical disturbance of the ventricles, ventricular contraction is
uncoordinated and ventricular filling ceases. Untreated ventricular fibrillation is
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invariably fatal, being the single most important cause of death in patients with
ischaemic heart disease.
The mechanisms of noradrenaline release during myocardial ischaemia will be
discussed here, rather than the post-synaptic events via which catecholamine
stimulation exerts its effects. However, in order to understand the role of
catecholamines in ischaemic heart disease it is first necessary to describe their
function under normal physiological conditions.
1.2 Autonomic regulation of cardiac contractility
The sympathetic nervous system is the primary mediator influencing the
contractility of the left ventricle in response to stress. Sympathetic activation
increases the release of endogenous catecholamines, which results in an elevation
in arterial pressure by increasing peripheral resistance, heart rate and
myocardial contractility. This response is mediated by stimulation of a and p
adrenergic receptors in the sarcolemma, predominantly via p1 receptors which
respond to neurally released noradrenaline. This, in turn, leads to a rise in
intracellular cyclic AMP via activation of adenylate cyclase. Cyclic AMP activates
cAMP-dependent protein kinases, resulting in phosphorylation of a number of
intracellular proteins. This has the overall effect of increasing calcium influx by
increasing the number of open channels and thus increasing contractility of the
myocardium (Braunwald efa/.,1988).
1.3 Circulating catecholamines
In contrast to neurally-released catecholamines, circulating catecholamines play
little, if any, role in modulation of myocardial contractility. Catecholamines are
released from the adrenal medulla into the blood stream in response to increased
sympathetic nervous activity. The changes in plasma catecholamines do not,
however, parallel changes in myocardial function (Young et al.,1985). The
concentration of neurotransmitter at the nerve terminal is critical and this is not
necessarily reflected by levels of circulating catecholamines.
1.4 Molecular mechanisms of nerve terminal function.
Much of the elucidation of the molecular mechanisms of synthesis, storage and
secretion of catecholamines has come from studies on isolated chromaffin cells
from the adrenal medulla and on isolated chromaffin granules, the secretory
vesicles of the chromaffin cell. Chromaffin cells share a common embryological
origin with sympathetic neurons, both being derived from the neural crest.
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Furthermore, after several days in culture, chromaffin cells send out axon-like
processes indicative of the neuronal character of chromaffin cells (Livett, 1984).
These morphological similarities to sympathetic neurons and their relative ease of
isolation have led to chromaffin cells being accepted as an ideal model for studying
sympathetic nerve function. Therefore, in the following description of nerve
terminal function it will be assumed that chromaffin cells are analogous to
sympathetic neurons, unless otherwise mentioned, and references will be made to
both systems.
1.4.1 Catecholamine synthesis.
The biosynthetic pathway of noradrenaline and, in chromaffin cells, its subsequent
conversion to adrenaline, has long been established (Kirchner, 1975). Dopamine
is formed from the sequential action of tyrosine hydroxylase and aromatic
L-amino acid decarboxylase, enzymes which are located in the cytosol. Tyrosine
hydroxylase is the rate-limiting enzyme, its catalytic activity being regulated by
the availability of the substrate, tyrosine,and cofactors, and by phosphorylation at
several sites. Cytosolic dopamine is then rapidly transported into secretory
vesicles by an ATP-driven carrier-mediated process. Once within the vesicles
dopamine is converted to noradrenaline by the enzyme dopamine p-hydroxylase
(DBH). DBH is present within the vesicles in both membrane-bound and soluble
forms. In chromaffin cells, the conversion of dopamine to noradrenaline within
the vesicles has a t1/2 of approximately 6h, the rate of conversion being
dependent on substrate availability as discussed by Corcoran et al. (1984). In
sympathetic neurons this is the final step in the synthetic process, while in
chromaffin cells noradrenaline may be further converted to adrenaline by the
cytosolic enzyme'noradrenaline N-methyl transferase. Noradrenaline leaks slowly
into the cytosol where it is rapidly converted to adrenaline which is transported
back into the vesicles. The adrenal medulla contains two types of chromaffin cells,
those which produce and store primarily adrenaline and others primarily
noradrenaline.
1.4.2 Storage of catecholamines.
Catecholamines are stored in chromaffin granules at a concentration of 0.6M, less
than 0.01% of total cell catecholamines being found in the cytosol (Phillips,
1982). This results in a very large concentration gradient across the granule
membrane. Within the membrane of the granules is a specialised
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proton-translocating ATPase that provides the driving force for the uptake of
catecholamines and maintainance of their high intravesicular concentration. The
ATPase hydrolyses ATP and translocates protons into the vesicles leading to the
generation of an electrochemical proton gradient, composed of ApH (inside acidic,
about pH 5.5) and Ay (inside positive, about 60mV) both of which are coupled to
catecholamine uptake (Apps efa/.,1980). An uncharged amine molecule is
believed to be the substrate for the amine translocator, but this is protonated on
release to the interior of the granule.
Chromaffin granules also contain high concentrations of nucleotides, 0.18M,
primarily ATP, which are taken up by a relatively non-specific nucleotide
translocase, driven by the membrane potential. This raises the question of how
such high catecholamine and ATP concentration gradients are maintained across
the membrane and how spontaneous osmotic lysis of the granules is prevented. The
granule membrane is relatively permeable to catecholamines which will leak out
into the cytosol down their concentration gradient. This diffusion is of
physiological significance in the synthesis of adrenaline. Active uptake of
catecholamines into the granules is able to counteract leakage to a certain degree.
Studies on artificial solutions of chromaffin granule components and intact
granules have shown that catecholamines and ATP interact, probably by charge
interaction and hydrophobic stacking. The consequent reduction of activities of the
components reduces leakage rates and renders the granules osmotically stable
(Koppell and Westhead, 1982). There is no defined stoichiometric relationship
between catecholamines and ATP (Winkler and Westhead,1980). Also, the
chromaffin granules are not uniform with regard to their catecholamine and ATP
content so any estimates of the catecholamine/ATP molar ratio represents an
average measurement. The catecholamine/ATP ratio is higher in
noradrenaline-storing synaptic vesicles than in noradrenaline-containing
chromaffin granules. Unlike chromaffin granules they do not contain very much
ATP but have high concentrations of noradrenaline which tends to leak more
rapidly from the vesicles than that in chromaffin granules (Phillips, 1982).
Furthermore, their noradrenaline content increases as they mature during
axoplasmic transport (Lagercrantz,1976).
1.4.3 Other components of chromaffin granules.
The major constituents of chromaffin granules are shown in Table 1.1. These will
be discussed briefly.
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Table 1.1 Maior constituents of chromaffin granules-









Dopamine p hydroxylase 210 140
Total enkephalin equivalents 4,000
Cytochrome b561 1750
Neuropeptide Y 428
Data taken from Winkler etal. (1986).
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A. Protein constituents.
The major matrix proteins found in chromaffin granules are the chromogranins.
Three groups of these acidic proteins have been identified, chromogranins A,B and
C, which together comprise the majority of total soluble protein
(Winkler,1988). Chromogranin alone makes up about 80% of this in bovine
granules. In addition to the chromogranins, enkephalin-containing peptides and
neuropeptide Y are present, comprising 1% and 0.2% of total soluble proteins
respectively.
Further constituents of known function are DBH (4%) and various proteases
involved in the processing of proenkephalin and other proteins. The physiological
function of the chromogranins, the major secretory proteins, is still unclear.
They were previously thought to play a role in the storage of catecholamines
although it has now been demonstrated that there is little interaction between
chromogranins and catecholamines (Winkler and Westhead, 1980). They may
play some role in stabilising secretory granules and in calcium binding within the
granule. More recently Simon et al (1988) have proposed a role for
chromogranin-derived peptides in the regulation of adrenal secretion.
DBH is the enzyme responsible for the conversion of dopamine to noradrenaline
within the secretory granule. It exists in two forms, a soluble form and a
membrane-bound form, present in approximately equal amounts in bovine
granules. The two forms of the enzyme are not identical, as suggested by their
behaviour in Triton X-114 (Pryde and Phillips, 1986) and their subunit
structures. The enzyme is a mixed function oxidase, requiring oxygen and
ascorbate as cofactors for its catalytic activity. Ascorbate is present in chromaffin
granules in high amounts, 13-22mM. It supplies two electrons to the DBH
catalysed reaction, itself being oxidised to semidehydroascorbate in the process.
Enzyme-bound copper acts as an intermediate electron-carrier. The
hydroxylation reaction is shown below:-
Dopamine + 02 + 2H+ + 2e~—»noradrenaline + H20
p. Membrane constituents,
Cytochrome b561, one of the most abundant proteins of the chromaffin granule
membrane (15 to 19% of the total), is transmembranous. Ascorbic acid is unable
to permeate the granule membrane, but cytochrome b561 is thought to transport
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electrons from cytosolic ascorbate to intragranular semidehydroascorbate.
Ascorbate is thus regenerated within the chromaffin granule and DBH activity is
maintained.
Other major membrane constituents include DBH and H+ATPase, both of which
have been discussed above. Other membrane proteins and glycoproteins have no
known function at present, those responsible for transport functions of
the granule remain to be characterised.
1.4.4 Catecholamine storing vesicles in sympathetic nerves.
There are two types of vesicles in sympathetic nerves, large dense core vesicles
and small dense core vesicles. The large vesicles take up catecholamines and
nucleotides by the same uptake mechanisms as chromaffin granules
(Lagercrantz,1976). They contain DBH so are able to synthesise noradrenaline
and, upon stimulation, secrete noradrenaline, ATP, chromogranins, enkephalins
and neuropeptide Y. The synthesis of noradrenaline occurs at a site removed from
the nerve terminal. Vesicles are formed near the Golgi apparatus and then
transported down the axon to the nerve terminal where they are available for
exocytosis (Reichardt and Kelly, 1983). In contrast, catecholamine synthesis and
storage mechanisms in chromaffin cells takes place at the same site. Unlike the
large dense core vesicles of sympathetic neurons, small dense core vesicles do not
contain soluble proteins and peptides. They can,however, take up catecholamines
and nucleotides. It has been suggested that they are formed from large vesicles
during membrane retrieval after exocytosis and then refilled with catecholamines
and ATP at a high rate near the nerve terminal rather than returning to the cell
body (Winkler, 1988). Both types of vesicles secrete their contents by exocytosis
and in all other aspects appear similar to chromaffin granules.
1.5 Mechanism of exocvtosis in isolated chromaffin cells and sympathetic neurons.
The evidence for exocytosis as the mechanism of secretion of catecholamines was
first presented by Schneider etal.(1967). They demonstrated that stimulation of
adrenal glands with the acetylcholine analog carbachol resulted in the co-release
of catecholamines and matrix proteins; the secretion of both being calcium
dependent. The ratios of catecholamines and protein secreted were the same as
those found in isolated chromaffin granules. These results, in conjunction with
earlier reports on the co-release of catecholamines and other granule components
and morphological evidence from electron microscopy, led to the conclusion that
secretion from the adrenal medulla occurs by exocytosis. This term, first used by
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de Duve (1963), describes the movement of a vesicle towards the plasma
membrane, its fusion with it and subsequent release of its contents into the
extracellular space.
Douglas etal. (1967) first reported that acetylcholine, the physiological
secretagogue, depolarises isolated chromaffin cells by increasing the permeability
of the cell membrane to certain ions which then activate secretion. It is now
known that depolarisation triggers the opening of calcium channels. There is a
transient increase in the cytosolic calcium concentration and a chain of events is
set in motion that leads to secretion. The use of electric fields (Baker and
Knight,1983) to create small holes in the plasma membrane has enabled workers
to manipulate cytosolic calcium levels in order to trigger exocytosis independently
of events at the plasma membrane. The use of permeabilised cells conclusively
demonstrated the calcium-dependence of exocytosis and also the dependence of
secretion on ATP and magnesium. Following secretion, surplus membrane is
retrieved and reinternalised by the process of endocytosis. Like exocytosis, many
of the mechanisms of endocytosis and vesicle recycling are yet to be elucidated.
1,5,1, Role of jpn channels and membrane potential,
In the nerve terminal depolarisation of the plasma membrane is triggered by
voltage-sensitive Na+ channels. In bovine chromaffin cells interaction of
acetylcholine with its nicotinic receptor causes the opening of the receptor's ion
channel which allows the entry of Na+and Ca2+. Influx of Na+ further depolarises the cells
activating the voltage-dependent Ca2+ channels. This allows entry of Ca2+ into the
cell and cytosolic Ca2+ levels rise. The rise in cytosolic Ca2+ then triggers
exocytosis. Catecholamine secretion can also be triggered by high extracellular K+
concentrations. Depolarisation by high K+ opens voltage-sensitive channels
directly, bypassing the acetylcholine receptor. The contribution of these various
ion channels to the secretory response depends on the concentration of
secretagogue. Tetrodotoxin, which selectively blocks the fast Na+ channels, has no
effect on secretion when maximal concentrations of agonists are used. At low
agonist concentrations, however, catecholamine secretion is reduced by
tetrodotoxin (Kilpatrick efa/.,1981). This suggests that, at low agonist
concentrations, membrane depolarisation is partly due to nicotinic ion channels
and partly due to opening of fast Na+ channels. At high agonist concentrations,
however, the resulting depolarisation is sufficient to directly open the Ca2+
channels without the contribution of fast Na+ channels. Consequently, secretion is
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not inhibited by tetrodotoxin or removal of extracellular Na+. Following an action
potential resting Na+ and K+ levels are restored by the Na+/K+ ATPase. The Na+
gradient that it maintains is essential to control intracellular osmolality and is
also utilised in co-transport of various substrates such as amino acids and
neurotransmitters.
1,5,2, Evidence fpr granule and plasma membrane fusion,
There is now overwhelming evidence that secretion of catecholamines following
stimulation takes place by an exocytotic mechanism. The first evidence was
provided by the observations that constituents of the chromaffin granules such as
the chromogranins and DBH are co-released with catecholamines. Furthermore,
the release of these proteins is calcium-dependent. Immunological techniques have
shown that chromogranin A and DBH are released in the same catecholamine:
protein ratios as are found in isolated chromaffin granules. In addition, the
cytoplasmic enzymes noradrenaline N-methyl transferase and lactate
dehydrogenase are not released. Evidence for the co-release of other granule
components such as neuropeptide Y, nucleotides and enkephalins has also been
obtained.
Secretion of catecholamines is not accompanied by release of the granule
membrane constituents, but specific membrane markers do appear on the plasma
membrane. This has been demonstrated by the use of antibodies against membrane
components, primarily DBH (Phillips efa/.,1983). Stimulation of chromaffin
cells with various secretagogues resulted in the exposure of DBH on the cell
surface. This was visualised by immunofluorescence microscopy, using anti-DBH
antibody and a fluorescent second antibody. The appearance of DBH on the cell
surface was calcium-dependent and inhibited by drugs that blocked catecholamine
secretion. Quantitation of the amount of DBH exposed on the plasma membrane
correlated closely with the degree of catecholamine secretion (Hunter and
Phillips,1989). Finally, the exocytotic event itself has been visualised using
freeze-fracture techniques (Aunis etal.,1979) and electron microscopy which
showed chromaffin granules adjacent to and fused with the plasma membrane
following stimulation. It is worth noting here that the co-release of a cell
component with catecholamines does not, however, imply that that component is
sequestered in the same subcellular compartment as the catecholamines. For
instance, the co-secretion of catecholamines and newly acquired ascorbate has
been reported by Knoth etal. (1987). Release of the newly acquired ascorbate,
1 0
however, displays different properties to that of catecholamines suggesting they
are released from different sub-cellular compartments.
Similar studies to those on chromaffin cells have established that noradrenaline
secretion from sympathetic neurons is via calcium-dependent exocytosis
(Winkler, 1988).
1.5.3 Role of calcium.
The absolute dependence of exocytosis on extracellular calcium has long been
recognised (Douglas and Rubin, 1961). Calcium enters the cell following
depolarisation through voltage-sensitive calcium channels and, in the case of
nicotinic stimulation, through nicotinic receptor-linked channels. The necessity
for calcium entry into the cells was conclusively demonstrated by Baker and
Knight (1978). They rendered the plasma membrane of chromaffin cells leaky by
exposure to a small number of high-voltage discharges. The plasma membrane is
permeable to small molecules allowing direct manipulation of the cytosolic
environment whilst the granules remain intact. They demonstrated that addition of
calcium to permeabilised cells caused catecholamine release in a dose dependent
manner. Mg2+-ATP was also required for exocytosis. The development of
fluorescent calcium indicators has enabled the change in intracellular calcium in
response to various stimuli to be monitored directly (Knight and Kesteven, 1983;
Burgoyne, 1984; Kao and Schneider, 1986; and Cobbold efa/.,1987). These
indicators, such as quin-2 and fura-2, permeate the plasma membrane as acetoxy
methyl esters and enter the cytosol where they are hydrolysed to yield the
impermeant indicators. This allows changes in cytosolic free calcium to be
determined in the nanomolar range. Using such indicators the resting cytosolic
[Ca2+] is found to be approximately 100nM, values ranging from 50 up to 150nM
having been reported. Upon stimulation with either nicotine or high K+ there is a
transient elevation of free calcium to micromolar levels. On measurements in
single cells injected with aequorin (Cobbold etal., 1987) this calcium transient
lasted only 60 to 90 seconds.
Fura-2 in particular has been used in the study of [Ca2+]j in both cell populations
and single cells. As an indicator it has many advantages over quin-2, including
sensitivity (Grynkiewicz etal., 1985). Recently O'Sullivan etal. (1989) have
used video digital imaging techniques to determine the spatial distribution of
[Ca2+]j in resting and stimulated single cells loaded with fura-2. Video imaging
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demonstrated a rise in [Ca2+]j less than 2 seconds after stimulation with nicotine
or high K+ that was initially restricted to a region immediately beneath the
plasma membrane. This is presumably due to the entry of Ca2+ via the
voltage-sensitive Ca2+ channels. Following diffusion of the Ca2+ to fill the
cytosolic space there was a second larger rise in [Ca2+]| throughout the whole
cell, due to release of Ca2+ from intracellular stores. Thus most of the elevation in
[Ca2+]| that is monitored by fluorescence measurements of cell suspensions
occurs, not at the site of exocytosis adjacent to the plasma membrane, but within
the cytoplasm. The release of Ca2+ from internal stores may be mediated by Ca2+
itself or by IP3 which is produced following nicotinic or high K+ treatment. It has
been suggested that Ca2+ influx itself may activate phospholipase C resulting in
production of IP3 from polyphosphoinositides (Eberhard and Holz, 1987). This
rise in cytosolic Ca2+ is now known to have numerous targets within the cell.
A Cvtoskeleton.
Before exocytosis can take place it is necessary for the granule to be translocated
to the plasma membrane. This has suggested a role for the cytoskeleton in granule
movement and membrane fusion that may be regulated by [Ca2+]j. The secretory
granules of unstimulated cells are trapped within a three-dimensional
filamentous mesh. A ring of F-actin adjacent to the cell periphery has been
observed in association with fodrin, a calcium-regulated protein that binds to and
forms cross-links with F-actin. Caldesmon, a calmodulin-regulated protein
which reversibly binds F-actin, is also exclusively located at the cell periphery.
This high density of actin filaments and actin-binding proteins form a barrier to
exocytosis at the cell periphery. Cheek and Burgoyne (1986) demonstrated that
nicotine stimulation of chromaffin cells resulted in a rapid, transient disassembly
of actin filaments that was consistent with the time course for catecholamine
secretion, providing evidence for the involvement of the cytoskeleton in
exocytosis. This disassembly was independent of extracellular calcium and
unaffected by trifluoperazine, a calcium-calmodulin inhibitor. This suggests that
granule movement may also be controlled by other second messengers which are
calcium-independent. Other proteins associated with actin are also, however,
activated by the calcium transient; for instance, caldesmon-actin cross-linking is
inhibited by an increase in calcium (Burgoyne and Cheek, 1987). Thus it has been
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proposed (Aunis and Bader, 1988) that the calcium transient activates proteins
that break the F-actin network such as fodrin and caidesmon. However, the ability
of nicotine stimulation to evoke cytoskeletal actin disassembly was not abolished
in the absence of Ca2+, unlike that produced by high K+. This suggests that, in the
case of nicotinic stimulation, mechanisms other than calcium-evoked actin
disassembly must be involved in secretion (Burgoyne et al., 1989). The
dissolution of the cytoskeletal barrier permits release of granules from the
cytoskeletal network, with consequent movement to and fusion with the plasma
membrane.
A similar mechanism has been proposed in nerve terminals. Synapsin 1, a
vesicle-binding protein not found in chromaffin cells, traps vesicles in the
cytoskeleton by binding to the vesicle membrane and actin filaments.
Depolarisation leads to a calcium-calmodulin dependent phosphorylation of
synapsin 1 resulting in detachment of the secretory vesicles from the cytoskeleton
De Camilli and Greengard (1986).
B Calcium-binding proteins.
In addition to calmodulin, a number of proteins have been described that bind
reversibly to chromaffin granule membranes in a calcium-dependent manner
(Geisow and Burgoyne, 1982). Calmodulin binds to chromaffin granules and
facilitates the binding of cytosolic proteins to granules. Furthermore, injection of
chromaffin cells with anti-calmoduiin antibodies inhibited catecholamine
secretion (Kenigsburg and Trifarb, 1985). When cytosolic proteins that have
leaked out of digitonin-permeabilised chromaffin cells are added back, exocytosis
is restored in the presence of calcium (Sarafian et al., 1987). One of these
proteins leaked from the cells was identified as calmodulin. Calmodulin alone,
however, cannot restore the secretory response suggesting a role for other
cytosolic proteins.
Several other proteins have been identified that reversibly bind to secretory vesicle
membranes in the presence of calcium, including a family of closely related
proteins, the annexins (Burgoyne and Geisow, 1989). One member of this family,
calpactin, has been identified as having a possible role in exocytosis. Calpactin is
localised at the inner surface of the plasma membrane and binds to fodrin and actin
in a calcium-dependent manner. Recently, Ali etai. (1989) demonstrated that
calpactin was able to restore the secretory response of permeabilised chromaffin
cells, which had been lost due to leakage of cytoplasmic proteins. This evidence
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indicates that calpactin, at least, is essential for exocytosis. Other
calcium-binding proteins have been identified but whether or not they play a role
in exocytosis has yet to be established.
0 R<?ie of MqATP,
Baker and Knight (1981) in their work on electrically permeabilised chromaffin
cells demonstrated that exocytosis requires not only calcium but also exogenous
MgATP. Readdition of either magnesium or ATP alone to electro -permeabilised
cells does not trigger exocytosis, both being required. Pretreatment of cells with
metabolic inhibitors which deplete cytoplasmic pools of ATP abolishes the
response of both intact and digitonin-permeabilised cells to secretagogues or
direct calcium challenge (Nakanishi eta!., 1988). Millimolar levels of MgATP
are required for exocytosis. Several roles have been suggested for MgATP in
exocytosis. For example, maintenance of the granule membrane electrochemical
gradient requires metabolic energy, but Knight and Baker (1985) demonstrated
that inhibition of the H+-translocating ATPase or dissipation of the granule
membrane potential or pH gradient does not affect exocytosis. A number of
proteins have been identified that are phosphorylated in a calcium-dependent
manner (Geisow and Burgoyne, 1987) but whether they are involved in
exocytosis is not known. The only phosphoprotein known to be involved in
exocytosis is Synapsin 1 and that is found in nerve terminals but not in chromaffin
cells (see section A Cytoskeleton).
The observations that certain phorbol esters can enhance the sensitivity of
exocytosis to calcium and that this is blocked by inhibitors of protein kinase C
have suggested the involvement of protein kinase C in exocytosis (Knight et al.,
1988; and Burgoyne etal., 1988). The sensitivity of secretion and protein kinase
C to the same inhibitors suggests that the latter is involved in the actual
mechanism of exocytosis rather than its modulation. This is supported by the
findings that protein kinase C is translocated to membranes in response to nicotine
stimulation or high K+ within seconds (Terbush etal., 1988). This leads to
increased protein phosphorylation. Protein kinase C has a specific requirement
for MgATP within the concentration range required for secretion. The targets of
this enzyme, however, still remain unknown and MgATP may be involved in
processes other than phosphorylation.
1.5.4. Calcium removal from the cytoplasm.
1 4
As has been discussed above, the cytosolic rise in [Ca2+]j that triggers secretion is
transitory, [Ca2+]j returning to basal levels within 1 minute following nicotine
or high K+ treatment in chromaffin cells (Cobbold etal., 1987). Therefore
specific mechanisms must exist to remove calcium and maintain basal levels in
the absence of any stimulus. Chromaffin granules have an internal calcium
concentration of approximately 20mM. Only about 0.03% of this is present as
free ions, the remainder being bound to acidic components inside the granules such
as the chromogranins and the interior of the granule membrane (Haigh etal.,
1989). As the granule calcium reserve constitutes the majority of total cell
calcium this suggests that granules may be important in removal of calcium from
the cytoplasm following a calcium transient. Calcium is taken up into the granules
via a Na+/Ca2+ exchange system linked to a Na+/H+ antiporter, described by Haigh
and Phillips (1989). The Na+ gradient set up by the antiporter can act as an
energy source to drive Ca2+ transport. Von Grafenstein and Powis (1989) have
recently suggested that the release of calcium from chromaffin granules by
exocytosis may be important in long term calcium homeostasis since ultimately
calcium must be removed from the cell.
Kao (1988) studied the uptake of 45Ca2+ into intracellular organelles following
stimulation of digitonin-treated chromaffin cells. In the short term the amount of
calcium taken up by the intracellular organelles accounted for only 5 to 10% of
that influx. Most of this calcium was taken up in an ATP-dependent manner into
the endoplasmic reticulum. Uptake by the mitochondria only became significant
when [Ca2+]j reached micromolar levels. Thus it seems that small fluctuations in
calcium levels during resting states are probably controlled by the endoplasmic
reticulum. Following depolarisation the bulk of the cytosolic calcium must be
immediately extruded from the cell via the calcium pump and Na+/Ca2+ exchange
system of the plasma membrane.
Similar mechanisms for removal of calcium from the cytoplasm have been
identified in nerve terminals; these being efflux via Na+/Ca2+ exchange and
Ca2+-dependent ATPase and, to a lesser extent, sequestration in intracellular
organelles (Reichardt and Kelly, 1983).
1.5.5. Inactivation of released catecholamines.
There are two mechanisms by which the action of noradrenaline at the sympathetic
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nerve terminal and catecholamines in the circulation is terminated.
A Re-uptake.
The neuronal uptake system, uptake^ represents the major mechanism for
terminating the action of noradrenaline at the sympathetic nerve terminal.
Uptake1 has been well characterised in neurons (Paton, 1976). PC12 cells, a
clonal cell line from rat phaeochromocytoma, have been used as a model system
for adrenergic neurons to characterise its molecular mechanism (Bonisch et
at.,1984).
Noradrenaline is taken up via a sodium- and chloride-dependent symporter.
Sodium forms a Na+-carrier complex at the side of the plasma
membrane where [Na+] is high (and [K+] low), that is, on the outside under
normal physiological conditions. Uptake is energy-dependent since it is driven by
an inwardly-directed Na+ gradient, maintained by the Na+/K+ ATPase. Both Na+
and CI" facilitate the binding of noradrenaline. When noradrenaline is bound the
complex becomes mobile and noradrenaline is transported together with its
co-substrates Na+ and CI*. Once inside, the high intracellular K+ concentration
competes with Na+ for a common binding site on the complex causing Na+ to
dissociate. K+ replaces Na+ in the carrier-complex and is transported out in the
direction of the K+ gradient. Noradrenaline transport is thus electroneutral, one
Na+ being exchanged for one K+. At the outside of the membrane where [Na+] is
high K+ is dissociated from the carrier and the Na+-carrier complex formed fixes
substrate binding sites at the outer face of the membrane. The energy dependence
of uptake1 has been demonstrated using metabolic inhibitors that rapidly deplete
cellular ATP thus dissipating the Na+ and K+ gradients across the plasma
membrane. Uptake1 is inhibited by drugs such as cocaine and tricyclic
antidepressants. The dependence of uptake1 on an inwardly directed Na+ gradient is
demonstrated by replacement of extracellular Na+ by other monovalent cations;
this results in efflux of noradrenaline from the axoplasm of adrenergic nerve
terminals (Paton, 1973). This efflux is mediated by reversal of the
Na+-dependent uptake1 carrier. The physiological significance of this
"carrier-mediated efflux" will be discussed in the next section.
A high affinity uptake system for catecholamines has also been characterised in
chromaffin cells (Kenigsburg and Trifaro, 1980; and Banerjee eta!., 1987).
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This uptake system possesses similar saturation kinetics and has an absolute
requirement for extracellular Na+. Uptake is dependent on maintenance of an
inwardly directed Na+ gradient by Na+/K+ ATPase and is also sensitive to
inhibition by cocaine and tricyclic antidepressants.
B Metabolism.
Cytosolic catecholamines comprise less than 0.01% of total chromaffin cell
catecholamines. The cytosolic catecholamine concentration is maintained at this
low level by rapid uptake into secretory granules, as discussed above, and
metabolism. Following re-uptake into sympathetic nerve terminals,
noradrenaline can be metabolised by monoamine oxidase. This is located on the
outer mitochondrial membrane and catalyses the oxidative deamination of amines.
The reaction catalysed by MAO, shown below, involves the dehydrogenation of the
amine at the carbon-nitrogen bond to form the corresponding imine, which is then
hydrolysed to give the aldehyde plus ammonia. Oxygen is essential to act as the
hydrogen acceptor.
RCH2NH2 + 02 + H20 * RCHO + NH3 + H202
At least two forms of the enzyme exist, MAO type A and MAO type B. These can be
distinguished by their substrate specificity and sensitivity to selective inhibitors
(Youdim et at., 1988). The substrate specificity of the two types is reflected in
their localisation. In adrenergic nerve endings the major form of MAO is type A
where noradrenaline deamination is needed for regulation of neurotransmission.
In contrast, chromaffin cells possess primarily MAO type B (Youdim et at.,
1986) which has a low affinity for noradrenaline as the physiological function of
these cells is to conserve and store catecholamines (Youdim etal., 1984).
Catecholamines can be methylated by catechol-O-methyl transferase prior to
deamination. Catechol-O-methyl transferase is associated with an additional,
extraneuronal, uptake mechanism (uptake2) that is found in smooth muscle,
myocardial and gland cells.
1.6 Catecholamine release during myocardial ischaemia and reperfusion.
Catecholamines are released during myocardial ischaemia and reperfusion, and
may be the primary mediators of ventricular arrhythmias. Following myocardial
infarction, plasma and urinary catecholamines levels are raised in man (Vettner
etal., 1974). Chronic cardiac denervation which depletes myocardial
catecholamine stores and chemical sympathectomy using 6-hydroxy dopamine
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both prevent arrhythmias during ischaemia and reperfusion (Ebert etai, 1970).
Such observations, although indirect, suggest that increased catecholamines
released in response to myocardial ischaemia are of fundamental importance in
arrhythmogenesis. Raised plasma catecholamine could come from two sources: the
adrenal medulla and peripheral nerve terminals; or from the sympathetic nerve
terminals within the ischaemic myocardium.
1.6-1, Peripherally-released catecholamines.
Experiments on anaesthetised rats in vivo (Daugherty etai., 1986) demonstrated
raised plasma catecholamines during acute myocardial ischaemia. There was a
relationship between catecholamine levels and the subsequent development of
ventricular arrhythmias. Adrenal demedullation or adrenalectomy abolished the
elevation of plasma catecholamine, but had no significant effect on the development
of arrhythmias. It was concluded that circulating catecholamines are not
responsible for triggering arrhythmias during myocardial ischaemia.
1.6.2. Locallv-released catecholamines.
The release of catecholamines within the ischaemic myocardium, either
spontaneously or in response to increased sympathetic activity, is controversial.
There are two main areas of dispute. There is the question of whether
catecholamines released are arrhythmogenic; and secondly whether they are
released into the extracellular space during ischaemia and then washed out during
reperfusion or are released only as a direct result of reperfusion. The very nature
of ischaemia has made it extremely difficult to separate the two events since, in
ischaemia, flow to the heart is very low or completely absent. Metabolites
released during ischaemia can only be measured in the venous effluent once flow is
returned to normal, that is, during reperfusion. Reperfusion itself, however,
exacerbates ischaemic myocardial injury and some metabolites will be released at
this stage rather than during the ischaemic event perse.
A Arrhvthmoaenic nature of locallv-released catecholamines.
Penny (1984) reported that chronic cardiac denervation, which depletes
myocardial catecholamine stores, prevented arrhythmias during ischaemia and
reperfusion. Both chemical sympathectomy using 6-hydroxy dopamine and p
adrenoceptor blockade prevent arrhythmias. Similarly, Daugherty etai. (1986)
reported a reduction in the severity of ventricular arrhythmias during ischaemia
following depletion of catecholamines from the sympathetic nerve terminals in
rats in vivo. To investigate the mechanism of this effect more closely these
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authors examined the release of [3H] noradrenaline in isolated perfused rat hearts
following coronary artery ligation. The onset of ventricular arrhythmias was
similar to that in rats in vivo but no enhanced release of [3H] noradrenaline was
seen; however, the release of [3H] noradrenaline may not be the same as the
release of endogenous catecholamines in vivo.
Riemersma and Forfar (1982) studied endogenous noradrenaline release in the
venous effluent from the ischaemic myocardium in dog in vivo. There was a 30%
incidence of ventricular fibrillation within the first 10 minutes of coronary
occlusion, but no concomitant noradrenaline release. An absence of noradrenaline,
however, does not necessarily imply that noradrenaline is not released at the
nerve terminals in the ischaemic myocardium. There is evidence of noradrenaline
loss from the nerve terminals during in vivo ischaemia using fluorescence
techniques (Muntz etal., 1984). Ischaemia was associated with a diffusion of
fluorescence away from the nerve terminal that remained within the ischaemic
zone suggesting that noradrenaline is released within the ischaemic myocardium
but remains trapped within this zone. Furthermore, early in ischaemia, cardiac
cAMP is raised and glycolysis activated, both effects mediated by catecholamines.
Thus, p adrenergic antagonists such as propranolol are antiarrhythmic due to
prevention of stimulation of adenylate cyclase and consequently decreased formation
of cAMP (Opie et at., 1979). Within the first 10 minutes of ischaemia there is
enhanced sympathetic activity leading to release of noradrenaline into the
extracellular space as shown by Schwartz and Stone (1980). At this time,
however, there may also be increased re-uptake and a-adrenoceptor modulation at
the nerve terminal accounting for the lack of noradrenaline in the venous effluent.
Blockade of re-uptake with desipramine and of a2-mediated negative feedback
with yohimbine revealed a significant noradrenaline release from dog ischaemic
myocardium within the first 10 minutes of coronary occlusion (Forfar etal.,
1985). The ligation of the coronary artery to induce ischaemia was shown to
enhance sympathetic nerve activity, but even so there was no detectable
noradrenaline release in the myocardial venous effluent, presumably due to
enhanced re-uptake at the nerve terminal.
The absence of noradrenaline release during the first 10 minutes of ischaemia is
also reported by Daugherty etal. (1986) who showed no elevation of
catecholamines in rats in vivo or in perfused rat hearts in vitro. In contrast,
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however, Hirche et al. (1980) reported an increase in noradrenaline from the
myocardium within the first 10 minutes after the onset of coronary occlusion in
pigs in vivo. This was associated with an early phase of arrhythmias. The
ischaemic model used by Hirche etal. (1980), however, was one of regional
ischaemia and it is possible that this noradrenaline came from normally perfused
regions of the heart. Furthermore, Wilde etal. (1988) have recently reported
that increased catecholamine release in the venous effluent is only observed after
ischaemic periods longer than 10 minutes in the isolated globally ischaemic rat
heart. This is in agreement with the findings of Schomig etal. (1984) and
Carlsson (1988) and it can be concluded that there is no significant release of
noradrenaline during the first 10 minutes of ischaemia.
The evidence for enhanced overflow during prolonged ischaemia is more
controversial. Schomig etal. (1984); Abrahamsson etal. (1984); Carlsson
(1988); and Knopf et al. (1988) have all reported a marked overflow of
noradrenaline in the venous effluent following 15 to 60 minutes ischaemia in the
isolated perfused rat heart, while in vivo studies in other species have suggested
overflow does not occur. For instance, Forfar etal. (1985) reported an absence of
catecholamine overflow following ischaemic periods of up to 75 minutes in dogs.
In contrast, there have been consistent reports of enhanced overflow during
subsequent reperfusion, (for example, Riemersma and Forfar ,1982).
Interpretation of the results from in vivo studies are complex as it is not clear
whether overflow occurs during reperfusion or during previous ischaemia. This *
is discussed in detail in the next section. Despite overwhelming evidence in favour
of ischaemic noradrenaline overflow in the isolated perfused rat heart, release
during myocardial ischaemia in vivo remains controversial and observations made
in isolated systems may not necessarily reflect the in vivo ischaemic event.
B Catecholamine overflow during ischaemia and reperfusion.
As discussed above, Riemersma and Forfar (1982) reported no overflow of
noradrenaline during the first ten minutes of ischaemia, but significant overflow
following reperfusion. This study, however, used a model of regional ischaemia
where it is not known what the relative contributions of the ischaemic and
non-ischaemic regions are in modulating levels of noradrenaline in the venous
effluent. Schomig et al. (1984) attempted to solve this problem using isolated
perfused rat hearts that were made globally ischaemic by complete abolition of
coronary flow. In this way the duration and extent of ischaemia could be precisely
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defined. Hearts were subject to "stop-flow" ischaemia for varying lengths of time
and the catecholamine overflow measured in the venous effluent during the first 5
minutes reperfusion. Ischaemic periods greater than 10 minutes resulted in a
progressive increase of noradrenaline overflow upon reperfusion. Furthermore,
most of the noradrenaline was detected after only 1 to 2 minutes reperfusion
suggesting that noradrenaline was released into the extracellular space during
ischaemia and then washed out upon reperfusion rather than being released by the
action of reperfusion itself.
The relative contributions of ischaemia and reperfusion to noradrenaline overflow
cannot be completely Separated by such a model. After 60 minutes stop-flow
ischaemia Abrahamsson et at. (1983) reported a marked overflow of
noradrenaline in the perfusate of isolated rat hearts. In order to examine the
possibility that overflow was induced by reperfusion, hearts were reperfused
with a calcium-free buffer (Abrahamsson etal., 1984). A major part of the
cellular damage caused by reperfusion is calcium-dependent, so it was suggested
that removal of calcium during reperfusion would significantly reduce
noradrenaline overflow if induced by reperfusion but have no affect if overflow
occurred during ischaemia. Calcium-free perfusion had no affect on noradrenaline
overflow following ischaemia suggesting that the overflow is ischaemia-induced.
Dart etal. (1987) developed experimental models that were not dependent on
stop-flow ischaemia followed by reperfusion in order to distinguish
ischaemia-induced from reperfusion-induced noradrenaline overflow. The model
used was one of anoxia whereby hearts were perfused at normal flow with
oxygen-free and substrate-free buffer. The flow to the myocardium remains
normal so any noradrenaline overflow will be in direct response to anoxia rather
than reperfusion. After 15 to 20 minutes anoxia there was a marked overflow of
noradrenaline of a similar order of magnitude to that seen during reperfusion
following stop-flow ischaemia. In conclusion, therefore, less than 10 minutes
ischaemia is not associated with significant noradrenaline release but with more
prolonged ischaemia there is a marked noradrenaline overflow that is associated
with the ischaemic episode rather than with reperfusion.
1.6.3 Mechanism of noradrenaline release during myocardial ischaemia.
A Earlv myocardial ischaemia.
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In the normal myocardium adrenergic stimulation causes an increase in
noradrenaline release and subsequent adrenergic stimulation of the myocytes.
During the first 10 minutes of ischaemia, however, when increased sympathetic
activity would be expected, there is little, if any, accumulation of noradrenaline
in the extracellular space (Dart et at., 1984a). Released noradrenaline is,
however, rapidly removed by uptake.,. Blockade of uptake1 with desipramine
increased noradrenaline overflow during early ischaemia as shown by Forfar etal.
(1985). In addition, stimulation-induced exocytotic release during ischaemia is
modulated through presynaptic receptors (Dart etal., 1984b; Schomig, 1988),
and inhibition of a2 adrenergic receptors with yohimbine and A1 adenosine
receptors with 8-phenyltheophilline enhances release. However, even with
combined inhibition of uptake1 and presynaptic modulation, exocytotic release of
noradrenaline is still significantly lower than that released by sympathetic
stimulation under conditions of normal flow. This suggests that early in ischaemia
there is a failure of stimulation-evoked noradrenaline release. Exocytosis is an
ATP-dependent process and ATP is probably depleted in neurons very rapidly
after the onset of ischaemia. Thus early ischaemia results in a loss of sympathetic
activity and after 20 minutes there is no release of noradrenaline in response to
sympathetic stimulation (Dart etal., 1984a). Therefore, during more prolonged
ischaemia noradrenaline release is unlikely to result from enhanced neural
sympathetic activity.
B Prolonged myocardial ischaemia.
Within 40 minutes after the onset of total ischaemia in the perfused rat heart
more than 30% of total noradrenaline content of the heart can be recovered during
subsequent reperfusion. If this noradrenaline were equally distributed throughout
the extracellular space during the ischaemic period the concentration of
noradrenaline is predicted to reach micromoiar levels, sufficient to cause
myocardial necrosis, even in the non-ischaemic myocardium. When
catecholamines exceed physiological doses the energy reserve of the myocytes is
depleted leading to complex biochemical and structural changes and ultimately
necrosis. The crucial event in the catecholamine-induced myocardial necrosis is
Ca2+ overload. This results in myofilament overstimulation, increase of
contractile force and oxygen requirement, and increased ATP breakdown, all of
which contribute to myocyte injury. In addition, several other mechanisms may
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contribute to myocardial necrosis induced by catecholamines including
mobilisation of free fatty acids; increased intracellular acidity; free radical
production; activation of phospholipases or proteases; and catabolite accumulation
(Rona, 1985).
The nature of this noradrenaline overflow was studied in detail by Schdmig et al.
(1984). There are three possible mechanisms by which this noradrenaline may
be released.
1. Exocytotic release could be triggered either by increased sympathetic activity
or by membrane depolarisation by extracellular potassium, which is known to
reach depolarising concentrations during prolonged ischaemia. In each case release
would be dependent on influx of extracellular Ca2+.
2. There may be increased leakage of noradrenaline from the nerve terminals by
passive diffusion. This process is unlikely to occur, however, unless there is
breakdown of cell membrane structure. This only occurs after ischaemic periods
greater than 60 minutes duration (Ganote etal., 1976).
3. A mechanism of carrier-mediated efflux of catecholamines from the cytoplasm
into the extracellular space may operate. It was postulated by Paton (1976) that
under certain conditions the uptake., carrier may operate in reverse.
Carrier-mediated efflux can be characterised by its sensitivity to uptake.,
blocking drugs such as desipramine and cocaine, and its independence of
extracellular calcium and presynaptic modulation.
Schdmig etal. (1984) demonstrated a noradrenaline overflow following 40
minutes stop-flow ischaemia that was inhibited by more than 80% by 100nM
desipramine. A similar effect was found with cocaine, nisoxetine and (+)
oxaprotiline, all uptake., inhibitors. These drugs all inhibited noradrenaline
overflow with the same concentration dependence as that required to block
uptake.,. In contrast, ischaemia-induced noradrenaline release within the first 10
minutes was enhanced by uptake., blocking drugs. Agents that inhibit presynaptic
modulation had no effect on this late ischaemia-induced noradrenaline overflow,
unlike early release which was enhanced (Riemersma and Forfar, 1982).
Perfusion with calcium-free buffer had no effect on the cumulative overflow of
noradrenaline after 20 minutes of ischaemia, even when 1mM EGTA was included
in the perfusate.
23
From this evidence it is suggested that there are three phases of noradrenaline
release during myocardial ischaemia. During the first 10 minutes (in the
perfused rat heart) noradrenaline is released in response to increased
sympathetic activity by an exocytotic mechanism that is calcium-dependent and
sensitive to presynaptic modulation. Noradrenaline levels remain low in the
extracellular space due to rapid re-uptake via neuronal uptake.,. The second phase
of ischaemia, 15 to 40 minutes, is characterised by a progressive overflow of
noradrenaline that is calcium-independent and blocked by uptake., inhibitors. It is
not modulated by a2 antagonists or electrical stimulation. Since exocytosis has an
absolute requirement for calcium and ATP this cannot be the mechanism of
release. Passive diffusion of catecholamines from the nerve terminal would not be
sensitive to uptake-, blockade. All the evidence thus points to this efflux being
catalysed by the uptake-, carrier, working in reverse. Finally, ischaemic periods
longer than 60 minutes result in further spontaneous overflow of noradrenaline
that is not blocked by uptake., inhibitors and is the result of progressive,
irreversible cell injury.
The main prerequisite for the carrier-mediated efflux postulated above for the
second phase of release would be a raised cytosolic catecholamine concentration.
Under normal conditions this is kept low by the action of MAO, which is oxygen
dependent, and the vesicular uptake of catecholamines which is dependent on an
intact proton gradient across the vesicle membrane. During ischaemia it is
postulated that this would be dissipated due to a rundown of ATP and cytoplasmic
acidosis causing uncontrolled leakage of catecholamines into the cytoplasm. MAO
will be ineffective due to a lack of oxygen so cytoplasmic catecholamine
concentrations will remain high. In conjunction with changes in the
transmembrane sodium and potassium gradients catecholamine efflux would occur
via reversal of the uptake., carrier.
1.7 Mechanism and metabolic requirements of ischaemia- and anoxia-induced
carrier-mediated efflux,
Dart et al. (1987) studied the metabolic conditions necessary to evoke
carrier-mediated efflux, measuring noradrenaline overflow from the heart
without changes in flow rate. In this way they were able to investigate the effects
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of modifying oxygen and substrate supply in the absence of the secondary effects of
low-flow ischaemia, such as alterations in metabolites and ion concentrations in
the extracellular space. Isolated rat hearts were made anoxic by perfusion with
nitrogen-saturated substrate-free perfusate. The noradrenaline overflow that
ensued had the same characteristics as that produced by total ischaemia, being
independent of calcium and inhibited by uptake., blockade. If glucose was present
in the anoxic perfusate, noradrenaline overflow was almost completely abolished.
Schomig etat. (1987) used three models of energy depletion to investigate this
further.
1. Total ischaemia.
A significant overflow of noradrenaline was observed only after ischaemic periods
greater than 10 minutes. If hearts were preperfused with substrate-free
normoxic buffer for 45 minutes, or glycolysis was blocked for 5 minutes prior to
ischaemia, this time lag was removed.
3- Anoxia.
Perfusion with substrate-free anoxic buffer produced a similar noradrenaline
overflow that reached a peak after 40 minutes and then declined, presumably due
to depletion of noradrenaline stores. The amount of noradrenaline released was far
in excess of that released during ischaemia raised by cessation of flow, probably
due to the continuous washout of noradrenaline in the anoxic model. During
ischaemia accumulation of noradrenaline in the extracellular space would reduce
the noradrenaline concentration gradient between the intracellular and
extracellular spaces. In other respects anoxia-induced overflow was the same as
that produced by ischaemia.
3. Cvanide intoxication.
The effects of anoxia could be mimicked using cyanide intoxication. Under these
conditions it was also possible to measure DOPEG. This is a major metabolite
produced by the oxidative deamination of noradrenaline, catalysed by MAO. DOPEG
is lipophilic and so, unlike noradrenaline, freely diffuses out of the nerve ending.
Cyanide intoxication, in the absence of glucose, mimics anoxia by inhibiting ATP
production whilst MAO remains functional as oxygen is still present. Thus DOPEG
can serve as an indicator of cytoplasmic noradrenaline concentrations under these
conditions. Noradrenaline overflow was preceded by a rise in DOPEG
concentrations; this remained high in the presence of desipramine, when
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noradrenaline overflow was inhibited.
These experiments indicate that the energy status of the sympathetic nerve
terminal must be the main determinant of non-exocytotic noradrenaline overflow.
Both inhibition of oxidative phosphorylation and the inhibition or exhaustion of
anaerobic glycolysis are required for noradrenaline overflow to occur. Complete
abolition of overflow in the presence of glucose during anoxia or cyanide
intoxication demonstrated that other changes that occur during ischaemia, such as
accumulation of metabolites and acidosis must be of secondary importance as in
models of ongoing flow they are present to a much lower degree. The parallel
overflow of DOPEG in the cyanide model provides evidence that noradrenaline must
enter the cytoplasm prior to efflux and further confirms a non-exocytotic
mechanism of release. If noradrenaline were released exocytotically there would
be no release of DOPEG since noradrenaline would not come into contact with MAO,
located on the outer surface of the mitochondrial membrane.
The importance of intracellular and extracellular ion concentrations, and of
Na+/K+-ATPase activity in noradrenaline release from the ischaemic or anoxic
myocardium has also been considered (Schomig etal., 1988; and Dart and
Riemersma, 1989). Pharmacological agents such as the monovalent ionophore
monensin and the vesicular amine-carrier inhibitor reserpine were used to
disrupt the ability of the secretory vesicles to maintain a high concentration of
catecholamines. In the presence of such agents cytoplasmic levels of noradrenaline
were elevated, as indicated by raised levels of the metabolite DOPEG. This
increased concentration of cytoplasmic noradrenaline alone was not sufficient to
cause carrier-mediated efflux. However, when combined with conditions designed
to cause alteration of the transmembrane sodium gradient there was a significant
efflux of noradrenaline. The transmembrane sodium gradient was reversed by
inhibiting Na+/K+-ATPase with ouabain, by opening voltage-sensitive Na+
channels with veratridine, or by replacing extracellular sodium with sucrose.
Alteration of the sodium gradient alone did not trigger efflux. Thus both elevated
cytoplasmic noradrenaline concentrations and an outwardly directed sodium
gradient are required for carrier-mediated efflux to occur.
These metabolic interventions have enabled a scheme of events that would lead to
noradrenaline overflow during myocardial ischaemia to be postulated. The rapid
depletion of energy stores is central in causing the metabolic changes required for
carrier-mediated efflux to occur. A rundown of ATP will lead to inhibition of the
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vesicular H+-ATPase. The transmembrane H+ electrochemical gradient will tend
to dissipate leading to accumulation of catecholamines in the cytoplasm. Under
ischaemic conditions MAO is inhibited so metabolism of these catecholamines is
prevented. At the plasma membrane Na+/K+-ATPase activity is blocked due to ATP
rundown. Furthermore, intracellular acidosis activates the Na+/H+ exchanger,
which plays a critical role in the regulation of intracellular pH (Lazdunski et al.,
1985). These two effects lead to intracellular sodium accumulation which
facilitates catecholamine efflux via the uptake1 carrier.
Thus there is good evidence to suggest that, in the absence of sympathetic nervous
activity, carrier-mediated efflux will occur. The role of the uptake 1 carrier
during myocardial ischaemia is a complex one. In regions where blood supply is
maintained uptake., will operate to prevent extracellular noradrenaline levels
rising. In regions where blood flow is inadequate severe ischaemia will ensue and
carrier-mediated noradrenaline efflux occur. Within the myocardium the
severity of ischaemia will vary, resulting in a heterogeneous overflow of
noradrenaline which, in itself, will further contribute to the development of
arrhythmias. All these studies, however, have been carried out on whole hearts,
and the changes that are predicted to occur at the nerve terminal can only be
inferred from observations made after the ischaemic event. Furthermore, all
measurements of metabolites related to energy metabolism that are made in the
ischaemic heart relate to the myocardium and not to the nervous system itself,
since sympathetic nerve terminals make up only a tiny fraction of the total mass
of the tissue. In order to overcome these difficulties there is a need for isolated
cell models in which to obtain direct measurements of the metabolic changes
leading to carrier-mediated efflux.
There is much evidence to suggest the use of chromaffin cells in such studies. As
discussed, chromaffin cells are closely analogous to sympathetic nerve terminals
and have the advantage of being readily available as a homogeneous population.
Furthermore, much of what is known about sympathetic nerve terminals has been
inferred from studies on isolated chromaffin cells so it would seem likely that the
latter would also behave in the same manner under pathophysiological conditions.
There are several lines of evidence to suggest that this may be the case.
1.8.1 Isolated sympathetic neurons.
Sweadner (1985) studied the mechanism of ouabain-evoked release of [3H]
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noradrenaline from primary cultures of sympathetic neurons from the superior
cervical ganglion of newborn rats. Inhibition of Na+/K+-ATPase with ouabain
resulted in release of [3H] noradrenaline. Ouabain caused an efflux of
approximately 50% of the total pool of [3H] noradrenaline within 1 hour. This
release was dependent on extracellular Na+ but not extracellular Ca2+ and was
inhibited by desipramine. This suggests that inhibition of Na+/K+-ATPase alone,
in sympathetic neurons in vitro, is sufficient to cause carrier-mediated efflux of
[3H] noradrenaline. Ouabain may, however, have pharmacological effects other
than inhibition of Na+/K+-ATPase, and efflux of [3H] noradrenaline may not
necessarily reflect the efflux of endogenous catecholamines under the same
conditions.
1.8,2 Cortical synaptcspmes,
Of more relevance to the overflow of noradrenaline in the ischaemic myocardium
is the release of glutamate that occurs during anoxia in isolated rat cerebral
cortical synaptosomes (Kauppinen and Nicholls, 1986; Kauppinen etal., 1988;
and Sanchez-Prieto and Gonzalez, 1988).
Anoxia in the brain is known to cause a large release of glutamate which may be
responsible for the irreversible damage to neurons that occurs under these
conditions. Two pools of glutamate were identified in brain synaptosomes. The
first, a vesicular pool, can be released by calcium- and energy-dependent
exocytosis. However, as in the ischaemic myocardium, this exocytotic release fails
within the first 5 minutes after cyanide treatment of isolated synaptosomes. The
second glutamate pool is cytoplasmic and can be released via reversal of the
Na+-dependent co-transporter in a Ca2+-independent manner. This
Ca2+-independent release is activated during anoxia and becomes the major mode
of glutamate efflux. In conjunction with carrier-mediated glutamate efflux there
is a parallel decline in ATP, demonstrating the importance of energy depletion in
triggering efflux.
Whilst there are many similarities between anoxia-induced glutamate release in
synaptosomes and ischaemia-induced noradrenaline overflow in the myocardium,
it should be noted that the bulk of synaptosomal glutamate is found in the
cytoplasm rather than being sequestered within vesicles. Efflux of glutamate is
observed within the first 5 minutes after the onset of anoxia and may well occur
spontaneously under normoxic conditions as vesicular depletion of glutamate or
rundown of energy stores are not prerequisite for efflux. In contrast, significant
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noradrenaline overflow is not observed for at least 10 to 15 minutes after the
onset of total ischaemia. Before this time anaerobic glycolysis is sufficient to
maintain energy-dependent processes and prevent elevation of intra and
extracellular noradrenaline levels.
1.8.3 PC12 cells.
PC12 cells are a clonal cell line obtained from a rat phaeochromocytoma, first
isolated by Greene and Rein (1977). Most PC12 cell lines express the same
properties as adrenal chromaffin cells, such as high levels of
catecholamine-synthesising enzymes and high endogenous concentrations of
catecholamines. As in chromaffin cells, catecholamines are sequestered in
reserpine-sensitive granules, catecholamines can be released by a
Ca2+-dependent mechanism upon exposure to nicotine or high K+. Greene and Rein
(1977) characterised a transport system for noradrenaline uptake by PC12 cells
that was energy- and sodium-dependent, and was sensitive to cocaine and
desipramine. It was concluded that this was similar to neuronal uptake.,.
The uptake., system of PC12 cells has since been extensively characterised
(Bonisch etai, 1984). When PC12 cells were loaded with [3H] noradrenaline in
the presence of reserpine, to inhibit vesicular uptake, and pargyline, to inhibit
MAO, the label accumulated in the cytoplasm. On exposure to agents that cause an
influx of sodium, such as veratridine, or to a sodium-free medium,
carrier-mediated efflux of [3H] noradrenaline was observed. This efflux showed
similar properties to that observed in ischaemic hearts in that it was
calcium-independent and sensitive to blockade by cocaine and desipramine. The
observation that carrier-mediated efflux occurs in PC12 cells suggests that,
under the right conditions, such a reversal of the uptake., carrier would also
occur in chromaffin cells. It should be noted that observations on PC12 cells
relate solely to [3H] noradrenaline, and not to efflux of endogenous
catecholamines, and this efflux was only observed in response to artificially
imposed conditions. There are no reports on the effects of anoxia on catecholamine
efflux in PC12 cells.
1.8.4 Adrenal glands in vivo and in vitro.
While there are no reports of carrier reversal in chromaffin cells there is
indirect evidence to suggest that such a system, as described in PC12 cells, will
also operate. Bulbring et al. (1948) studied the secretion of adrenaline from
29
perfused dog adrenal glands. When perfused with nitrogen-saturated blood there
was a significant overflow of adrenaline within 30 minutes. A similar effect was
demonstrated by injection with potassium cyanide which produced an immediate
increase in adrenaline output.
More recently, hypoxia during birth has been associated with a large release of
catecholamines from the adrenal medulla in humans. These catecholamines are
essential in protecting the neonate from the harmful effects of hypoxia, and in
survival outside the womb (Lagercrantz and Slotkin, 1986). In neonatal rats the
release of adrenal catecholamines caused by hypoxia occurs independently of
sympathetic stimulation since splanchnic control of adrenomedullary function is
absent at birth (Slotkin and Seidler, 1988). This suggests that some alternative
mechanism, in direct response to the hypoxic state, is responsible for the release
of adrenomedullary catecholamines during birth.
1.9 Outline of project.
It was proposed to use isolated bovine adrenal chromaffin cells as a model for
sympathetic nerve terminals to study the mechanism of catecholamine release
under "ischaemic" conditions. Non-exocytotic release can be identified by its
calcium-independence and sensitivity to uptake1 blockers. Although
carrier-mediated efflux has been demonstrated in isolated sympathetic neurons
and PC 12 cells, it has not been demonstrated under conditions designed to simulate
myocardial ischaemia. Pilot experiments carried out in this laboratory suggested
that such a release does occur. Chromaffin cells made anoxic with oxygen-free,
substrate-free buffer released catecholamines within the first hour. This release
was reduced in the presence of desipramine. It was proposed to use isolated
chromaffin cells to establish the exact metabolic conditions required to evoke
catecholamine release, that is, the dependence of release on oxygen deprivation and
lack of glycolytic substrates. The cellular events leading up to efflux, such as
release from granules to cytosol, could then be investigated.
Energy depletion of the cells under anoxic conditions could be monitored by
measuring cytosolic ATP levels, following the bioluminescence of the firefly
luciferase/luciferin reaction. It is possible to gain direct access to the cytosol by
permeabilisation of chromaffin cells with digitonin, a process that leaves granule
membranes intact. This method would also allow direct measurement of other
cytosolic parameters such as Na+ and catecholamines. The Na+-dependence of
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carrier-mediated efflux could also be investigated not only by altering
extracellular Na+ concentrations but also by monitoring the routes of Na+ influx
under anoxic conditions with 22Na+. Similarly, fluorescent indicators could be
utilised to measure changes in intracellular pH and calcium levels. It was hoped
that detailed understanding of the mechanism of catecholamine release might
suggest new methods of preventing such release which would be effective under
ischaemic conditions but would not interfere with normal adrenergic regulation of
cardiovascular function.
During the development of this project it was observed that the release of
catecholamines from chromaffin cells evoked by "ischaemic" conditions did not
share the same characteristics as carrier-mediated efflux. Furthermore, this
release was found to be distinct from normal exocytotic release evoked by nicotine
or high K+. Therefore, this project developed into an investigation of the
mechanism of this "ischaemia"-induced release and a reassessment of the
observations in ischaemic hearts that led to the mechanism of carrier-mediated
efflux being postulated. It has also raised important questions concerning the







All chemicals were of analytical grade or the highest chemical purity available and
were supplied by the Sigma and BDH Chemical Companies, both of Poole, Dorset,
U.K. All radiochemicals were obtained from Amersham International, Amersham,
Bucks, U.K. Scintillation fluid was obtained from LKB, Loughborough,
Leicestershire, U.K.
Cell culture materials were obtained from Gibco-Ltd, Paisley, Scotland. Luciferin
and luciferase were obtained from Boehringer Mannheim GmbH, Biochemica, West
Germany. Fura-2/AM was obtained from Novabiochem (U.K) Ltd, Nottingham,
England.
Ethylisopropylamiloride was kindly supplied by Prof. F. Lang, Institut Fur
Physiologie, University of Innsbruck, Austria.
Samples of (+) and (-) oxaprotiline were a gift from Dr. J. Stephens, Institute of
Psychiatry, London, England.
Caicium-free Locke's solution
154mM NaCI; 5.6mM KCI; 5.5mM glucose; 5.0mM Hepes; 3.6mM NaHC03; 5
i.u/ml penicillin; and 5p.g/ml streptomycin; pH 7.4.
Calcium-free Krebs Rinaer buffer
145mM NaCI; 5.0mM KCI; 1 .OmM NaH2P04; 10mM glucose; and 20mM Hepes; pH
7.4.
Locke's solution
154mM NaCI; 5.6mM KCI; 5.5mM glucose; 5mM Hepes; 2.2mM CaCI2; and
1.2mM MgS04;pH 7.4.
ATP assay buffer
154mM NaCI; 2.6mM KCI; 2.15mM K2HP04; 0.85mM KH2P04; 2.2mM CaCI2;
1.18mM MgS04; and 10mM glucose; pH 7.4.
Veronal buffer
50mM Na barbitone; 85mM NaCI; 0.5% (w/v) BSA; and 0.01% (w/v) NaN3;
pH8.0.
Horse serum buffer
2.5% (w/v) BSA; 0.5mg/ml NaN3; 5% (v/v) inactivated horse serum; 20mM
Tris-HCI; and 0.9% (w/v) NaCI; pH 7.2.
Krebs-Henseleit solution
144.14mM NaCI; 4.02mM KCI; 1.85mM CaCI2; 1.05mM MgS04; and 10mM
glucose; pH 7.4; and 26mM NaHC03.
Diaitonin permeabilisation buffer




2.2 Isolation and maintenance of bovine adrenal medullary chromaffin cells .
Two methods have been employed to isolate chromaffin cells.
Method 1
Chromaffin cells were isolated from bovine adrenal glands by a modification of the
method of Wilson and Viveros (1981). All solutions used were obtained sterile or
were prepared in deionised water and sterilised by filtration through 0.22pm
filters. All glassware was sterilised by autoclaving. Bovine adrenal glands were
obtained from the local slaughterhouse as soon as possible after slaughter of the
animal. Glands were transported to the laboratory encased in fat, in calcium-free
Locke's solution (CFL). All glands collected were trimmed of fat and only those that
were a healthy pink colour in appearance with no obvious deformities were used.
Three to four glands were generally selected for further processing. These were
fine-trimmed of fat leaving a "collar" round the adrenal vein for cannulation. The
adrenal vein was cannulated with plastic tubing attached to a 20ml syringe
containing CFL prewarmed to 37°C. Any leakages were stopped with ligatures.
Multiple slits, 1 mm in depth, were made in the cortex of the gland to allow
perfusion of the buffer through the gland. The cannulated glands were then attached
to a multichannel peristaltic pump, and the glands perfused retrogradely with CFL
at 37°C for 20min at a flow rate of 5 to 10ml/min, to wash out red blood cells.
Perfusion of the glands was then changed to CFL containing 0.1% (w/v)
collagenase; 0.5% (w/v) bovine serum albumin (BSA); and 15pg/ml
deoxyribonuclease for 15 to 30min. Perfusion time was adjusted depending on the
specific activity of the collagenase preparation. The glands were washed free of
collagenase by perfusion with CFL for a further 5 to 10min. The medullae were
then removed by dissection and finely minced in a small volume of CFL under
sterile conditions. The mince was further digested for 10min, 37°C, with fresh
collagenase solution with intermittent stirring. The crude cells were filtered
through 250pm nylon mesh and collected by centrifugation for 10min at
1000rpm (85xg). Pellets were resuspended in CFL, washed and filtered through
85pm nylon mesh a further two times. Cells were resuspended in DMEM, 37°C,
after the final wash and recentrifugation. Resuspended cells were mixed with
Percoll (14ml cells per 12.6ml Percoll), the latter prepared by mixing 9 vol of
Percoll with 1 vol of 10x CFL and adjusting to pH 7.4. Each Percoll gradient took
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approximately 100x106 cells. The cell suspensions were placed in sterile
polycarbonate centrifuge tubes with caps and centrifuged at 15000rpm
(20000xg) for 20min at 20°C in a Beckman rotor (50.2Ti type). The chromaffin
cell fraction was collected and washed three times in DMEM by centrifugation at
1000rpm (85xg) for 10min. Finally the cells were resuspended in DMEM prior
to plating.
Method 2
The second method used to isolate chromaffin cells was modified from that of
Knight and Baker (1983). Four adrenal glands collected and trimmed of fat, as
described above, were injected via the adrenal vein with 3x10ml calcium-free
Krebs Ringer buffer (KRB) to wash out red blood cells and tissue debris. Each
gland was then injected with 2x5ml 0.1% (w/v) protease, incubating the glands
for 15min, 37°C, after each injection. Medullae were then removed by dissection
and minced in KRB under sterile conditions. The minced medullae were further
digested with 0.1% (w/v) collagenase and 15(ig/ml deoxyribonuclease, in a tissue
culture flask, made up to a final vol of 10ml plus 10ml per gland with KRB. After
gassing the mince for 2min with 95% 02/5% C02 the flask was vigorously
shaken at room temp for 20 to 30min. The resulting cell suspension was filtered
through muslin prior to filtering through 250p.m nylon mesh. All subsequent
washing and purification steps were carried out as described in Method 1.
2.2.1 Cell viability
Cell viability and yield were determined by diluting 50pJ cell suspension with
50pl trypan blue (0.04% (w/v) in phosphate buffered saline). Trypan blue
exclusion indicated cell viability as observed using phase contrast microscopy.
Usually 90 to 95% of cells isolated by these methods are viable.
2.2.2 Culture conditions
Cells were diluted to the required density with plating medium consisting of 50%
DMEM and 50% Ham's F-12 nutrient mix with 5mM Hepes and 2.438g/l NaHC03
(pH 7.4 at 37°C and 5% C02). This was supplemented with 4% (v/v) foetal calf
serum; 10i.u/ml penicillin; 10|ig/ml streptomycin; 10pg/ml gentamycin;
25pg/ml fluorodeoxyuridine; and 0.25pg/ml fungizone. Just before use 3jj.g/ml
cytosine arabinoside and 50pg/ml ascorbate (pH 7.4) were added to the medium.
Cells were plated at a density of 0.5x10® cells/ml in 24-well tissue culture
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plates, 1 ml/well, unless otherwise stated. Cell cultures were maintained at 37°C
in a humidified atmosphere containing 5% C02. Cultured cells were utilised after
a minimum of 2 days in culture. If utilised after 4 to 5 days in culture plating
medium was replaced with fresh medium minus foetal calf serum and cytosine
arabinoside, supplemented with fresh ascorbate.
2.3 Catecholamine secretion
Chromaffin cells cultured in multiwell plates were utilised for secretion
experiments. Plating medium was replaced with 1ml Locke's solution with or
without secretagogue. After 10min at 20°C the supernatant was removed and cells
were lysed by addition of 1ml Locke's solution plus 1% (w/v) Triton X-100. Both
cell supernatants and cell lysates were assayed for catecholamine content
immediately, or frozen and assayed at a later date.
2AI3H] Noradrenaline labelling of chromaffin cells.
Chromaffin cells in multiwell dishes were incubated overnight at 37°C with
0.3ml DMEM containing 1|i.Ci(37Bq)/0.3ml d,l [3H] noradrenaline, specific
activity 8 to 15Ci (296 to 555Bq)/mmol and 0.01% (w/v) ascorbic acid
(Kilpatrick et a/., 1980). The cells were then washed 2x by incubating in 1 ml
DMEM for 15min at 37°C. Total uptake of [3H] noradrenaline by the ceils was
determined by lysing the cells with 0.3ml Locke's solution plus 1% (w/v) Triton
X-100 and counting aliquots in a liquid scintillation counter. Alternatively, when
[3H] labelled cells were used to study secretion, experiments were initiated by
replacing the DMEM with 0.6ml Locke's solution with or without secretagogues.
After time the supernatant was removed and the radioactivity remaining in each
well determined by adding 0.3ml Locke's solution plus 1% (w/v) Triton X-100.
Aliquots of supernatant and cell lysates were then counted for radioactivity (see
section 2.5).
2.5 Uptake of 22Na+ bv chromaffin cells.
Medium was aspirated from chromaffin cells in multiwell dishes and replaced
with Locke's solution, 250jxl/well, containing 2.6pCi (96.2Bq)/ml ^NaCI. After
time 10Ojxl aliquots were removed for catecholamine determination. The
remainder was aspirated and wells washed 3x with Locke's solution within 10sec.
Cells were lysed with Locke's solution plus 1% (w/v) Triton X-100,
350(il/well, and 50pl aliquots taken for catecholamine determination or
measurement of 22Na+ by scintillation counting. 22Na+ uptake was calculated
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from the initial specific activity of the Locke's solution and expressed as nmol of
22Na+ taken up/well.
2.6 Scintillation counting
Radioactive samples were mixed with 2ml Optiphase 'Safe', a multi-purpose
liquid scintillation cocktail. Cpm were measured for 2min and automatically
corrected for quenching to give dpm. External standards of known radioactivity
were also counted for calibration. All samples were treated in the same way.
2.7 Assay Methods
2.7.1 Catecholamine assay
Catecholamines were assayed fluorimetrically by the trihydroxyindole method of
von Euler and Lishajko (1961). Cell supernatants or lysates were adjusted to pH
6.2 with 0.01 M potassium phosphate buffer (pH6.2) in a final vol of 1ml.
Oxidation of catecholamines was carried out for 3min by addition of 0.1 ml 0.25%
(w/v) potassium ferricyanide. The strongly fluorescent trihydroxyindole formed
by the addition of alkali was stabilised by including ascorbic acid and 1,2
diaminoethane in the mixture. Two ml of this alkali-ascorbate were added (9vol
4M NaOH: 1vol 2% (w/v) ascorbic acid: 0.2vol 1,2 diaminoethane). Fluorescence
was measured after 15min and within 2h at 2 sets of excitation/emission
wavelengths 395/490nm and 436/540nm using a Perkin Elmer 300
fluorescence spectrophotometer. Calibration was carried out by comparison with
known adrenaline and noradrenaline standards which fluoresce at different
intensities at the 2 sets of wavelengths.
Catecholamine content was calculated as follows:
Aa - fluorescence of 1 nmol adrenaline at a)
Ab - fluorescence of 1nmol adrenaline at b)
Na - fluorescence of 1 nmol noradrenaline at a)
Nb - fluorescence of 1 nmol noradrenaline at b)
where a) = 395/490nm and b) = 436/540nm.
Noradrenaline (nmol) = y = (M Ab/Aa) -N
(Na Ab/Aa) - Nb
Where M = fluorescence at 395/490nm and N = Fluorescence at 436/540nm
Adrenaline (nmol) = x = N - v Nb
Ab
Results were corrected to give catecholamine content (nmol/ml) and expressed as
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a percentage of the total catecholamine content of the cells. All release
experiments were carried out on triplicate wells.
This method enabled a differential estimation of noradrenaline and adrenaline to be
made by measuring the excitation-emission of a single sample at two different
wavelengths. Fluorescence readings were found to increase for the first 15min but
were then stable for at least 2h, allowing a large number of samples to be
processed at any one time. Like other available methods for determining
catecholamines, such as HPLC or radioenzymatic assay, this method is only as
accurate as the standards used. There is a linear relationship between fluorescence
intensity and catecholamine concentration over the range found in chromaffin cells
(Fig. 2.1). Standards were always assayed in triplicate, dilutions being made up
fresh each time and the concentration adjusted by measuring the absorbance of a
1/100 dilution at 280nm. The stock (10mM) was then diluted accordingly to give
a working concentration of 1mM. The reproducibility of the assay was assessed by
comparing the fluorescence readings of adrenaline and noradrenaline standards at
the two sets of wavelengths from 30 different assays (Table 2.1). The coefficient
of variation was calculated for these standards and was less than 10% in each case.
This gives an indication of the reliability of the assay as a reproducible method for
measuring catecholamines.
Table 2.1
Differential estimation of noradrenaline and adrenaline.
Ab Na Nb
mean±SE 15.4 ±0.24 14.0 ±0.24 25.3 ± 0.42 4.5 ±0.1
Values are the absolute fluorescence means ± SE of 30 estimates of 1 nmol
adrenaline or noradrenaline measured at 395/490nm (Aa and Na) and
436/540nm (Ab and Nb).
2.7.2 Lactate dehydrogenase assay
Lactate dehydrogenase was measured by monitoring the formation of NADH from
NAD at 340nm as described by Kelner et al. (1986). Aliquots (1 OOjil of cell
supernatant or lysate) were microfuged at high speed for 5min then incubated
with 60mM lactate/1 OOmM Tris, pH 9.0 and 1 mM NAD in a final vol of 1.1 ml at
20°C for 30min.
2.7.3 Protein estimation bv dve binding
The method used was that described by Bradford (1976). The dye binding assay
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used gave an absorbance change of 0.25/5pg of BSA and was linear between 2 to
8(j.g. The concentration of BSA was calculated from its absorbance at 280nm.
2.7.4 ATP assay method
ATP was assayed by monitoring the bioluminescence of the firefly
luciferase/luciferin system, (White etai, 1987; Rojas etal., 1985). Highly
purified luciferase and luciferin were used. Luciferase was made up in 1ml
ice-cold Tris-acetate buffer, 0.5M, pH 7.5, to give a luciferase concentration of
1mg/ml. This could be stored frozen. When required aliquots were diluted with
assay buffer plus 0.5% (w/v) BSA to give a working concentration of 200pg/ml.
Luciferin was made up fresh each time in assay buffer to a final concentration of
1.25mg/ml. Luciferin solutions were stable for up to 48h when stored at 4°C.
ATP (disodium salt) for calibration was made up in 0.01 M potassium phosphate
buffer containing 4mM magnesium sulphate, pH 7.4. Concentrations were
quantitated spectrophotometrically at 259nm = 0.154). Serial dilutions
of the stock solution were made in the potassium phosphate buffer. The assay was
performed as follows: equal volumes of luciferase and luciferin were mixed prior
to use; 20pl ATP standard of known concentration was added to 180p.l assay buffer
in a glass scintillation vial; 10pl luciferase/luciferin mixture was added and
bioluminescence monitored over3min in a Packard 3330 Tri-carb scintillation
spectrometer, with coincidence counting. Mean cpm were plotted on a log-log scale
to give a standard curve that was linear between 10"6M and 10"8M ATP, (Stanley
and Williams, 1969) as shown in Fig 2.2. The light intensity was essentially
constant for at least 10min in response to low concentrations of ATP. The enzyme
concentration used was kept to a minimum so that the rate of ATP consumption was
low enough to prevent the ATP concentration changing during the reaction.
2.7.5 On-line detection of ATP release from isolated chromaffin cells in
suspension.
Freshly isolated chromaffin cells were plated in bacteriological petri dishes at a
density of 0.5x106 cells/ml, in plating medium as previously described. Cells
treated in this way do not attach to the plates but remain in suspension. 20pl of
cell suspension (approximately 1000 to 2000 cells) was added to 180pl assay
buffer in the presence or absence of secretagogues, plus 10pl luciferin/luciferase
mixture. Light output was monitored over time as described. At the end of each
assay total ATP content of the cells was determined by addition of 20jxl assay




Fig 2.1 Catecholamine standard curve. Fluorescence of known standards of
adrenaline and noradrenaline was measured at two different















Fig 2.2 ATP standard curve. The light intensity of a range of ATP concentrations
was recorded and plotted as log cpm versus log [ATP] M, means ± SE of
triplicate determinations.
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from the standard curve (Fig 2.2) the system being calibrated after every assay
(see Chapter 6).
2.7.6 Detection of granule marker proteins usinn ELISA.
Ninety-six well Falcon ELISA plates were coated with poly-L-lysine (20mg/m!
in 10mM Mes/Tris buffer, pH 6.5) for 1h at 37°C. The antigen was added to
coated plates, 10OfxI/well and incubated for 90min at 37°C. If necessary the
antigen was diluted in 10mM Mes/Tris buffer, pH 6.5. The antigen used comprised
either chromaffin granule lysate or supernatants from chromaffin cells subjected
to a variety of conditions. Excess buffer was removed by washing 4x with Veronal
buffer. After washing wells were blocked by incubation with 100|i.l/well Veronal
buffer for 1 h, 4°C. First antibody (diluted 1 in 100 in horse serum buffer) was
added and wells incubated for 90min, 37°C. After washing 4x with Tris-buffered
saline (TBS) plus 0.1% (v/v) Tween 20 wells were treated with second antibody
anti-rabbit IgG-biotin (diluted 1 in 1000 in TBS plus 5% (v/v) sheep serum)
for 2h, 37°C. After further washing plates were incubated with
streptavidin-peroxidase (diluted 1 in 1000 in TBS) for 1h. A final washing took
place prior to development of the plates. To develop 100pJ ABTS (0.55mg/ml in
phosphate/citrate buffer) plus 0.002% (v/v) H202 was added to the wells and
incubated for 10min, 37°C. Colour development was stopped with 0.1 M citric
acid. Colour intensity was quantitated by measuring the absorbance of each well at
410nm using a Dynatech Microplate reader.
2.7.7 Determination of neuropeptide Y
Endogenous neuropeptide Y was determined by radioimmunoassay as described by
Richardt et at. (1988). RIA was carried out on cell supernatants following 10min
treatment with Locke's buffer alone or plus 10pM nicotine or metabolic
inhibitors. Neuropeptide Y determination was carried out by Dr. M. Haass, Dept. of
Cardiology, University of Heidelberg, Heidelberg, Federal Republic of Germany,
and this assistance is gratefully acknowledged.
2.7.8 Cortisol determination
Cortisol was measured in fractions taken from Percoll gradients by
radioimmunoassay by Mr. E. Lightly, Dept. of Clinical Chemistry, Edinburgh
Royal Infirmary, Edinburgh, Scotland.
2.8 Detection of chromaffin granule proteins bv PAGE and Western blotting.
Proteins were separated on 10% acrylamide gels in the presence of SDS, (Douglas
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and Butow, 1973). The discontinuous buffer system of Laemmli and Favre
(1973) was used. After separation on polyacrylamide gels proteins were
electrophoretically transferred to nitrocellulose for decoration with antibodies.
Cell supernatants and granule lysate were microfuged at high speed for 2min to
remove any cell debris and then diluted 3:1 in sample buffer plus 0.001 %(w/v)
bromophenol blue and 10jiM DTT. The protein content of granule iysate was
determined by Bradford assay and then diluted accordingly to give a predicted
protein content of 0.05 to 0.4p.g (that predicted to be present in the cell
supernatants).
2.8.1 Immunoblottino.
A horizontal electroblotting apparatus was used to transfer proteins from
polyacrylamide gels to nitrocellulose sheets using wetted filter paper as the only
buffer reservoir as described by Kyhse-Anderson (1984). Electrophoretic
transfer took 1 h at a constant current of 0.8mA/cm2. The nitrocellulose was
blocked by washing for 1h in TBS plus 0.5% (v/v) Tween 20, (Batteiger et
al.A 982); this buffer was also used for all subsequent washing steps. The blot
was then incubated with first antibody (diluted 1 in 100 in horse serum buffer)
for 90min, 20°C. Following four washes the blots were incubated for 2h, 20°C,
with anti-rabbit IgG-biotin (diluted 1 in 1000 in TBS plus 5% (v/v) sheep
serum). Finally blots were decorated with 12^l-streptavidin (5cps/pJ) for 1h
and washed a further 4x. After drying autoradiography was carried out at "70°C.
Scanning of autoradiographs using a Joyce-Loebl chromoscan 3 and measurement
of peak integrals gave a numerical value for band intensity.
2.9 Overflow of noradrenaline from electrically-stimulated and ischaemic rat
hearts.
Perfusion of hearts in situ was carried out as described below by Dr. X. Du,
Cardiovascular Research Unit, Hugh Robson Building, George Square, Edinburgh,
Scotland and his assistance and advice is gratefully acknowledged. Rats (Sprague
Dawley strain) weighing 200 to 250g were anaesthetised with thiobutabarbital
(60mg/kg, i.p.). The thorax was opened and a cannula inserted and tied into the
ascending aorta for retrograde coronary perfusion (Langendorff technique).
Hearts were perfused at 4.5ml/min with a modified Krebs-Henseleit solution,
KHS, (Dart et a/.,1984), gassed with oxygen and with pH adjusted to 7.4 with
C02. Temperature at the point of entry into the aorta was 37.5°C. A polyethylene
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cannula was introduced into the heart through the inferior vena cava for collection
of coronary venous effluent. The left cervicothoracic ganglion and exciting cardiac
nerves were dissected free for electrical stimulation. Stimulation was performed
with bipolar platinum electrodes with a frequency of 5Hz for 1min. Hearts were
subjected to 40min stop-flow ischaemia during which time their temperature was
maintained by covering the heart with a thermostatted chamber. Coronary venous
effluent was collected for 1,5min after 2x1 min periods of nervous stimulation,
with a 15min interval between each period, and for 3x1 min periods by
reperfusion following stop-flow ischaemia. Oxaprotiline (300nM) was introduced
15min prior to the second nervous stimulation and was present throughout the
subsequent experiment. Hearts were weighed at the end of each experiment.
Samples for noradrenaline estimation were placed on ice and stabilised by addition
of an equal vol of perchloric acid to give a final concentration of 6N. All samples
from these experiments were assayed by the radioenzymatic method of Da Prada
and Zurcher (1976) by Miss M. Millar, Cardiovascular Research Unit, and this is
gratefully acknowledged.
2.10 Fura-2 measurement of cvtosolic free Ca2+ in suspensions of chromaffin
ceils.
Cells were plated at a density of 1x106 cells/ml in petri dishes. After a minimum
of 3 days in culture the media was removed and replaced with 5ml DMEM plus 1%
(w/v) BSA at 37°C. The cells were gently scraped off the dish and incubated at
room temp with 2|j.M Fura-2/AM, with gentle shaking. After 1h the cells were
spun down and washed 2x with Ca2+-free KRB at 37°C. Cells were finally
resuspended at a density of 1x106 cells/ml. Loaded cells were kept in the dark on
ice to minimise leakage of the fluorescent indicator. All assays were performed at
37°C using a thermostatted cuvette holder fitted with a magnetic stirrer.
[Ca2+]| was measured as follows: small aliquots of cells, approximately 2x105
were transferred to cuvettes containing KRB or Ca2+-free KRB (to a final vol of
2.5ml). Ceiis were aiiowea to equilibrate for 5min with continuous stirring.
Continuous monitoring of Fura-2 fluorescence was carried out in a Perkin-Elmer
LS3B spectrometer linked to an IBM PC. Software supplied by Perkin-Elmer Ltd
provided the means of controlling the spectrometer, driving the excitation
monochromator between 2 wavelengths alternately (340 and 380nm) whilst the
emission monochromator remained fixed at 510nm. Recording was paused to allow
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addition of secretagogues. Following each experiment 1mM C12Eg was added to the
cells allowing measurement of Rmax to be recorded. 50p.l of 0.2M EGTA and 1M
Tris (pH 10.2) was then added to reduce the Ca2+ concentration to subnanomolar
levels, thus allowing Rmin to be recorded.
Data was collected and ratioed. Calcium concentration was determined using the
equation of Grynkiewicz et at. (1985) and a Kd value of 225nM.
[Ca2+]| = R-Rmin x Kd x SFB
Rmax - R
SFB is the ratio of the Fura-2 fluorescence values at 380nm in Ca2+-free and
Ca2+-saturated solutions. This was determined as described by Malgordli et at.
(1987) using reference standards of suspensions of intact cells in which [Ca2+]j




Isolation of Bovine Adrenal Chromaffin Cells
3.1 Introduction
Isolated adrenal medullary chromaffin cells have long been used to study
synthesis, storage and secretion of catecholamines in vitro (Douglas etal., 1967).
Many different methods for isolation of chromaffin cells and maintenance in
culture have been described (for review of methods see Livett, 1984). Two
methods utilised in this study are discussed, and characterisation of a functional
chromaffin cell system is described.
3.2 Results
3.2.1 Isolation.
Both isolation methods described (Chapter 2.) gave an optimum yield of up to 50 x
106 cells/ gland. More than 95% of these were viable, as shown by exclusion of
trypan blue. This is comparable with yields obtained by other workers, for
example, Fenwick etal. (1978) and Wilson and Viveros (1981).
The collagenase digestion step is critical in obtaining a high yield of viable cells.
The time required for collagenase digestion was varied from 15 to 30min
depending on the enzymic activity of the particular collagenase preparation used.
Most collagenase preparations also contain a number of protease activities which
are highly variable. Thus not all batches of collagenase could be relied upon to
behave in the same way and numerous batches tested caused overdigestion of tissue
and subsequent cell lysis. This could be prevented to some extent by altering the
collagenase digestion time and keeping the concentration used to a minimum. The
problems of collagenase overdigestion have been reported elsewhere (Livett,
1984; and Almazan etal., 1984) and it would seem that it is the contaminants in
the mixture that are responsible rather than the collagenase itself.
The second method employed consistently gave higher yields than the first method,
possibly due to a more reliable collagenase preparation. It is important to include
DNAse type 1 in the digestion cocktail to minimise the amount of filamentous
material present and prevent cell aggregation. It should be noted that once isolated,
chromaffin cells obtained from either method behaved identically under all
conditions described.
3.2.2 Purification of cells.
Chromaffin cells have a different buoyant density and different sedimentation
properties from the much smaller erythrocytes or lipid-containing cortical cells,
enabling them to be purified on a self-generating Percoll gradient. The top 5ml of
the gradient which comprises cell debris was discarded. Below this is found a
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broad band of cortical cells (density 1.054g/ml), which was also discarded. These
cortical cells cannot be distinguished from chromaffin cells by their appearance
in the light microscope. Comparison of Cortisol with catecholamine content in this
fraction, however, demonstrates that this band contains the majority of cortical
cells (Table 3.1). Chromaffin cells form a broad band of density about 1.06g/ml
in Percoll. They were collected from a density of approximately 1.06g/ml to
1.08g/ml as determined using density gradient marker beads. Below this is a thin
band of erythrocytes, density 1.13g/ml.
Purification of chromaffin cells from contaminating cortical cells and
erythrocytes can be demonstrated by measurement of Cortisol and catecholamines
in each fraction. Table 3.1 shows that the chromaffin cell fraction contains the
highest level of catecholamines compared with other fractions. Furthermore,
contamination with cortical cells is minimal.
3.2.3. Cell morphology.
The morphology of purified chromaffin cells was examined after 0,1,2 and 3
days in culture with a phase contrast microscope. On day 0, only a few hours after
isolation, chromaffin cells are beginning to attach to the culture wells and are
spherical in shape. The majority of cells are phase bright with large nuclei and a
granular cytoplasm, and are about 20p.m in diameter; there are a few much
smaller contaminating erythrocytes. After 24h in culture the cells have begun to
spread out over the plastic surface and have a tendency to form into adherent
chains. Within the next 2 to 3 days the cells are firmly attached and have flattened
out. When seeded at low density (0.5 x 106/ml) the cells send out axon-like
processes which are a characteristic feature of chromaffin cells grown in the
presence of serum as shown in Fig 3.1. Serum supplementation is required for
cell attachment but after this time (2 days) cells can be maintained in
serum-free medium.
3.2.4, Maintenance pf ceils in culture,
Under the conditions described chromaffin cells maintained a constant
catecholamine content, as shown in Fig. 3.2, for up to 9 days in culture. Other
workers report that chromaffin cells retain their catecholamine content and
functional properties for at least 3 weeks (Wilson and Viveros, 1981). I found,
however, that after more than 7 days in culture chromaffin cells tend to lose their
ability to respond to secretagogues (Fig. 3.3) and an increasing number of cells





































































































Fig 3.1 Phase-contrast micrograph of isolated chromaffin cells after 3 to 4 days
in culture. Cells were plated at a density of 0.5x106 cells/well, at which density
they produced axon-like processes, characteristic of chromaffin cells in culture
after a few days.
U;:
,)'v-
ft - .;c> :.v-.





• . ••• .





• 0 • .
. -w
0 ''•••*
• • • ' -
•••*■*• * • ■ • •
\ • • • •; r. .1
•••
' r ■ ■ . V
■ t
47
chromaffin cells were never used for experiments beyond day 7.
As discussed, chromaffin cells require at least 1 day in culture to adhere firmly to
the culture surface. Furthermore, freshly isolated cells show a relatively poor
secretory response to nicotine, but this improves with time, reaching a peak on
the third or fourth day of culture. It has been suggested (Almazan et at. 1984)
that the impaired responsiveness after isolation results from the collagenase
digestion step. This effect is not seen with K+-evoked release, suggesting that the
collagenase treatment is affecting the nicotinic receptor selectively. After a few
days in culture, however, the secretory response is fully restored. In
consequence, cells were always cultured for at least 2 days before experiments.
3.2.5. Biochemical studies on secretion.
The secretory response of chromaffin cells in culture was assessed by measuring
the release of catecholamines in response to a variety of secretagogues. The
response of the cells to the agonist nicotine was generally used as an indicator of
cell viability prior to any experiments being carried out. Endogenous
catecholamines were measured by spectrofluorimetry (as described in Chapter
2.). A wide variation was found in both basal and stimulated catecholamine release
between different batches of cells. On average there was a 3 to 4 fold increase in
catecholamine release in response to 10p.M nicotine (basal release 4.1% ±2.9
compared with a nicotine-stimulated release of 14.8% ±4.4, n=20). In general,
results given in this thesis are expressed as amount secreted as percent of total
catecholamines ± SE for triplicate determinations from one batch of cells. All
experiments were, however, carried out on more than one cell preparation.
Incubation of chromaffin cells for 10min with a range of secretagogues resulted in
a significant release of catecholamines above basal levels (Fig. 3.4). Both the
physiological secretagogue, acetylcholine, and its analogue, nicotine, show a
similar response. High K+ bypasses the nicotinic receptor and elicits a response
by direct depolarisation of the plasma membrane. Ba2+ evokes a response that is
almost 3 times greater than that seen with other secretagogues. It is thought that
Ba2+ is able to enter chromaffin cells via both voltage-sensitive and nicotinic
Ca2+ channels and induce secretion, possibly by substituting for Ca2+ since
Ba2+-induced secretion is independent of external Ca2+ (Forsberg and Pollard,
1988). Alternatively, Ba2+ may trigger secretion by displacing Ca2+ from
internal sites.





















Fig 3,2 Maintenance of catecholamine content with time in culture. The total
catecholamine content of chromaffin cells was measured over 9 days.
Results are expressed in nmol/10* cells, means ± SE of triplicate




















Fig 3.3 Responsiveness of cells to nicotine as a function of time in culture.
Catecholamine release was measured after 10min treatment with
Locke's buffer or Locke's buffer plus 10p.M nicotine. The results shown
are means ± SE of triplicate determinations (error bars lie within the
symbols used). Basal release values have not been subtracted from













Basal 10(iM Nicotine 0.1 mM ACh O.lmMKCI Ba 2+Locke's
Fiq 3.4Catecholamine release in response to various secretagogues. Cells were
challenged for 10min with Locke's buffer or Locke's buffer plus
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Fig 3.5Responsiveness of cells to nicotine, 0 to 40p.M. Cells were challenged for
10min with a range of nicotine concentrations. Results are expressed as
percentage catecholamine release, means ± SE of triplicate
determinations (error bars lie within the symbols used).
50
secretagogue. Fig. 3.5 shows the response to a range of nicotine concentrations,
maximal secretion being evoked by lOpM nicotine after exposure for 10min. This
is similar to that reported by other workers (Knight and Baker, 1983;
Marley, 1988) in that the concentration of nicotine giving half-maximal release
was approximately 10"6M and high concentrations of nicotine released less
catecholamine. The latter effect is due to desensitisation of the secretory response.
Desensitisation also occurs during maintained exposure to the agonist (Fig. 3.6).
Secretion is transient and returns to basal levels within a few min of exposure to
nicotine. This is consistent with other studies which monitored the time course of
secretion by continuous assay of ATP release (Rojas etal., 1986). This type of
response has been associated with a rapid nicotine-induced actin disassembly
which occurs within the first min of stimulation (Cheek and Burgoyne, 1986):
actin filament reassembly in the cortical region of the cell may then prevent
further exocytotic release. The Ca2+ dependence of nicotine-evoked catecholamine
secretion is shown in Fig. 3.7. When stimulated with nicotine in a Ca2+-free
buffer or in the presence of the Ca2+-channel blocker, verapamil, secretion was
completely abolished.
Chromaffin cells exist as two populations of cells, those containing mainly
adrenaline, and those containing mainly noradrenaline. These two cell types
respond differentially to a variety of secretagogues. In terms of absolute amount,
adrenaline levels are higher than noradrenaline in the bovine adrenal medulla. For
example, one cell preparation gave values of 29.2 ± 0.4 nmol/106 cells
noradrenaline and 60.2 ± 0.7 nmol/106 cells adrenaline (n=9). The agonists
acetylcholine, nicotine and high K+, however, caused a preferential release of


















The results shown are percentage release of noradrenaline or adrenaline,
measured after 10 min treatment with a range of secretagogues and expressed as
means 1SE of triplicate determinations.
3.2.6. Identification of a high affinity uptake system for catecholamines.
A high affinity uptake system for noradrenaline was first characterised in
chromaffin cells by Kenigsberg and Trifard (1980). Uptake of [3H] noradrenaline
into chromaffin cells was followed for 24h (Fig 3.8). Uptake was found to be
linear over the first 8h. The rate of uptake, however, appeared to be very slow
compared to that reported by Kenigsberg and Trifaro (1980). They reported
uptake of approximately 2 to 3 pmol/5min/106 cells when cells were incubated
with 0.2p.M noradrenaline. The results shown here suggested an uptake of only
0.13 pmol/5min/106 cells. It was postulated that this discrepancy in the uptake
of noradrenaline was due to a high extracellular concentration of cold
catecholamines that would compete with the label for the uptake carrier. In order
to test this cells were treated as for uptake of [3H] noradrenaline but the label
was omitted. Samples of the incubating medium were taken over 24h and
catecholamine content determined by radioenzymatic assay (Chapter 2.). A mean
value of 732 ± 19 pmol catecholamine/106 cells (165 ± 4.5 pmol noradrenaline
and 567 ± 13 pmol adrenaline, n=15) or 1.2 p.M in the medium, was obtained
from three cell preparations. This value remained relatively constant for the
whole time course. When the concentration of cold catecholamines is taken into
consideration the rate of uptake is similar to that previously reported by
Kenigsberg and Trifaro (1980), a value of 3.610.2 pmol
noradrenaline/5min/106 cells (n=6) being calculated from my data. It was
necessary, however, to use prolonged incubations in order to allow cells to
accumulate sufficient radioactivity for subsequent experiments.




















Fig 3.6 Percentage catecholamine release in response to 10^M nicotine with
time. Results shown are means ± SE of triplicate determinations (error













Control - Calcium 10|iM Verapamil
Fig 3.7 Calcium dependence of nicotine-stimulated exocytosis. Catecholamine
release was measured after 10min treatment with Locke's buffer or
Locke's buffer plus 10tiM nicotine in the presence or absence of
extracellular calcium or plus 10p.M verapamil. The results shown are







Fig 3.8Uptake of [TH] noradrenaline. Cells were incubated with [*H]
noradrenaline for up to 24h. Uptake is expressed as pmol PH]
noradrenaline/106 cells when culture media were replaced with DMEM
plus 0.2p.M [*H] noradrenaline (Chapter 2). Values shown are means ±






Fig 3.9Inhibition of uptake of [?H] noradrenaline by uptakel blockers.
Chromaffin cells were incubated with pH] noradrenaline for 12h in the
presence of different concentrations of desipramine (DMI) and, (+) and
(-) oxaprotiline (OXA). Results are expressed as percent inhibition,
uptake in the absence of inhibitor being 100%. Results shown are means
± SE of 6 determinations.
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uptake system described by Kenigsberg and Trifard (1980). Uptake was blocked
by low temperature, metabolic inhibition and sodium depletion (results not
shown). The uptake., inhibitors desipramine and, (+) and (-) oxaprotiline
blocked the uptake of [3H] noradrenaline in chromaffin cells with a similar
sensitivity to that reported previously (Banerjee etal., 1987) and also reported
for isolated rat synaptosomes (Waldmeier etal., 1982). Fig. 3.9 shows the
sensitivity of uptake to these drugs over a concentration range of 10"8 to 10"3M.
Oxaprotiline exists as two isomers, the (+) enantiomer being up to 1000 times
more potent than the (-) form (Waldmeier etal., 1982). In chromaffin cells
(Fig 3.9) there is a 200 fold difference in the sensitivity of the two isomers for
the uptake carrier. Both forms are, however, identical in their non-specific
effects on adrenergic responses. Therefore, this sensitivity of (+) oxaprotiline
over (-) oxaprotiline to block uptake of [3H] noradrenaline must be due to its
affinity for the uptake carrier rather than to any non-specific action of the drug.
Both (+) oxaprotiline and desipramine show a similar affinity for the uptake
carrier, approximately 10"7M being sufficient to cause 50% inhibition of uptake.
Kenigsberg and Trifaro (1980) reported 60 to 80% inhibition of uptake with
10"7M desipramine. In this study it was not possible to make a direct comparison
with their results as only one concentration of noradrenaline was used. This
concentration of desipramine is, however, low enough to be almost totally
selective for the uptake carrier.
3.3. Discussion,
The evidence presented here confirms previous reports on the utilisation of
isolated chromaffin cells for studies on secretory processes. Morphological studies
show that the cells isolated by the methods described are a relatively homogeneous
population and possess all the characteristics indicative of chromaffin cells.
Catecholamines are secreted in response to various secretagogues. Acetylcholine,
nicotine and high K+ evoke secretion that is coupled to voltage-sensitive Ca2+
channels. Ba2+ elicits a much higher response that is also maintained at these high
levels for a much longer time, 55% of total catecholamine having been lost after
60min (Hunter and Phillips, 1989). In contrast, the response to physiological
secretagogues such as acetylcholine is transient and is essentially over within
10min. The response to the acetylcholine analog, nicotine, shows many of the
characteristics of exocytosis in that release is Ca2+-dependent. It is also
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temperature and energy dependent (results not shown), release being abolished at
low temperature or after depletion of ATP with metabolic inhibitors.
These studies have also identified an uptake system for noradrenaline that is
similar to that previously described in chromaffin cells (Kenigsberg and Trifarb,
1980) and in PC12 cells (Bonisch etal., 1984) Uptake of [3H] noradrenaline
was energy and Na+-dependent and sensitive to blockade by the tricyclic
antidepressants desipramine and oxaprotiline. The existence of oxaprotiline as two
isomers with differing sensitivities for the uptake1 carrier has proved
particularly useful in distinguishing the uptake-blocking capacity of the drug
from other non-specific effects.
In conclusion, the results presented here confirmed that chromaffin cells can be
maintained in culture for at least one week while retaining physiological
properties. Furthermore, these results confirm predictions that isolated
chromaffin cells will be a suitable model for studying the effects of ischaemia on
an isolated cell system.
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Chapter Four
A Model of Anoxia in Isolated Chromaffin Cells
4,1 Introduction,
Having established a viable population of cells that demonstrated all the
morphological and functional properties of chromaffin cells, it was possible to
investigate the conditions that would mimic the ischaemia-induced overflow of
noradrenaline observed in isolated rat hearts. Ischaemia itself could not be
imposed since this, by definition, implies a cessation or reduction of blood flow.
Hypoxia, where the p02 in the ischaemic zone is less than 20mmHg, is a major
feature of myocardial ischaemia and could be produced in isolated cells. Anoxia,
itself, where the p02 equals OmmHg, is only found in total global ischaemia.
Schomig etal. (1987) have demonstrated that the release of noradrenaline evoked
by anoxia in rat hearts is essentially the same in mechanism of release as that
observed during myocardial ischaemia, imposed by a cessation of blood flow. The
conditions used to induce anoxia were perfusion of the hearts with oxygen-free and
glucose-free media, or perfusion with glucose-free medium supplemented with
1 mM cyanide. A similar method of cyanide intoxication was used by Kauppinen and
Nicholls (1986) to induce anoxia in isolated cortical synaptosomes.
Non-neurogenic release of adrenal catecholamines in neonatal rats has also been
studied using conditions of hypoxia, that is, 7% oxygen for 2h (Slotkin and
Seidler, 1988), and Bulbring (1948) used conditions of nitrogen-saturation or
cyanide injection to evoke release in isolated perfused adrenal glands. This latter
model has considerable relevance to a possible model of anoxia in chromaffin cells.
It was proposed, therefore, to simulate ischaemia in chromaffin cells either by
using conditions of substrate-free anoxia, or by chemical metabolic inhibition.
Non-exocytotic release could be characterised by its calcium-independence and
sensitivity to uptake., blockade (see Chapter 1.).
4.2 Results.
4.2.1 Catecholamine release under conditions of 'anoxia' or metabolic inhibition.
Three different experimental designs were used to study the effects of anoxia on
catecholamine release from chromaffin cells.
i) Hypoxia (p02<20mmHg) was induced using a nitrogen-flushed chamber and a
cell medium of glucose-free Locke's buffer which had been deoxygenated and then
regassed with nitrogen.
ii) Total anoxia i.e p02 of OmmHg could not be achieved by deoxygenation. Anoxia
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could, however, be mimicked using metabolic inhibition, induced by using 1mM
sodium cyanide and 1 mM iodoacetate in Locke's buffer in a normal atmosphere,
iii) An alternative model of metabolic inhibition was investigated using 1pM
antimycin A and 6mM 2-deoxy D-glucose to distinguish between a real release of
catecholamines in response to anoxia and any non-specific effects induced by the
inhibitors themselves.
Initial experiments monitored catecholamine release for up to 2h since, in
isolated perfused hearts, noradrenaline overflow did not become significant until
at least 15min after the onset of ischaemia (Dart etal., 1986). Fig 4.1 shows the
release of catecholamines in response to anoxia or metabolic inhibition. A
significant release (p<0.001) of catecholamines was observed within the first
10min of anoxia or metabolic inhibition. This release was 2 to 3 times higher
than basal levels and the catecholamine was not reaccumulated over at least 2h.
Beyond this time non-specific cell lysis occurs and cells tend to lift off the culture
plates, as observed by phase contrast microscopy. Over the first hour of anoxia,
however, the chromaffin cells remained intact and morphologically identical to
control cells, demonstrated by their ability to exclude trypan blue. A similar
release of catecholamines was observed under all three conditions suggesting this
is a real response and not due to some non-specific drug action. To discount the
possibility that this observed release was limited to one cell preparation this time
course was repeated on several different batches of cells. Fig 4.2 shows the
responses obtained from three different cell preparations under conditions of
metabolic inhibition, with 1mM cyanide and 1mM iodoacetate. All three models
gave similar, and reproducible, responses in different cell preparations.
All subsequent experiments were carried out using metabolic inhibition (1mM
cyanide and 1mM iodoacetate) to simulate and study anoxic catecholamine release.
In order to prevent metabolism of catecholamines occurring under these
conditions, which are aerobic compared to the anoxic model, cells were
pre-incubated with 0.1 mM pargyline for 15min prior to metabolic inhibition.
Pargyline was used to inhibit MAO activity as previously described by Bonisch et
al. (1984). There was very little difference (p>0.1) in catecholamine release in
the presence of metabolic inhibitors with or without pargyline (Fig 4.3)
indicating that metabolism of catecholamines under these conditions is not a
problem. It is also further evidence that the cells retain their integrity since
non-specific cell lysis would result in the release of MAO into the extracellular
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Time (min)
Fig 4.1 Time course of catecholamine release under conditions of hypoxia or
metabolic inhibition. Cells were treated for 2h with Ni-saturated,
glucose-free Locke's bufferftypoxia) or Locke's buffer plus metabolic
inhibitors (1mM sodium cyanide and 1mM iodoacetate, M.I., or 1pM
antimycin A and 6mM 2-deoxy D-glucose, AntiA + 2DG). Results are
expressed as percentage catecholamine release above basal levels,
means ± SE of triplicate determinations.
15 -|
Time (min)
Fig 4.2 Response of three different cell preparations to metabolic inhibition
(1mM sodium cyanide and 1mM iodoacetate). Results are expressed as






Release of catecholamines in response to metabolic inhibition in the
presence or absence of the MAO inhibitor, pargyline. Cells were
preincubated for 15min with 0.1 mM pargyline prior to the addition of
Locke's buffer plus metabolic inhibitors. Results are expressed as
percentage catecholamine release above basal levels, means ± SE of
triplicate determinations.
Time (min)
Fig 4.4 Ten minute time course of catecholamine release under conditions of
metabolic inhibition. Results are expressed as percentage catecholamine
release above basal levels, means ± SE of triplicate determinations.
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medium with subsequent metabolism of any released catecholamines. As with the
response to nicotine, catecholamine release under conditions of metabolic
inhibition reached a maximum within 10min (Fig 4.4). Unlike the nicotinic
response (Fig 3.6), however, where catecholamine release is essentially over
within the first 60sec, there is a time lag of 2min before any significant
(p<0.001) catecholamine release is observed (Fig 4.4).
4.2,2 Characterisation of catecholamine release,
As discussed, carrier-mediated efflux of noradrenaline from ischaemic rat hearts
was characterised by its calcium-independence and sensitivity to the uptake1
inhibitor, desipramine (Dart et at., 1987). Once a model of "ischaemia-induced"
catecholamine release had been established in chromaffin cells these same criteria
were applied. Chromaffin cells were treated with metabolic inhibitors (1mM
cyanide and 1 mM iodoacetate) in Locke's buffer in the presence or absence of
extracellular calcium or in the presence of the calcium-channel blocker,
verapamil (Fig 4.5). Catecholamine release induced by metabolic inhibitors was
independent of calcium and unaffected by the calcium channel blocker, verapamil,
unlike nicotine-induced catecholamine release (Fig 3.7).
The second feature of carrier-mediated efflux, its sensitivity to uptake blockade,
was also examined. Cells were pretreated with 100nM desipramine for 15min
prior to addition of Locke's buffer plus metabolic inhibitors. Desipramine was
present throughout the experiment. As shown (Fig 4.6) there was no significant
reduction in release in the presence of 100nM desipramine (p>0.01); if
anything, there was slight enhancement of release, perhaps due to inhibition of
re-uptake. This lack of an inhibitory effect by desipramine raised the question of
whether this concentration of drug was really sufficient to block the cellular
uptake mechanism under these conditions, particularly as the extracellular
catecholamine concentration is higher (approximately 10pM) than it was during
the experiments on blockade of uptake of [3H] noradrenaline (approximately
1jiM), described in Chapter 3.100nM desipramine was found to be sufficient to
inhibit uptake of [3H] noradrenaline by at least 60% by Kenigsberg and Trifaro
(1980), and see Fig 3.9. The effect of raising the extracellular non-radioactive
catecholamine concentration on the ability of uptake1 blockers to inhibit uptake of
[3H] noradrenaline was, therefore, examined. Uptake of [3H] noradrenaline in the
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Fig 4.5 Calcium independence of catecholamine release in response to metabolic
inhibition. Results are expressed as percentage catecholamine release
after 10min treatment with Locke's buffer or Locke's buffer plus
metabolic inhibitors in the presence or absence of calcium or 10pM
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Fig 4.6 Effect of 100nM desipramine on catecholamine release in response to
metabolic inhibition. Cells were pretreated for 15min with 100nM
desipramine prior to the addition of Locke's buffer plus metabolic
inhibitors. Results are expressed as percentage catecholamine release
above basal levels, means ± SE of triplicate determinations.
Calcium
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described in Chapter 2. Non-radioactive noradrenaline and adrenaline were
included in the incubating medium at a concentration and ratio within the range
released by either nicotine-stimulation or metabolic inhibition (3.5pM
noradrenaline and 6jiM adrenaline). These added catecholamines had no significant
effect (p>0.1) on the ability of the uptake1 blockers to inhibit uptake of [3H]
noradrenaline (Fig 4.7).
Desipramine is a competitive inhibitor of the carrier, exerting its inhibitory
effect by direct competition with an amine substrate for its binding site (Bonisch,
1984). Although non-radioactive catecholamines in the medium did not appear to
have any effect on inhibition of uptake, it is possible that intracellular
catecholamines released during metabolic inhibition could compete with
desipramine for the uptake carrier and reduce its effectiveness as an inhibitor.
Therefore, the effect of a range of desipramine concentrations on the release of
catecholamines under conditions of metabolic inhibition was examined. 1pM
desipramine was sufficient to inhibit catecholamine release by 50% (Fig 4.8).
However, it was found that desipramine inhibited nicotine-evoked catecholamine
release to the same degree. This latter effect has previously been reported in the
perfused adrenal gland (Wakade and Wakade, 1984), catecholamine secretion
being reduced in a dose-dependent manner. This ability of desipramine to inhibit
secretion of catecholamines has also been reported in the isolated perfused guinea
pig heart (Richardt etal., 1988), where nicotine-induced noradrenaline release
was almost completely abolished by 1pM desipramine. Nisoxetine, another
uptake1 blocker had a similar effect. In the case of chromaffin cells, desipramine
cannot be used to distinguish between nicotine-stimulated exocytosis and
catecholamine release induced by metabolic inhibitors. If one assumes that it will
be an effective blocker of carrier-mediated efflux at the same low concentrations
as are effective in inhibiting carrier-mediated uptake (Fig 4.7), these
observations suggest that the carrier is not involved. Furthermore, the
observations raise questions about noradrenaline overflow blockade in ischaemic
rat hearts, since it is hard to show whether inhibition of overflow by desipramine
is due to its ability to block uptake.,, or might be due to some other non-specific
action of the drug.
To resolve these questions oxaprotiline was utilised to distinguish between













Fig 4.7 Effect of extracellular catecholamines on blockade of uptake of [3H]
noradrenaline. Cells were incubated with [JH] noradrenaline for 12h in
the presence of different concentrations of desipramine (DMI) and, (+)
and (-) oxaprotiline (OXA). Uptake was measured in the presence (+
cold catecholamines) or absence of nonradioactive extracellular
catecholamines. Results are expressed as percentage inhibition, means
± SE of 6 determinations.
Log [DMI] M
Fio 4.8 Ability of desipramine to inhibit catecholamine release in response to
10|iM nicotine or metabolic inhibition. Cells were pretreated for
15min with a range of desipramine concentrations prior to addition of
Locke's buffer plus 10p.M nicotine or metabolic inhibitors.
Desipramine was present throughout the experiment. Catecholamine
release was measured after 10min and results are expressed as











Control DMI (+) OXA {-) OXA
Fig 4.9 Catecholamine release evoked by 10pM nicotine or metabolic inhibitors
in the presence of uptake blockers. Cells were preincubated for 15min
with 100nM desipramine (DMI) or 1p.M (+) or (-) oxaprotiline
(OXA), prior to the addition of Locke's buffer plus 10p.M nicotine or
metabolic inhibitors. Drugs were present throughout the experiment.
Catecholamine release was measured after 10min and results are
expressed as percentage release, means ± SE of triplicate
determinations.
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two isomers of the drug. Chromaffin cells were preincubated for 15min with
100nM desipramine or 1|iM (+) or (-) oxaprotiline (the concentration at which
there was the greatest difference in the uptake blocking capacity of the two
isomers, Fig 4.7). Fig 4.9 shows the catecholamine release after 10min treatment
with Locke's buffer or Locke's buffer plus 10p.M nicotine or metabolic inhibitors.
Catecholamine release evoked by 10pM nicotine was reduced by desipramine and
oxaprotiline (approximately 40% inhibition). There was no difference between
release in the presence of (+) or (-) oxaprotiline suggesting that this reduced
release is due to some non-specific action of the drug and not due to blockade of the
uptake carrier. Catecholamine release induced by metabolic inhibition was not
inhibited by desipramine, (+) or (-) oxaprotiline. The finding that 1)o.m desipramine
also inhibited nicotine-evoked noradrenaline release in isolated guinea pig hearts
(Richardt etai, 1988) suggests that it may be unsafe to conclude that inhibition
by this drug is an indication of a carrier-mediated efflux mechanism for
ischaemia-induced noradrenaline release.
4.2.3 Sensitivity of noradrenaline overflow in perfused rat hearts to (+) and (-)
oxaprotiline.
Ischaemia-induced noradrenaline overflow in rat hearts was therefore
reexamined using an in situ model of stop-flow ischaemia. The left cervicothoracic
ganglion was electrically stimulated (for 1min intervals at 5Hz) in the presence
or absence of (+) and (-) oxaprotiline prior to the onset of stop-flow ischaemia
in order to Compare the action of the two isomers on both exocytotic and
non-exocytotic noradrenaline release. Fig 4.10 shows the noradrenaline overflow
in response to 3min electrical stimulation of the left cervicothoracic ganglion in
the presence or absence of (+) or (-) oxaprotiline. There was no significant
difference (p>0.5) between release in the presence of either drug compared with
that observed on stimulating the ganglion in its absence. Following electrical
stimulation noradrenaline efflux was allowed to return to basal levels before
stop-flow ischaemia was induced. Noradrenaline overflow was then measured
during the initial 3min reperfusion following 40min stop-flow ischaemia, (Fig
4.11). Ischaemia-induced noradrenaline overflow was significantly reduced in the
presence of 3 x 10"6M (+) oxaprotiline from 117 ± 21.5 pmol/g (n=8) to 26
±6.0 pmol/g (n=6), p<0.01. While there was an apparent reduction of noradrenaline
overflow in the presence of (-) oxaprotiline, 74 ± 17.7 pmol/g (n=6), this was
not significantly different to overflow in the absence of drug; p>0.5. This appears
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Fig 4.10 Release of noradrenaline from the perfused rat heart before (Basal) or
during 3min continuous electrical stimulation (5Hz/min) of the left
cervico-thoracic ganglion in the presence or absence of (+) or (-)
oxaprotiline at a flow rate of 4.5ml/min. The drug was added at 3x10"7M
15min prior to the second stimulation. Cumulative release is expressed
in pmol/g heart weight, means ± SE from 8 hearts.
Fig 4.11 Overflow of noradrenaline from the perfused rat heart following
40min stop-flow ischaemia. Drug, 3 x 10""'M (+) or (-)
oxaprotiline was present throughout the experiment. Cumulative
overflow is expressed in pmol/g, means ± SE from 6 to 8 hearts.
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to confirm that the ability of (+) oxaprotiline to inhibit ischaemia-induced
noradrenaline overflow in the perfused rat heart can only be attributed to its
uptake-i blocking activity. This provides further evidence that noradrenaline
overflow in the ischaemic rat heart occurs by carrier-mediated efflux.
4.3 Discussion.
Conditions of anoxia or metabolic inhibition produced a significant release
(p<0.001) of catecholamines above basal release in chromaffin cells (Fig 4.1).
This reached a maximum of 5 to 10% of cell content above basal release within
10min, a similar magnitude to release evoked by nicotine or high K+. Anoxia or
cyanide intoxication of the isolatecf perfused rat heart produced an overflow of
noradrenaline only after a lag period of 5 to 10min that reached a peak after 30 to
40min and then declined (Schomig et at., 1987). This lag period is thought to be
due to ongoing glycolysis, a significant overflow of noradrenaline only occurring
after cessation of glycolytic ATP production. Reduction of cardiac glycogen stores
by glucose-free preperfusion reduced this lag period. Chromaffin cells do not have
significant glycogen stores so energy depletion would be expected to be more rapid.
The response of perfused adrenal glands to stimulation with acetylcholine was
completely abolished following 10min perfusion with cyanide and iodoacetate
(Kirchner and Smith, 1969). This indicates a complete rundown of metabolic
energy within this time. Furthermore, Corcoran et al. (1986) reported a rapid
decline in the cytosolic pool of ATP in chromaffin cells with a t1/2 of 5min, using
a combination of cyanide, 2-deoxy D-glucose and p glucono 1,5 lactone.
Catecholamine release in response to metabolic inhibition occurred after an initial
lag phase of 2min (Fig 4.4). This may be due to an initial depletion of energy
stores prior to catecholamine overflow and there may be other prerequisite
metabolic changes.
Anoxia or cyanide intoxication in the perfused rat heart produced a maximum
overflow of 80 pmol/g/min noradrenaline (Schomig etai, 1987) which is much
greater than that achieved with stimulation of the left cervicothoracic ganglion.
These conditions in isolated chromaffin cells did not produce such a large increase
in release, the maximal catecholamine release in response to metabolic inhibition
being no greater than that evoked by nicotine.
Noradrenaline overflow in isolated rat hearts induced by anoxia is
calcium-independent (Schomig etai, 1987). When similar conditions were
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imposedon chromaffin cells, catecholamine release was also found to be
calcium-independent. Furthermore, catecholamine release was unaffected by
10|iM verapamil which completely abolished nicotine-stimulated release.
Noradrenaline overflow induced by cyanide intoxication in the perfused rat heart
was more than 40% higher in the absence of calcium (Schomig etal., 1987). The
time lag was also reduced in the absence of calcium. Calcium ions have been shown
to inhibit sodium entry through sodium channels so the absence of calcium would
be expected to facilitate sodium entry via this route. This would lead to a more
rapid rise in intracellular sodium, facilitating sodium-linked carrier-mediated
efflux. Such a sequence of events, however, has yet to be demonstrated
experimentally. There appeared to be a slight enhancement of catecholamine overflow from
chromaffin cells in the absence of calcium (9.0 ± 0.4%, calcium-free compared
with 8.1 ± 0.3%, plus calcium), but this difference is not significant (p>1.0).
Desipramine inhibited catecholamine release induced by metabolic inhibitors but
only at concentrations of 10"6M and higher (Fig 4.8). Nicotine-stimulated
exocytosis was also inhibited at this concentration to a similar degree. This effect
has previously been reported in the perfused adrenal gland (Wakade and Wakade,
1984), secretion evoked by acetylcholine, splanchnic nerve stimulation and high
K+ being affected similarly, suggesting that exocytosis is inhibited at a common
site under these conditions. In each case, secretion was inhibited by 50 to 70% by
3pM desipramine. A similar degree of inhibition is seen in isolated chromaffin
cells (Fig 4.8). This inhibitory effect of desipramine has been attributed to its
ability to bind to calmodulin. This was not measured directly in the perfused
adrenal gland and it is possible that desipramine may have other sites of action.
Desipramine has also been reported to inhibit nicotine-evoked noradrenaline
release in the perfused guinea pig heart (Richardt etal., 1988). However, unlike
that observed in the adrenal gland, desipramine did not inhibit noradrenaline
release in response to electrical stimulation (Haass etal., 1989). Nisoxetine had
the same effect, so this inhibitory action is not drug-specific. The inhibition of
nicotine-evoked secretion but not secretion in response to electrical stimulation
suggests an interaction of these uptake1 blockers with presynaptic cholinergic
receptors. It is unlikely that this is the mechanism of inhibition in chromaffin
cells, however, since the response to metabolic inhibitors is not associated with
receptor-mediated secretion. Regardless of the mechanism by which desipramine
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inhibits catecholamine release evoked by nicotine or metabolic inhibition it
follows that desipramine cannot be used to differentiate between exocytosis and
carrier-mediated efflux in the chromaffin cell or in the perfused heart.
To overcome this problem the effect of the two isomers of oxaprotiline on
chromaffin cells (Fig 4.9) and on perfused rat hearts (Figs 4.10 and 4.11) was
examined. Oxaprotiline did not inhibit catecholamine release produced by
metabolic inhibition in chromaffin cells. There was a significant reduction in
noradrenaline overflow in response to 40min stop-flow ischaemia in the rat heart
in the presence of (+) but not (-) oxaprotiline. It should be noted that the
magnitude of noradrenaline overflow in response to ischaemia was considerably
lower (117 ±21 pmol/g) than that previously reported by other workers (for
example, Schomig et ai, 1984, reported an overflow of 817 ± 110 pmol/g after
40min ischaemia). The model of ischaemia used by Schomig etal. (1984) was one
of isolated perfusion of the rat heart, whereby the heart is removed from the chest
cavity, the aorta cannulated and the heart maintained in a humidified, warmed
perfusion chamber. In the model of ischaemia used in the present work hearts
were not excised. It is possible that the difference in noradrenaline overflow is
due to modulation of release by the sympathetic nerve supply, as this is still
intact. The studies of Schomig etal. (1984) were, however, performed on Wistar
rats whereas the present experiments were carried carried out on Sprague
Dawley rats so the differences observed may be due to strain variation.
Catecholamine release from isolated chromaffin cells in response to metabolic
inhibition possesses several features that suggest it is distinct from
carrier-mediated efflux of noradrenaline observed in the rat heart. Catecholamine
release is no greater than that observed in response to other secretagogues. A
much greater release was anticipated from the magnitude of noradrenaline
overflow in ischaemic rat hearts. Furthermore, although release is
calcium-independent it is not enhanced in the absence of calcium, in contrast to
predictions from the model of neuronal sodium homeostasis and non-exocytotic,
calcium-independent noradrenaline release proposed by Schomig etal. (1988).
Finally, catecholamine release was not inhibited by (+) oxaprotiline at a
concentration shown to inhibit noradrenaline overflow in the ischaemic rat heart
and to block the uptake carrier by almost 100%. These observations suggest that
the mechanism of catecholamine release is distinct from that observed in the





Role of Na+ in Catecholamine Release and Examination of the
Reversibility of the Uptake Carrier in Chromaffin Cells
5.1 Introduction
The catecholamine release described in Chapter 4. could not be distinguished from
an exocytotic mode of release by its sensitivity to uptake blockade. In order to
elucidate the mechanism of release evoked by conditions of metabolic inhibition
the role of extracellular sodium was investigated since sodium influx is central to
both exocytosis in chromaffin cells (Amy and Kirshner, 1982) and
carrier-mediated efflux in the ischaemic myocardium (Schomig etal., 1988).
Resting concentrations of cytosolic sodium are maintained at a low level primarily
by the ATP-dependent Na+/K+ pump. Stimulation of chromaffin cells with a range
of secretagogues results in a rapid influx of sodium which may be involved in
mediating catecholamine secretion, as demonstrated by Amy and Kirshner
(1982). Nicotine-stimulated catecholamine secretion was accompanied by a
marked uptake of 22Na+. Secretion was not, however, completely dependent on
extracellular Na+ as long as Ca2+ was present. In contrast, other workers have
reported reduced catecholamine release in the absence of external sodium (Wada et
at., 1984). It seems that, where nicotinic stimulation is maximal, this alone is
sufficient to trigger calcium influx and evoke secretion. When nicotinic
stimulation, however, is submaximal sodium influx via receptor-mediated sodium
channels may facilitate calcium influx. Nicotinic secretion is thus partially
dependent on external sodium under certain conditions.
Veratridine-stimulated catecholamine secretion is completely abolished by
removal of external sodium since, in this case, catecholamine secretion is
triggered by direct depolarisation of the plasma membrane following Na+ influx
via voltage-sensitive Na+-channels. Thus under certain conditions Na+ influx via
receptor-linked channels or voltage-sensitive channels; or both, may be a
prerequisite for secretion in chromaffin cells, probably by facilitating the
subsequent influx of calcium.
Ischaemia-induced noradrenaline overflow in the heart requires an elevated
cytosolic catecholamine concentration and a reduction of the inwardly
directed sodium gradient. Noradrenaline efflux will therefore be triggered
following an influx of sodium to raise cytosolic sodium levels or by reversal of the
sodium gradient by removal of external sodium. The role of sodium in
noradrenaline overflow induced by ischaemia, anoxia or cyanide intoxication in
rat hearts was investigated by Schomig etal. (1988). Sodium fluxes via different
pathways were modulated using selective inhibitors and the resultant effect on
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noradrenaline overflow studied. A raised cytosolic sodium concentration caused an
efflux of noradrenaline only when cytosolic amine concentrations were also
artificially elevated. In the presence of reserpine to deplete vesicular amine
stores inhibition of the Na+/K+ ATPase with ouabain or stimulation of sodium
influx with veratridine mediated a rapid efflux of noradrenaline. This use of
pharmacological inhibitors demonstrated that carrier-mediated efflux was a
plausible mechanism for release from cardiac sympathetic neurons.
There is evidence for intracellular sodium accumulation in myocytes (Fiolet et
al., 1984) but no direct evidence in sympathetic neurons under
pathophysiological conditions, although pharmacological evidence suggests that
sodium influx is involved in ischaemia-induced efflux. Thus, this overflow was
inhibited by amiloride and ethylisopropyl-amiloride (EIPA) but not by
tetrodotoxin, indicating that sodium influx via the Na+/H+ exchanger is the
predominant route for sodium entry.
In contrast, noradrenaline release in response to cyanide intoxication was not
inhibited by EIPA but was reduced by tetrodotoxin (Schomig et al., 1988). It was
suggested that intracellular acidosis under conditions of ischaemia would inhibit
sodium influx through tetrodotoxin-sensitive channels whereas the Na+/H+
exchanger would be activated under these conditions (i.e reduced cytosolic pH).
During cyanide intoxication, in contrast, there was continuous washout of
metabolites, reducing intracellular acidosis, so that the tetrodotoxin-sensitive
Na+ channels appeared to be the major route for Na+ entry.
The role of sodium in relation to catecholamine release under conditions of
metabolic inhibition was initially investigated to determine whether there was a
sodium influx as predicted from the work of Schomig etal. (1988). However,
once it became evident that the mode of catecholamine release differed from that in
the myocardium it was hoped that comparison of the influx of sodium with that
observed during exocytosis might provide some indication of the mechanism of the
calcium-independent catecholamine release. In addition, pharmacological agents
were utilised to attempt to induce carrier-mediated efflux under conditions
demonstrated to be effective in cardiac sympathetic neurons (Schomig et al.,
1988) and in PC12 cells (Bonisch etal., 1984).
5,2 Resets
5.2.1 ^Na* influx and catecholamine secretion.
Sodium influx was measured in parallel with catecholamine release using a
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number of different agents known to promote 22Na+ uptake (Fig 5.1). Amy and
Kirshner (1982) previously reported an increase in 22Na+ uptake within 10min
in the presence of 10pM nicotine or 100pM veratridine. They found values of 8.3
and 14.2nmol 22Na+/well/10min (27.7 and 47.3 nmol/106cells); and 23.2 and
34.4% catecholamine secretion in the presence of 1 OjiM nicotine and 10OpM
veratridine respectively. Similar results were obtained here, 14 and 19.5 nmol
22Na+/well/1 Omin (28 and 39nmol/106cells) and 18.7 and 20.5%
catecholamine release being found. The catecholamine secretion in response to
100|iM veratridine may be lower than that reported by Amy and Kirshner
(1982) since veratridine-stimulated secretion was maximal at 50mM Na+ ( Na+
level present in their study) rather than at 154mM Na+ (the Na+ concentration
used in these experiments).
Monensin, a monovalent cation ionophore, also induces Na+-dependent
catecholamine secretion from chromaffin cells (Suchard etal., 1982). However,
catecholamine release and 22Na+ influx are not observed until at least one hour
after exposure to the ionophore. In this study, catecholamine release and ^Na"1"
influx above basal levels were seen after 1 h exposure.
Like the secretagogues, metabolic inhibition caused an influx of 22Na+ within
10min as with catecholamine release, suggesting a possible involvement of Na+ in
catecholamine release under these conditions.
5.2.2 Effect of Na+ concentration on 22Na+ uptake and catecholamine release.
Fig 5.2 illustrates the effect of altering the external Na+ concentration on
catecholamine release and 22Na+ influx in response to 10pM nicotine (A) and
metabolic inhibition (B) respectively. 22Na+ uptake in the presence of 10pM
nicotine increased proportionally with increasing Na+ concentration.
Nicotine-stimulated catecholamine release was much less dependent on
extracellular sodium as found previously by Amy and Kirshner (1982).
Catecholamine secretion was partially reduced at low concentrations of Na+, being
36% lower at 10mM Na+ than at 154mM Na+.
Catecholamine release in response to metabolic inhibition was markedly reduced
at Na+ levels below 75mM. There was no influx of 22Na+ above basal levels until
the external Na+ concentration reached 75mM. This suggests that Na+ influx is
coupled to catecholamine release. Release may not occur until intracellular Na+
concentrations reach a certain level or are high enough to mediate a secondary
response that is the immediate trigger. Both veratridine and monensin-induced
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Fig 5.1 Catecholamine release and uptake of21Na7 Cells were treated with
Locke's buffer or Locke's buffer plus 10|iM nicotine, 100pM
veratridine or metabolic inhibitors for 10min; or 1p.M monensin for
60min. Results are expressed as percentage catecholamine release, or
z2Na+ uptake, nmol/well (0.5x106 cells/well), after subtraction of










Fig 5.2 Catecholamine release and ^Na* influx as a function of extracellular Na+
concentration. Cells were treated with Locke's buffer or Locke's buffer
containing reduced Na+was adjusted with sucrose to maintain osmosity.
Results are expressed as percentage catecholamine release or^a*"
uptake (nmol/well/10min) above basal, means ± SE of triplicate
determinations. A response to nicotine, B response to metabolic inhibition.
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catecholamine secretion are also dependent on external sodium.
Veratridine-stimulated secretion declined sharply at Na+ levels below 25mM
(Amy and Kirshner, 1982) and monensin-induced secretion was reduced by 30%
at 10mM Na+ (Suchard eta!., 1982).
In strong contrast, noradrenaline efflux in the anoxic myocardium was greater
when external sodium was reduced and was replaced with either LiCI, Tris or
sucrose (Dart and Riemersma, 1989). This was in keeping with the proposed
model of carrier-mediated efflux (Schomig etal., 1988), dependent on reversal
of the inwardly directed sodium gradient to an outwardly directed gradient.
5.2.3 Effect of inhibitors of Na+ entry on catecholamine release.
The effect of a range of inhibitors of different Na+ channels on catecholamine
release under conditions of nicotine-stimulation and metabolic inhibition was
investigated. 22Na+ influx following nicotine-stimulation is sensitive to
hexamethonium which blocks nicotinic receptor-linked Na+ channels, but not to
inhibitors of voltage-sensitive Na+ channels such as tetrodotoxin (Wada etal.,
1984).
Noradrenaline overflow in the heart induced by ischaemia (Schomig etal., 1988)
or substrate-free anoxia (Dart and Riemersma, 1989) was significantly reduced
by amiloride and EIPA, inhibitors of the Na+/H+ exchanger, but not by
tetrodotoxin or lignocaine, both inhibitors of voltage-sensitive Na+ channels.
Amiloride inhibits the Na+/H+ exchange system competitively so that high
(millimolar) concentrations of amilo.ride are required to block the Na+/H+
exchanger at physiological sodium concentrations. Near maximal inhibition of the
exchanger has been reported at 0.1 mM amiloride in 3T3 cells, chick skeletal
muscle cells and chick cardiac cells (Vigne etal., 1983). Fig 5.3 demonstrates the
sensitivity of catecholamine release (A) and 22Na+ uptake (B) to 0.1 mM
amiloride. 22Na+ influx in response to nicotine-stimulation was significantly
reduced in the presence of 0.1 mM amiloride (p<0.001). There was a parallel
reduction of catecholamine release. Unlike ischaemia-induced noradrenaline
overflow from the perfused rat heart, catecholamine release induced by metabolic
inhibition was not inhibited by 0.1 mM amiloride (p>0.5) nor was there any
reduction in 22Na+ influx.
Amiloride is known not to be specific for the Na+/H+ exchanger, inhibiting the
Na+/ Ca2+ exchanger and the Na+/K+ ATPase in some systems (Lazdunski etal.,




Fia 5.3 Sensitivity of catecholamine release and uptake of^Na^to amiloride.
Catecholamine release and^Na"*" uptake were measured after 10min
treatment with Locke's buffer plus 10p.M nicotine or metabolic
inhibitors in the presence or absence (normal response) of 100[iM
amiloride (AMI). Results are expressed as percentage catecholamine
release (A) or ^Na"*" uptake nmol/well/10min (B) above basal levels,
means ± SE of triplicate determinations.
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Fig 5.4 Sensitivity of catecholamine release and uptake of^a^to EIPA or
lignocaine. Percentage catecholamine release and ^a* influx
nmol/well/10min were measured after 10min in the presence or
absence (normal response) of 0.1 and 10p.M EIPA or 0.1 mM lignocaine











amiloride (Vigne etal., 1983) was also examined (Fig 5.4). 10pM EIPA
significantly reduced catecholamine release (A) and 22Na+ influx (B), p<0.001,
under conditions of both nicotine-stimulation and metabolic inhibition. 0.1 pM
EIPA had no inhibitory effect on catecholamine release under these conditions.
Influx of 22Na+ appeared to be potentiated, but this was not significant (p>0.5).
Lignocaine, which inhibits voltage-sensitive Na+ channels, did not significantly
alter either catecholamine release or 22Na+ influx in response to nicotine (Fig
5.4). Both, however, were markedly increased (p<0.001) by 0.1 mM lignocaine
in the presence of metabolic inhibitors (Fig 5.4).
5.2.4 Reversibility of the chromaffin cell Na+ /catecholamine svmporter.
The imposition of anoxic conditions in chromaffin cells did not induce a release of
catecholamines that demonstrated any of the features predicted for
carrier-mediated efflux. This raised the question of whether a carrier-reversal
mechanism could operate in chromaffin cells. Experiments were based on those
performed by Bonisch etal. (1984) on noradrenaline transport in PC12 cells. In
this work, PC12 cells were loaded with [3H] noradrenaline in the presence of
reserpine, to prevent vesicular uptake, and pargyline, to inhibit MAO-catalysed
oxidation of the noradrenaline accumulating in the cytosol. When these cells were
then exposed to Na+-free conditions there was a marked efflux of [ 3H]
noradrenaline via the uptake carrier, demonstrating that this carrier, like that in
adrenergic nerve terminals (Paton, 1973) is bidirectional.
Chromaffin cells were treated with 0.5pM reserpine plus 0.1 mM pargyline for
24h. Previous studies on reserpine-treated cells showed that the cellular
catecholamine content was reduced by approximately 50% under these conditions
(Caughey and Kirshner, 1987). It should be noted that at the dilution used DMSO,
the solvent for reserpine, did not affect the ability of the cells to respond
normally to nicotine or high K+. In the presence of pargyline it is expected that
cytosolic catecholamines will increase in concentration, but will not be
metabolised.
Following reserpine treatment the total cellular catecholamine content was found
to be depleted by 36% (in the absence of pargyline). Fig 5.5 confirms the results
of Caughey and Kirshner that prolonged reserpine treatment reduced but did not
inhibit the secretory response. Exposure of reserpine-treated cells to Na+-free
buffer ( Na+ replaced with sucrose to maintain osmosity) did not result in any
significant extra release of catecholamines compared to that released from
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untreated cells in the presence of 0.1 mM pargyline only (Fig 5.5).
In order to demonstrate that the cytosolic catecholamine concentration is indeed
elevated following reserpine-treatment, despite this lack of efflux, cells were
treated for 10min with 10(iM digitonin. Digitonin selectively permeabilises the
plasma membrane of chromaffin cells, enabling direct stimulation of secretion on
the addition of micromolar levels of calcium (Dunn and Holz, 1983). This is
confirmed in the experiment shown in Fig 5.6, the response of cells to readdition
of calcium following 10min permeabilisation with 10jxM digitonin being shown.
There was a catecholamine release of 18.3% in the presence of calcium compared
with only 9.4% in the absence of calcium. When reserpine-treated cells were
permeabilised with digitonin 9.9% catecholamines were released compared with
2.6% released from untreated cells (Fig 5.5), suggesting that reserpine
treatment has indeed elevated the cytosolic concentration of catecholamines.
Calcium-free buffer alone, in the absence of digitonin, did not release
catecholamines much above basal levels (Fig 5.5). These results suggest that,
unlike previous assumptions concerning the similarity of the chromaffin cell
carrier to that in adrenergic neurons, the chromaffin cell uptake carrier is not
reversible under conditions of elevated cytosolic catecholamines, and reduced
extracellular Na+.
Bonisch et al. (1984) loaded PC12 cells with [ 3H] noradrenaline in the presence
of reserpine in order to study noradrenaline transport. In order to make a direct
comparison with their experiments chromaffin cells were incubated with [ 3H]
noradrenaline in the presence of 0.5p.M reserpine and 0.1 mM pargyline for 24h
prior to permeabilisation with digitonin or exposure to Na+-free conditions. As in
the previous study (Fig 5.5) Na+-free conditions did not cause release of [ 3H]
noradrenaline following reserpine pretreatment (Fig 5.7). [ 3H] noradrenaline
was, however, sequestered in the cytosol in the presence of reserpine as
demonstrated by its release from the cells on permeabilisation with digitonin.
Tyramine, a sympathomimetic amine, is taken up into isolated chromaffin
granules and displaces endogenous catecholamines, possibly by disruption of the
granule electrochemical proton gradient (Johnson et al., 1982). Chromaffin cells
take up tyramine via a cocaine sensitive mechanism (Youdim etal., 1986) and
tyramine has been reported to displace catecholamines from whole adrenal glands
from pigs (Nakai and Yamada, 1983) but not from rats (Wakade and Wakade,
1984). It was postulated that tyramine, like reserpine, would displace
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Fig 5.5 Response to Na*"-free conditions after depletion of granule catecholamine
stores with reserpine. Cells were subjected to 0.5pM reserpine plus
0.1 mM pargyline for 24h in culture medium. They were then exposed
to Locke's buffer plus 10p.M nicotine or 50mM KCI for 10min. Where
Na+-free Locke's was used, Na+was replaced with sucrose. Cells were
also exposed to Ca^-free buffer plus or minus 10pM digitonin for
10min. Results show percentage catecholamine release evoked by these
conditions on treated (0.5p.M reserpine) and untreated (normal
response) cells, above basal levels, means ± SE of triplicate
determinations.
after 10min + 10(xM Digitonin
Fig 5.6 Response to extracellular calcium following permeabilisation with
10pM digitonin. Cells were permeabilised for 10min with 10(iM
digitonin in Ca^-free buffer. They were then exposed to buffer+4.43mM Ca2+
of minus Ca^for a further 10min. Results are expressed as percentage
catecholamine release, means ± SE of triplicate determinations.
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Fig 5.7 Response to Na+-free conditions after depletion of endogenous
catecholamines and labelling of the cytosolic pool with [3H]
noradrenaline. Cells were incubated for 24h with 0.5pM reserpine
plus 0.1 mM pargyline and [aH] noradrenaline in DMEM (conditions as
previously described for uptake of [3H] noradrenaline, Chapter 2.).
Cells were then treated with Caz+-free buffer, Caz+"-free buffer plus
10pM digitonin, or Na+-free buffer for 10min. Results are expressed as
percentage release of [H] noradrenaline from untreated (control) cells
or reserpine-treated (0.5pM reserpine) cells, means ± SE of
triplicate determinations.
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catecholamines from isolated chromaffin cells and elevate cytosolic catecholamine
concentrations. Exposure of chromaffin cells to 0.1 mM tyramine for up to 4h
caused no reduction in total cell catecholamine content, nor did this treatment
induce any increase in release following permeabilisation with digitonin (results
not shown). This lack of tyramine effect in chromaffin cells has previously been
reported by Youdim et al. (1986) but in their work chromaffin cells were only
treated with tyramine for 15min. PC12 cells, however, did demonstrate a
tyramine releasable pool of catecholamines within this time (Youdim etal.,
1986).
5.3 Discussion.
Stimulation of catecholamine secretion by nicotine or by the voltage-dependent
Na+ channel activator veratridine, was accompanied by an increase in cellular
uptake of 22Na+ (Fig 5.1). These observations were similar to those previously
reported by Amy and Kirshner (1982). Nicotine-stimulated release is partially
dependent on extracellular sodium, secretion being inhibited by 36% at 10mM
Na+ (fig 5.2A). This has been attributed to the ability of the cells to elicit a Ca2+
influx independently of activation of the voltage-dependent Na+ channels (Marley,
1988). The sensitivity of nicotine-evoked secretion to extracellular Na+ seems to
vary with different cell preparations (personal observations), and may explain
the Na+-independent release reported by Amy and Kirshner (1982) compared
with the Na+-dependence of nicotine-evoked release reported by Wada etal.
(1984).
Na+ influx in response to nicotine-stimulation was not inhibited by the
voltage-dependent Na+ channel inhibitor, lignocaine (Fig 5.4A). This confirms the
observations of Wada etal. (1984) that stimulation with nicotine causes an influx
of Na+ through receptor-linked but not through voltage-dependent Na+ channels.
The Na+/H+ exchange inhibitor, amiloride, blocked both catecholamine secretion
and Na+ influx in response to nicotine stimulation (Fig 5.3A and B). A similar
result was seen with its more potent analog, EIPA, at a concentration of 10pM but
not at 0.1 pM. There have been few reports on the effect of amiloride on
chromaffin cells. Friedman etal. (1986) reported that heavy meromyosin could
stimulate catecholamine secretion, that this was dependent on extracellular Na+,
and that 22Na+ uptake caused by heavy meromyosin was inhibited by 10jiM
amiloride. Acetylcholine-stimulated secretion and 22Na+ uptake were both
enhanced by the incorporation of heavy meromyosin into chromaffin cells using
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lipofection. In conjunction with these observations they reported that 100p.M
amiloride almost abolished catecholamine secretion induced by both heavy
meromyosin and acetylcholine, in agreement with the observations reported here
(Fig 5.3).
Amiloride is a competitive inhibitor of the Na+/H+ exchanger and is only effective
at high concentrations. The Kj for amiloride, as measured in chromaffin granule
membranes, was 0.26mM (Haigh and Phillips, 1989). Consequently at a Na+
concentration of 154mM, 100|iM amiloride will not be sufficient to inhibit
Na+/H+ exchange. The inhibition of the nicotinic response is, therefore, probably
due to a non-specific effect of the drug acting at the nicotinic receptor-linked Na+
channel.
EIPA is approximately 1000x more potent than amiloride and also highly specific
for the Na+/H+ exchanger, not having the non-specific action on other ion
channels that are seen with amiioride. EIPA has a Kf value of 0.15pM at 140mM
Na+ (Lazdunski etal., 1985). At a concentration of 10pM, EIPA may have
inhibitory action other than inhibition of the Na+/H+ exchanger. Inhibition of the
nicotinic response with 10jiM EIPA may be due to a similar effect as that seen
with amiloride. No inhibition of 22Na+ uptake was seen with 0.1 pM EIPA when the
drug will be totally selective for the Na+/H+ exchanger. The Na+/H+ exchanger is
unlikely, therefore, to play a role in stimulus-secretion coupling in chromaffin
cells.
Metabolic inhibition, like nicotine-stimulation, caused an influx of 22Na+,
associated with catecholamine secretion (Fig 5.1). Unlike the nicotinic response,
however, this 22Na+ uptake showed a marked dependence on extracellular Na+
concentration. Whereas veratridine-induced 22Na+ uptake was proportional to the
Na+ concentration in the external media (Amy and Kirshner, 1982), metabolic
inhibition did not produce any significant 22bia+ influx over 10min until an
external Na+ concentration of more than 75mM was reached (Fig 5.2B).
Catecholamine secretion exhibited a parallel sensitivity to the external sodium
concentration.
The Na+ influx also differed from that evoked by veratridine in that it was not
inhibited by blockers of voltage-dependent Na+ channels, in this case lignocaine
(Fig 5.4B). In fact both catecholamine release and Na+ influx caused by metabolic
inhibition were significantly enhanced by 0.1 mM lignocaine. The reason for this
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enhanced response is not known though it is striking that both increase in
parallel. It is possible that inhibition of the voltage-dependent Na+ channels
activates Na+ influx and thus catecholamine release through some other route.
10mM EIPA but not 0.1pM EIPA or 0.1mM amiloride inhibited 22Na+ influx and
catecholamine release caused by metabolic inhibition. Whilst it is clear that
catecholamine release under these conditions has an absolute requirement for
external Na+, and this must attain a certain level before release is promoted, the
discrepancy in the actions of amiloride and EIPA make it difficult to assess the
route of Na+ entry. Possible mechanisms for Na+-dependent catecholamine release
have, however, been suggested from the action of other pharmacological agents on
chromaffin cells.
5.3.1 Na+ influx and catecholamine release evoked bv other pharmacological
agents.
A Monensin
Prolonged exposure to 1pM monensin, an ionophore for monovalent cations,
resulted in catecholamine release and 22Na+ influx in chromaffin cells (Fig 5.1).
Exposure of isolated rat hearts to monensin for 10min did not cause an overflow of
noradrenaline (Schomig etai, 1988). There was a large overflow of DOPEG,
however, indicative of a large cytoplasmic noradrenaline concentration, released
by disruption of the vesicular proton gradient by monensin. In the rat heart
monensin did not promote a neuronal sodium influx until concentrations higher
.than 10|iM were used (Schomig etal., 1988). The response of chromaffin cells to
1pM monensin is linear for at least 6h (Suchard etal., 1982) and observations
in this study (results not shown). Monensin-induced catecholamine release was
Na+-dependent but Ca2+-independent (Suchard etal., 1982), as is true for
catecholamine release caused by metabolic inhibition (Fig 5.2B and 4.5) but
clearly differing from noradrenaline overflow observed in the rat heart (Dart and
Riemersma, 1989). From these observations , Suchard etal. (1982) postulated
that the monensin-mediated rise in intracellular Na+ raises intracellular Ca2+
independently of extracellular Ca2+, and that this , in turn, stimulates exocytosis.
This Na+-dependent, Ca2+-independent catecholamine release has also been
reported by Izumi et at. (1986). Release of catecholamines in their study was not,
however, accompanied by release of DBH, which is co-released with
catecholamines during exocytosis. Monensin also caused an influx of 22Na+ into
isolated chromaffin granules. The consequent Na+-dependent catecholamine loss
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was accompanied by loss of DBH, suggesting granule lysis. Lysis of isolated
chromaffin granules and granules in intact cells evoked by monensin has
previously been reported by Geisow and Burgoyne (1982). This would result in a
rise in cytoplasmic catecholamine. Only catecholamines are released from the cell
suggesting a non-exocytotic mechanism of release that is Ca2+-independent
(Izumi etal., 1986). This release may be carrier-mediated. However, it was
inhibited by low external Na+, unlike anoxia-induced release that is enhanced by
reduction of external Na+.
P Ouabain,
The cardiac glycoside, ouabain, which inhibits the Na+/K+ ATPase, also triggers
catecholamine release from chromaffin cells (Suchard et al., 1982). The time
course for catecholamine release is essentially the same as that evoked by
monensin. Ouabain causes an elevation of intracellular Na+ which is thought to
mediate catecholamine release by elevating intracellular calcium. Pocock (1983a
and b) studied the possible mechanism of action of ouabain extensively.
Ouabain-evoked secretion was shown to be exocytotic by the parallel release of
DBH but not lactate dehydrogenase. The catecholamine secretion had an absolute
requirement for extracellular sodium and was nominally independent of
extracellular calcium. Torok and Powis (1988) have reported that ouabain evoked
catecholamine release from chromaffin cells was totally Ca2+-dependent. A
further discrepancy has been observed in the sensitivity of ouabain-stimulated
secretion to tetrodotoxin (Pocock, 1983a; and Powis etal., 1989).
Pocock (1983b) suggested that ouabain elicits release through a direct inhibitory
effect on the calcium-extrusion mechanism, leading to a rise in the resting level
of cytosolic calcium. In the absence of extracellular sodium, calcium efflux is not
inhibited by ouabain and this would account for the sodium-dependence of release.
This catecholamine release is inhibited by cocaine and desipramine at
concentrations which block catecholamine uptake (Powis etal., 1989). This has
also been reported by Sweadner (1985) in rat sympathetic neurons,
ouabain-evoked release being sensitive to desipramine, Na+-dependent and
Ca2+-independent. Consequently a mechanism of carrier-mediated efflux was
proposed. However, such a mechanism of release would be expected to be
stimulated in the absence of extracellular sodium rather than inhibited. This
mechanism of release has been discounted in chromaffin cells in response to
ouabain for this very reason (Powis etal., 1989). These authors suggest that
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ouabain-mediated Na+ accumulation leads to a Ca2+ influx since this Na+
accumulation itself may cause depolarisation and opening of the
tetrodotoxin-sensitive Na+ channels. This in turn would lead to further Na+
accumulation and enhance Ca2+ influx, and subsequent catecholamine release by
exocytosis.
Such a mechanism may also be attributed to the release of [ 3H] noradrenaline in
sympathetic neurons reported by Sweadner (1985). However, the possibility that
Na+/K+ ATPases in different tissues respond differently to ouabain cannot be
discounted. Furthermore, the different observations on ouabain-evoked
catecholamine release in chromaffin cells discussed here suggest that the mode of
action of this glycoside has yet to be completely elucidated.
5.3.2 Na+ influx and catecholamine release caused bv metabolic inhibition.
Metabolic inhibition caused a similar Na+-dependent catecholamine release to that
evoked by ouabain. Metabolic inhibition, like ouabain, would be expected to cause a
rapid inhibition of Na+/K+ ATPase activity. Such an effect was reported by Pocock
(1983b). Anoxic chromaffin ceils quickly lost their ability to transport sodium
and potassium ions and there was a concomitant rise in intracellular sodium. In
the present study this sodium influx was observed within 10min after the onset of
metabolic inhibition in conjunction with catecholamine release. In contrast, cells
were exposed to ouabain for at least 60min before any significant changes were
observed (Powis etal., 1989). Consequently catecholamine release caused by
metabolic inhibition cannot be the result of Na+/K+ ATPase inhibition alone.
22Na+ influx and catecholamine release evoked by metabolic inhibition was not
inhibited by 0.1 mM amiloride orO.lpM EIPA (Fig 5.3 and 5.4). As discussed
above, 0.1 mM amiloride may not be sufficient to inhibit the Na+/H+ exchanger at
an external sodium concentration of 154mM. In retrospect 1mM amiloride should
have been used to ensure Na+/H+ inhibition. EIPA had the same effect on the
response with metabolic inhibitors as on the nicotinic response. This implies that
the Na+/H+ exchanger is not involved in the response evoked by metabolic
inhibitors. At such a high extracellular Na+ concentration, however, Na+ may
compete out any inhibitory action of the drug, 0.1 jxM being lower than the
reported Kj for EIPA. The Na+-dependence of the response prevented the use of
lower extracellular Na+ concentrations. Consequently under the conditions used it
is not possible to determine whether or not the Na+/H+ exchanger is involved in
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the response caused by metabolic inhibition.
During ischaemia in the isolated rat heart the Na+/H+ exchanger has been
identified as being the major pathway for sodium entry (Schomig eta!., 1988). At
physiological pH0 noradrenaline overflow during substrate-free anoxic perfusion
was inhibited by amiloride and EIPA (Dart and Riemersma, 1989). Under
conditions of metabolic inhibition in chromaffin cells it may be postulated that the
rapid rundown of cytosolic ATP would lead to an intracellular acidosis. The Na+/H+
exchanger would be maximally activated leading to a Na+ influx especially as the
Na+/K+ ATPase will be suppressed. This Na+ influx may then mediate
catecholamine release through the mobilisation of internal Ca2+ stores even in the
absence of extracellular Ca2+. As discussed above, however, it has not been
possible to demonstrate such a mechanism of release by monitoring 22Na+ influx
under conditions of metabolic inhibition in chromaffin cells.
In rat neocortical brain slices veratridine stimulates a substantial release of
[3H] noradrenaline that is independent of extracellular Ca2+ (Schoffelmeer and
Mulder, 1983). This release appears to be mediated by an increase in
intracellular Na+ and subsequent mobilisation of internal Ca2+ stores. Veratridine
in the absence of Ca2+ has also been reported to cause a Na+-dependent release of
noradrenaline from the vas deferens (Alberts etal., 1981). In chromaffin cells,
however, veratridine-mediated catecholamine release is Ca2+-dependent
(Kilpatrick et al., 1981). Catecholamine release induced by heavy meromyosin in
chromaffin cells did not appear to be Ca2+-dependent (Friedman etal., 1986).
They suggested that the rise in intracellular Ca2+ required for secretion was
mediated by Na+ influx, heavy meromyosin-induced catecholamine release being
Na+-dependent and abolished by amiloride. Therefore, a Na+-mediated
catecholamine release may occur in chromaffin ceils under certain conditions.
5.3.3 Carrier-mediated efflux in bovine chromaffin cells.
The occurrence of carrier-mediated efflux mechanisms in myocardial sympathetic
neurons (Schomig etal., 1984) and PC12 cells (Bonisch etal., 1984) led to a
more detailed examination of carrier-reversibility in chromaffin cells.
Reserpine was used to inhibit the catecholamine/H+ exchanger of the granule
membrane and raise cytosolic catecholamines in the presence of pargyline, to
inhibit metabolism. Following treatment with 0.5|iM reserpine, permeabilisation
with 10|iM digitonin released 10.3% total catecholamines compared with 2.6%
89
released from untreated cells. This increase of 6.9% can be assumed to be from
the cytosolic pool. Taking a cytoplasmic volume for 0.5x106 cells of 0.58pJ
(cytoplasmic volume representing 75% of the total cell volume, Friedman etal.,
1985) the concentration of catecholamines in the cytoplasm was calculated to be
approximately 2.6mM. The cytosolic sodium concentration is unknown but is
thought to be in the order of 1 to 5mM (Haigh and Phillips, 1989). Therefore, in
the absence of extracellular Na+ there would be an outwardly directed
catecholamine and Na+ gradient. The results presented here, however, suggest that
efflux does not occur. It is possible that the conditions imposed on the cells are not
sufficient to cause efflux. This seems unlikely from the observations of efflux
under essentially identical conditions in PC12 cells (Bonisch etal., 1984).
Alternatively, it may be postulated that the uptake carrier is in fact
unidirectional and is "gated" in some way so that a mechanism of carrier-mediated
efflux is not favoured.
A recent report by Powis etal. (1989) has also suggested that carrier-reversal
is not a general mechanism of catecholamine release in chromaffin cells.
Conditions of reduced extracellular Na+ and Ca2+ did not produce an efflux of [ 3H]
noradrenaline within 60min. There was an efflux in the presence of Ca2+ but this
was not inhibited by cocaine so is unlikely to have been the result of
carrier-reversal. It was also found in the present study that, even in the presence
of Ca2+, exposure of chromaffin cells to Na+-free conditions for up to 6h produced
no release of catecholamines above basal levels (results not shown). Under the
experimental conditions used, however, reversal of the plasma membrane Na+
gradient alone would not be sufficient to mediate efflux since it has been shown in
other systems (Schbmig etal., 1988; and Bonisch etal., 1984) that both this and
elevated cytosolic catecholamines are required for carrier-reversal to occur.
Incubation of chromaffin cells with radiolabeled ascorbic acid results in a rapid
uptake into the cells, this "newly-acquired" (NA)-ascorbate being initially found
in the cytosol (Knoth etal., 1987). NA-ascorbate, but not endogenous
catecholamine, was released from digitonin permeabilised cells in the absence of
Ca2+. NA-ascorbate release evoked by veratridine was also dependent on
extracellular Na+. It is suggested that NA-ascorbate is released from the cytosol
by a non-exocytotic mechanism of release; this being reversal of the Na+-linked
ascorbate symporter. In other words, some forms of carrier-reversal may occur
in chromaffin cells.
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The observations that the catecholamine uptake carrier does not appear to be
reversible, and the well-known inability of tyramine to displace endogenous
catecholamines suggest that the chromaffin cell system may be more dissimilar to
adrenergic neurons than previously suspected. PC12 cells possess a tyramine
releasable pool of catecholamines (Youdim etal., 1986) and also demonstrate
carrier-mediated efflux (Bonisch etal., 1984). Furthermore, both PC12 cells
and adrenergic nerve endings possess MAO type A, in contrast to MAO type B found
in chromaffin cells (Youdim etal., 1984). The lack of tyramine effect in
chromaffin cells was suggested to be due either to lack of a tyramine accessible
pool of catecholamines or absence of a specific site on the plasma membrane for
release (Youdim etal., 1986); When cells were permeabilised with digitonin
following 4h treatment with tyramine there was no release of catecholamines
above that released from untreated cells (results not shown). This suggests that
chromaffin cells do not possess a catecholamine pool that is available to tyramine.
In conclusion, catecholamine release caused by metabolic inhibition in chromaffin
cells may be mediated by a Na+-dependent mobilisation of internal Ca2+ stores.
Intracellular acidosis may activate the Na+/H+ exchanger leading to a Na+ influx
through this antiporter prior to catecholamine secretion. A mechanism of
carrier-mediated efflux which has been proposed to occur under similar
conditions in cardiac sympathetic neurons does not occur in chromaffin cells,
possibly due to the uptake carrier being "gated" in some way. These observations




Measurement of Granule Proteins and ATP as Markers for
Exocytosis
6.1 Introduction
When granules fuse with the plasma membrane during exocytosis they release not
only catecholamines but also ATP and a variety of soluble proteins including DBH,
chromogranins and a range of peptides. The co-release of these granule
components, but not cytosolic proteins, with catecholamines has been used to
distinguish exocytosis from other mechanisms of catecholamine release such as
passive diffusion or carrier-mediated efflux (Kirshner and Kirshner, 1971). It
has been demonstrated using specific antibodies directed against chromogranin A
that this is co-released with catecholamines in the same ratio as that present in
intact vesicles upon nicotinic stimulation (Kirshner and Kirshner, 1971).
Measurement of granule proteins released from chromaffin cells treated with
metabolic inhibitors would thus enable identification of the mode of catecholamine
release, the co-release of proteins and catecholamines being indicative of a
mechanism of exocytosis. In conjunction, measurement of the cytosolic protein
lactate dehydrogenase can be used to distinguish exocytotic release from
non-specific cell lysis.
The co-release of ATP with catecholamines has also been demonstrated by Rojas et
al. (1985) using an online detection system, monitoring the ATP-dependent
bioluminescent oxidation of firefly luciferin during acetylcholine-stimulated
secretion. Measurement of ATP released together with catecholamines would
provide further evidence for a mechanism of exocytosis. Under conditions of
metabolic inhibition ATP is rapidly depleted from the cell and nicotine-stimulated
secretion is abolished (Nakanishi etal., 1988). The ATP sequestered within the
chromaffin granule is metabolically inert and only exchanges with difficulty with
the cytoplasmic pool (Corcoran etal., 1986). Morita etal. (1988) demonstrated
that it is the labile cytoplasmic pool of ATP that is involved in exocytosis.
Digitonin permeabilisation was used to deplete the cytoplasmic pool of ATP and
this led to loss of the calcium-stimulated exocytotic response. This response was
restored by the addition of exogenous ATP, thus demonstrating the dependence of
exocytosis on cytoplasmic ATP. By combining digitonin permeabilisation with the
online bioluminescent detection of ATP it was anticipated that cytoplasmic ATP
could be measured and its depletion with metabolic inhibitors demonstrated.
6.2 Results
6.2,1 Detection of granule proteins.
Two methods were used to determine the presence of, and to quantitate the
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co-release of granule proteins with catecholamines. The first method used an
ELISA system. A range of dilutions of granule lysate of known protein
concentration were probed with specific antibodies to either DBH or chromogranin
A, as described in Chapter 2. Following development of the ELISA plates the amount
of antigen present in each well could be quantified by measuring the absorbance of
each well at 41 Onm. These results are shown in Fig 6.1. There was a linear
relationship between absorbance and the logarithm of the protein concentration
when lysate was probed with anti-DBH within the range of 0.1 pg to 1mg/ml of
total lysate protein. Below this concentration the assay system was not sensitive
enough to distinguish between wells of differing protein levels.
When probed with anti-chromogranin A the plot of protein concentration versus
absorbance was bell-shaped. This suggested there was an optimal range over
which chromogranin A can be detected using this system. At higher concentrations
there was a fall in absorbance. At high protein concentrations the protein may
leach off the wells and bind the antibody in suspension, the complex then being
washed off the plates. Consequently a much lower signal is obtained that does not
reflect the original protein concentration in the well. At concentrations below the
optimum there is a decrease in absorbance with decreasing protein concentration,
as is seen with detection of DBH, within the sensitivity limits of the assay.
Cell supernatants from cells treated for 10min with Locke's buffer (control),
10pM nicotine or metabolic inhibitors (M.I.) were serially diluted, following
centrifugation to remove any cell debris, applied to ELISA plates and probed with
either anti-DBH or anti-chromogranin A. Fig 6.2A illustrates the results plotted
as log dilution factor versus absorbance at 41 Onm. It was not possible to
distinguish between the three samples when probed with DBH. The dilution range
used was quite broad so the difference in levels of DBH in the three samples may
not be great enough to be able to detect any variation in absorbance.
The supernatants targeted with chromogranin A gave a similar bell-shaped graph
to that seen with granule lysate (Fig 6.2B). Within what appears to be the optimal
protein concentration range both the 'nicotine' and 'metabolic inhibition'
supernatants contained significantly higher levels of chromogranin A than the
control supernatants as indicated by the higher absorbance values (p< 0.001 for
dilutions of 50-fold and 100-fold). The 'nicotine' supernatant possessed the
highest level of chromogranin A as predicted from the catecholamine release
measured in the undiluted supernatants (12% catecholamine release from
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6.1 Detection of DBH and chromogranin A in granule lysate using an ELISA
system. Wells were coated using 0.1ml of diluted lysate of whole
chromaffin granules for 90min at 37°C. Absorbance is plotted as a
function of the log of the protein concentration used during coating.
Antibodies were used as described in Chapter 2. Results are expressed























































Fig 6.2 Detection of DBH in cell supernatants by ELISA. Cells were treated for
10min with Locke's buffer plus or minus 10|iM nicotine or metabolic
inhibitors. A range of dilutions were probed for DBH (A) or
chromogranin A (B). Results are plotted as mean absorbance, 410nm
± SE of 4 determinations versus log dilution factor.
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nicotine stimulated cells compared with 10.3% from cells treated with metabolic
inhibitors, and 2.9% basal release).
This result suggests that under both conditions described chromogranin A is
co-released with catecholamines, indicative of a mechanism of exocytosis. These
results are, however, only qualitative, not quantitative, due to the lack of a simple
correlation between protein content and signal, the latter being disproportionately
lower at higher protein concentrations. Without a quantitative measurement of
protein in the supernatant it was not possible to determine whether the
catecholamine/protein ratio reflected that in the granules.
In order to quantitate the amount of chromogranin A being released under
conditions of metabolic inhibition compared with nicotinic stimulation PAGE and
Western blotting was utilised. It was assumed that all the protein entered the gel
and the majority transferred to nitrocellulose (as indicated by staining the
residual gel following transfer). In case transfer was not uniform across the
nitrocellulose/gel sandwich each cell supernatant was applied several times
across the full width of the gel. Granule lysate of known protein content was
treated identically. Blots were then developed with antiserum, biotin-labelled
second antibody and [125l] streptavidin, and autoradiographed. The two gels were
run, blotted and labelled in parallel so that it was possible to make a direct
comparison of band intensities between the two resulting autoradiographs.
Chromogranin A was targeted in preference to DBH since the former is sequestered
solely within the granule matrix. DBH is found both in the granule matrix and
bound to the granule membrane. Following exocytosis membrane-bound DBH is
exposed at the cell surface (Hunter and Phillips, 1989) so possible contamination
of the samples with cell membrane debris could lead to a false positive result.
An approximation of the amount of protein derived from the interior of the
secretory granules and present in the culture supernatants was calculated, using
the known percentage of cellular catecholamine that was released in the
experiment. This was then used as a guide in order to obtain a standard curve
relating protein content to the intensity of the chromogranin band on the
autoradiographs.
The mean catecholamine content of the three culture supernatants was 4.7
nmol/ml (Table 6.1). Using a value of 2.5|i.mol catecholamine/mg protein for the
soluble content of a granule (Winkler and Westhead, 1980), the mean protein
content of the culture supernatants was reckoned to be 1.9pg/ml. Of this, about
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80% should be chromogranin A. Therefore dilutions of granule lysate to give
values around this order of magnitude (0.05 to 0.4pg) were applied to separate
tracks on the gel in order to construct the standard curve (of band intensity
versus protein content).
The resultant autoradiograph (Fig 6.3A) and the plot of protein concentration
versus peak integral (Fig 6.3B) showed a direct, linear relationship between
protein concentration and band intensity, as measured using densitometry. Fig 6.4
illustrates the parallel autoradiograph obtained from the culture supernatants of
treated cells, probed with the same anti-chromogranin A and 125l streptavidin.
Band intensities of 'nicotine' and 'metabolic inhibition' samples were significantly
higher than those of the control samples. From the integrals of the densitometric
peaks for each band the concentration of total soluble granule was calculated using
the standard curve (Fig 6.3B). These results are shown in Table 6.1.
Table 6.1
Content of soluble granule proteins in culture supernatants under conditions of
nicotine stimulation or metabolic inhibition. Catecholamine release is measured as
percentage of total catecholamine in the cells, and protein was calculated from the
standard curve (Fig 6.3) and is presented in pg/ml of culture supernatant (mean
± SE of three determinations).
Sample Catecholamine Catecholamine Soluble granule Ratio











1.56 ± 0.02 1.51
3.88 ± 0.05 1.95
3.25 ±0.03 1.58
The amount of protein released from the stimulated cells was significantly higher
than that released under basal conditions (p<0.001). Taking a value of 2.5|imol
catecholamine/mg protein in the granules it was predicted that if granule proteins
were co-released with catecholamines values of 0.95pg (control); 3.0pg (10pM
nicotine); and 2.05pg (metabolic inhibition) were expected. The actual values
obtained (Table 6.1) were all higher than the predicted values. The
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Fig 6.3 A. Autoradiograph of chromogranin A detected in granule lysate over a
protein range of 0.05 to 0.4p.g. Chromogranin A was detected using
anti-chromogranin A and IgG-biotin linked to l2Sl-streptavidin
following PAGE and Western blotting.
B. Plot of band intensities measured by densitometry (integral of peak,
arbitrary units) versus total protein loaded on gel track (p.g).
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6.4 Autoradiograph of chromogranin A detected in culture supernatants
from cells treated with Locke's buffer (tracks 1), 10p.M nicotine
(tracks 2), or metabolic inhibitors (tracks 3).
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The catecholamine content of granules is approximately 2.5pmol/mg total protein
(Winkler and Westhead, 1980). As only 80% of this is soluble protein the
catecholamine/soluble protein ratio is probably closer to 3pmol/mg protein.
There will, however, be deviations from this value as the relative amounts of
catecholamines and protein varies in different cell populations, and also
noradrenaline containing granules may differ from adrenaline containing
granules. In addition, catecholamines may be taken up again or metabolised. The
evidence presented here is strongly suggestive of chromogranin A being
co-released with catecholamines under conditions of both metabolic inhibition and
nicotine stimulation.
This was backed up by measurement of neuropeptide Y by radioimmunoassay
(Richardt etal., 1988) which is also sequestered within the secretory granules.
These results are presented in Table 6.2.
Table 6,2
Detection of neuropeptide Y in culture supernatants under conditions of
Sample Catecholamine release Neuropeptide Y
nmol/ml nmol/ml
Control 2.68 0.07 ±0.008
(3.1%) (8)
10pM Nicotine 5.18 0.19 ±0.02
(12.0%) (9)
Metabolic Inhibition 4.42 0.23 ±0.01
(10.3%) (6)
Catecholamine release is presented in nmol/ml with percentage release in
parenthesis. Neuropeptide Y is presented in nmol/ml ± SE (number of
determinations in parenthesis).
There was a significant increase in the release of neuropeptide Y following
stimulation with either nicotine or metabolic inhibitors (p<0.001). It was not
possible, however, to make a direct comparison of neuropeptide Y with
catecholamine release as even in the control samples the amount of neuropeptide Y
present was at the upper limit of the detection system. The 'nicotine' and
'metabolic inhibition' samples may have been too concentrated for the
radioimmunoassay and so the values obtained are probably underestimates of the
amount of neuropeptide Y present. This might account for the higher neuropeptide
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Y concentration in the 'metabolic inhibition' samples despite the percentage
catecholamine release being lower than that obtained with nicotinic stimulation.
6.2.2 Detection of the cvtosolic protein, lactate dehydrogenase.
The results presented above suggest that both chromogranin A and neuropeptide Y
are co-released with catecholamines under conditions of metabolic inhibition. This
is indicative of a mechanism of exocytosis. It is plausible, however, that these
conditions could cause non-specific cell lysis although from evidence discussed in
Chapter 4 this would appear unlikely. To confirm that the cells maintain their
integrity under conditions of metabolic inhibition lactate dehydrogenase was
assayed in parallel with catecholamines. There was no release of lactate
dehydrogenase above basal levels under conditions of either metabolic inhibition
or nicotine stimulation (Fig 6.5). In contrast, digitonin permeabilisation which
renders the plasma membrane leaky caused 18% of the total cellular lactate
dehydrogenase to be released over 10min. There was only 0.9% catecholamine
release, under these conditions, indicating that the granules remain intact. In
conclusion, therefore, under the conditions described, the cells maintain their
integrity and catecholamines are released by a mechanism of exocytosis.
The method of digitonin permeabilisation was used in a further confirmation of
this. Leakage of catecholamines from the granules into the cytosol under conditions
of metabolic inhibition should result in an increase in catecholamines released by
permeabilising the cells with digitonin. Cells exposed to 10jiM digitonin following
10min metabolic inhibition showed no elevation of catecholamine release
compared to release from control cells, even in the presence of pargyline (results
not shown), further confirming that release by the action of metabolic inhibitors
is exocytotic in origin.
6.2.3 Bioluminescent detection of ATP.
ATP released during exocytosis can be directly and continuously detected by the
luciferin-luciferase assay method. As shown in Fig 2.2 the light response was
logarithmically related to the concentration of ATP present.
Initial assays using chromaffin cells in suspension were carried out on
approximately 104 cells. It was found, however, that the ATP content measured
following cell lysis with Triton X-100 was consistently about 100 times lower
than was predicted from the catecholamine content of the cells. This could be due to
the presence of some factor in the cell suspension inhibiting the




























Control 10jxM Nicotine M.I. 10jiM Digitonin
Fig 6.5 Measurement of lactate dehydrogenase. Cells were treated for 10min
with Locke's buffer (control), 10^.M nicotine, metabolic inhibitors
(M.I.), or 10|xM digitonin (in calcium-free buffer). Catecholamine
and LDH were measured in culture supernatants and residual amounts
measured following lysis with 1% Triton X-100. Results are
expressed as percent release, means ± SE of triplicate determinations.
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by ATPases which are released on cell lysis. Therefore, following cell lysis
internal standards of known ATP concentration were included in the assay system.
Exogenous ATP was added at a concentration similar to that found in the cells
(5x105 cells contain 50nmol catecholamine which is equivalent to 11 nmol ATP,
assuming a catecholamine/ATP ratio of 4.5) and the light intensity monitored for
20min. Over this time there was no reduction in the light intensity and this was
the same as that obtained in the absence of cells, indicating that the assay system
is not affected by the presence of cells or by the detergent Triton X-100. In
addition, over this time, loss of ATP by hydrolysis does not seem to be a problem.
Inclusion of an ATP regenerating system (1pmol phosphoenolpyruvate and 5ml)
pyruvate kinase) did not affect the light intensity of exogenous ATP in the
presence of cells. Thus the discrepancy between the amount of ATP measured by
this assay method and the predicted amount could not be accounted for.
One possibility was that ATP released into the immediate cell surroundings was
hydrolysed by local ATPases which did not come into contact with exogenous ATP.
Alternatively there may be some factor co-released from the granules with ATP
that affected its detection. For instance, within chromaffin granules ATP is in
association with catecholamines and possibly also matrix proteins (Koppell and
Westhead, 1982). This could reduce the amount of ATP available to the assay
system, which would not be seen with exogenous ATP. Therefore the ATP content of
lysed granules was measured over a range of dilutions and the catecholamine
content measured in parallel.
Granule lysate was diluted with assay buffer over a 10,000 fold range and
samples assayed in triplicate for ATP and catecholamine content. Fig 6.6 shows the
relationship between ATP and catecholamine contents. There.was a good correlation
(r=0.98) between the two variables. From the regression line a molar ratio of
8.6 catecholamine/ATP was calculated. Winkler and Westhead (1980) reported a
molar catecholamine/ATP ratio of 4.5. However ratios of 8.2,10 and 12 have also
been reported (for discussion see Winkler and Westhead, 1980). Chromaffin
granules appear to be non-homogeneous in terms of catecholamine and ATP content
so the ratio obtained here is not necessarily inconsistent with other observations.
In any case, it can be concluded that the ATP assay is not affected by any granule
components and ATP in the matrix can be assayed by this method.
Rojas et al. (1986) reported that emitted light was linearly related to ATP levels
in chromaffin cells, provided the concentration of cells in the reaction mixture
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was kept below 105 cells/ml. In their experiments they generally used less than
2.5x105 cells/ml in order to minimise ATP hydrolysis by ecto-ATPases. I
therefore used approximately 10,000 cells in 200pJ samples (i.e. 0.5x105
cells/ml), assaying their ATP content following lysis with Triton X-100. Under
these conditions the amount of ATP measured was close to that predicted from the
catecholamine content (assuming a catecholamine/ATP ratio of 4.5). Values
ranging from 15 to 40nmol/106 cells were calculated. Taking an average
catecholamine content of 100nmol/106 cells (Phillips, 1977) the ATP content
was predicted to be about 22nmol/106 cells. The values found were generally
within the predicted range for these very dilute cell suspensions, taking into
consideration the variability in catecholamine content of different cell
preparations and consequent likely variations in ATP content, and also the fact that
the number of cells in each assay was only known approximately.
The release of ATP in the presence or absence of different secretagogues was
monitored over 10min. Readings were taken every min and a time course of
secretion plotted (Fig 6.7). After 10min a known amount of ATP was added to
check the calibration of the system. The signals from exogenous ATP did not
significantly deviate from the signal obtained with the same ATP concentration in
the absence of cells. Alternatively at the end of each time course cells were lysed
with Triton X-100 to determine the total cell ATP content. After 10min the %
total ATP released was 2.5% ±0.8 (control); 8.3% ± 1.0 (10p.M nicotine); and
6.1% ± 1.6 (metabolic inhibition). These values are similar to those reported by
Rojas et al. (1985), 10p.M acetylcholine releasing approximately 8% of total
ATP in 2min in their experiments. The time course of secretion was consistent
with that obtained for catecholamine secretion (Figs 3.6 and 4.4).
Nicotine-stimulation gave the greatest response, the bulk of secretion occurring
within 2min of the addition of the agonist. In contrast, the release evoked by
metabolic inhibitors was smaller and the response slower, a gradual increase in
ATP being seen with time. Therefore under conditions of both cholinergic
stimulation and metabolic inhibition ATP release seems to parallel catecholamine
secretion, suggesting that both are released from the same cellular pool.
1 04
50 -|
1 2 3 4 5 6
ATP nmol/ml
Fig 6.6 Plot of catecholamine nmol/ml versus ATP nmol/ml measured in
granule lysate. Results are the means of triplicate determinations
(error bars omitted for clarity) and the best-fit line drawn by
regression analysis.
Time (min)
Fia 6.7 Time course of ATP release over 10min from lO4"cells in 200pl
treated with Locke's buffer (control), 10|iM nicotine or metabolic
inhibitors (M.I.). Results are expressed as pmol ATP/106 cells, means




Immunological techniques have been used to demonstrate an exocytotic mechanism
of release after stimulation of chromaffin cells with various secretagogues.
Following stimulation with nicotine or metabolic inhibitors there was a
significant release of chromogranin A from the cells compared with basal release.
The catecholamine/chromogranin A ratio in the supernatant was similar
to that in intact granules, indicating that both are released from the same cellular
store. Elevated neuropeptide Y was also found following stimulation of cells. It was
not possible, however, to obtain a reliable quantitative estimate of the molar ratio
of neuropeptide Y to catecholamine. Neuropeptide Y is known to be sequestered
within the chromaffin granule along with catecholamines and other soluble
proteins (Winkler and Westhead, 1982).
The co-release of neuropeptide Y has also been reported in isolated perfused
guinea pig hearts following nicotine or electrical stimulation (Richardt etal.,
1988; and Haass etal., 1989). Release of both catecholamines and neuropeptide Y
were Ca2+ sensitive and modulated by presynaptic regulation. Non-exocytotic
release of noradrenaline induced by tyramine perfusion of hearts did not evoke
co-release of neuropeptide Y. Similarly anoxia evoked a noradrenaline overflow
which was sensitive to desipramine, but there was no concomitant release of
neuropeptide Y (Haass et al., unpublished observations). This absence of
neuropeptide Y was taken as a further indication of carrier-mediated efflux of
noradrenaline during anoxia.
Sympathetic neurons contain both large and small dense core vesicles (Winkler,
1988). The large dense core vesicles contain catecholamines, ATP,
chromogranins, enkephalins and neuropeptide Y. The small dense core vesicles are
known to contain noradrenaline and ATP, but do not contain chromogranin A,
enkephalins or neuropeptide Y. It might be postulated that under conditions of
anoxia the sensitivity of the two different types of vesicles to the metabolic
changes is altered so that only the small dense core vesicles release their contents
to the exterior, accounting for the absence of neuropeptide Y. Furthermore small
dense core vesicles located at the nerve terminal seem to go through several cycles
of release. Under anoxic conditions they may be more readily able to release their
contents, even in the absence of ATP, being close to the site of release, unlike large
dense core vesicles. The latter are formed in the cell body and transported to the
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nerve terminal by axoplasmic flow. In the absence of ATP the processes required
for transport of the large dense core vesicles to the sites of release and subsequent
exocytosis would be inhibited.
Chromaffin cells possess only one type of secretory vesicle. In these cells the
co-release of chromogranin A, neuropeptide Y and catecholamines under conditions
of metabolic inhibition suggests that release was exocytotic, the absence of lactate
dehydrogenase in the supernatant indicating that the cells maintained their
integrity.
Exocytotic secretion from electrically permeabilised chromaffin cells has an
absolute requirement for-exogenous Mg-ATP (Baker and Knight, 1981).
Additionally, conditions of metabolic inhibition cause a rapid reduction in
cytoplasmic ATP and catecholamine secretion evoked by carbamylcholine in intact
chromaffin cells and by direct calcium challenge in digitonin permeabiiised cells
(Nakanishi etal., 1988). in contrast, Reynolds etal. (1982) reported that
metabolic inhibitor-induced depletion of cellular ATP in PC12 cells did not result
in any inhibition of acetylcholine or dopamine release evoked by carbachol or high
K+.
Recently Holz etal. (1989) reported that in the absence of Mg2+ and ATP both
intact and permeabilised chromaffin cells secrete a small, but significant amount
of catecholamine in response to elevated Ca2+. It is suggested that intact cells are
primed by intracellular ATP so that upon permeabilisation there is an element of
release that is ATP-independent. Furthermore, if granules are adjacent to the
plasma membrane, ATP may not be required and exocytosis could occur
spontaneously under certain conditions, such as metabolic inhibition.
6.3.2 ATP measurements
By monitoring the bioluminescent oxidation of luciferin it should be possible to
demonstrate a rundown of cytoplasmic ATP in the presence of metabolic
inhibitors. The cytoplasmic pool of ATP represents only 10% of the ATP in the
cell. Therefore, initial experiments concentrated on measuring granule ATP
released following nicotine stimulation, and total cell ATP liberated by detergent
in order to establish a suitable method of detection. However, it became apparent
that this assay method had severe limitations. Both the enzyme system and ATP are
highly labile which necessitated repeated calibration. In addition, when a
scintillation counter is used 'in-coincidence' as a photon counter it is necessary
for two pulses, one from each photomultiplier, to be detected within 3x10"8sec to
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record a signal. This limits the sensitivity of the assay since the number of signals
is much lower than the number of photons produced at very low ATP
concentrations. At this lower end of the standard curve background noise also
masks the real signal. At high ATP concentrations more than a single pair of
photons are produced at any one time and the detection system is not sensitive
enough to discriminate between them, the reading obtained being an underestimate
of the light produced (as discussed by Stanley and Williams, 1969).
Additionally it was found that with an increasing number of cells in the assay (up
to 5x105/ml) the signal was approximately 100 times lower than that expected.
Only when less than 105 cells/ml were assayed did the amount of ATP correlate
with the catecholamine release. The reason for this apparent discrepancy is not
very clear. This has previously been reported by Rojas et al. (1985), being
attributed in that case to ecto-ATPases.
It has, however, been possible to demonstrate the co-release of catecholamines and
ATP following treatment of cells with either nicotine or metabolic inhibitors; the
extent of ATP release being greater than basal release and of a similar magnitude
and time course to catecholamine release.
The cytosolic ATP pool, which represents only approximately 10% of the total
cellular ATP, has been measured following digitonin permeabilisation (Rojas et
al., 1985). Treatment of cells with metabolic inhibitors specifically depletes this
cytoplasmic pool and secretion after 30min in the presence of dinitrophenol
(Nakanishi eta!., 1988). Under the conditions described here it did not prove
possible to make a direct measurement of the cytoplasmic ATP pool or to
demonstrate its depletion with metabolic inhibitors. There is, however, indirect
evidence: following 10min treatment with metabolic inhibitors, the response to
nicotine stimulation or to high K+ is completely abolished. Uptake of [3H]
noradrenaline is also inhibited in the presence of metabolic inhibitors. These
observations provide indirect evidence for the depletion of the cytoplasmic ATP
pool as it is this pool that is metabolically active. Thus this exocytotic release is
apparently independent of cytoplasmic ATP.
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Chapter Seven
Role of [Ca2+]j in Catecholamine Release Induced by Metabolic
Inhibition
7,1 introduction
It is now widely recognised that exocytosis in the chromaffin cell has an absolute
requirement for extracellular Ca2+. Following stimulation with a nicotinic agonist
or direct depolarisation with high K+, the influx of Ca2+ through
voltage-dependent Ca2+ channels raises cytosolic Ca2+ and triggers a chain of
events that leads ultimately to exocytosis.
The rise in [Ca2+]j is transient, returning to basal levels within minutes (as
described in cell populations loaded with quin-2, Knight and Kesteven, 1983; and
in single cells loaded with aequorin, Cobbold etai, 1987). There are probably
several mechanisms for maintaining resting Ca2+ levels and for removing Ca2+
from the cell following exocytosis. Intracellular organelles such as mitochondria,
endoplasmic reticulum and chromaffin granules are potential storage sites for
calcium. The chromaffin granules may also play a role in removal of Ca2+ from
the cell via exocytosis, along with the Ca2+ pump and Na+/ Ca2+ exchanger of the
plasma membrane itself.
The role of intracellular organelles in calcium homeostasis was investigated in
permeabilised cells by Kao (1988). Following stimulation with acetylcholine it
was found that only 5 to 10% of the resultant calcium influx was subsequently
sequestered by intracellular organelles. Most of this was taken into the
endoplasmic reticulum which is thought to be responsible for buffering small
fluctuations in resting calcium levels. The chromaffin granules and mitochondria
did not appear to have an important role. Consequently, following a rise in [Ca2+],
most must be removed from the cell across the plasma membrane via the Ca2+
pump and the Na+/Ca2+ exchanger. Exocytotic release of calcium from chromaffin
granules has been demonstrated (von Grafenstein and Powis, 1989), but this is
thought to be of relevance mainly to long term Ca2+ homeostasis rather than to the
immediate restoration of resting Ca2+ levels following stimulation and Ca2+
influx.
The use of Ca2+-sensitive fluorescent indicators and permeabilisation techniques
has allowed direct access to the cytosol and visualisation of the changes in [Ca2+]j
in situ during the exocytotic event itself. These studies have revealed the potential
involvement not only of extracellular Ca2+ but also of intracellular Ca2+ released
from subcellular organelles in stimulus-secretion coupling.
Using the fluorescent indicator quin-2 Knight and Kesteven (1983) made direct
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measurements of the resting [Ca2+]j and found it to be approximately 100nM. It
increased transiently on stimulation with acetylcholine or high K+; this rise was
complete within seconds, and decayed over minutes. An elevation of [Ca2+]j to
around 300 to 500nM was sufficient to trigger catecholamine release following
stimulation with carbamylcholine (Burgoyne, 1984); and this rise in [Ca2+]j
was totally dependent on external Ca2+. However, an elevation of [Ca2+]j to
300nM induced by application of the Ca2+ ionophore A23187 was not sufficient to
trigger secretion, suggesting the involvement of an additional second messenger in
the nicotinic response.
Studies on single chromaffin cells microinjected with aequorin have revealed that
the Ca2+ transient in response to nicotinic stimulation lasts only 60 to 90s. The
transient is more prolonged in cell populations loaded with quin-2 due to the
heterogeneity of the response within a population of cells (Cobbold et a/.,1987).
Use of the Ca2+-sensitive indicator, Fura-2, has allowed monitoring of changes in
[Ca2+]j in single cells within the range of hundreds of milliseconds and
visualisation and spatial resolution of the calcium signal using digital video
imaging. This technique has revealed details of the calcium signal in response to a
variety of secretagogues (O' Sullivan etal., 1989; and 0' Sullivan and Burgoyne,
1989).
Within 2s after stimulation with nicotine or high K+ there was an elevation of
[Ca2+]| that was limited to a region just beneath the plasma membrane. This is
attributed to entry of extracellular Ca2+ via voltage-dependent and, in the case of
nicotine, receptor-linked Ca2+ channels. Following this there is diffusion of
calcium throughout the cell and a second larger rise in Ca2+ internally. This latter
event is due to the release of Ca2+ from intracellular storage sites and itself
depends on the initial entry of external Ca2+. Secretion occurs over the whole
surface of the cell, as demonstrated in single chromaffin cells cocultured with
Fura-2 loaded NIH-3T3 cells, the latter fluorescing in response to ATP which is
co-released with catecholamines from the chromaffin cell (Cheek etal., 1989a).
The catecholamine release evoked by metabolic inhibition may be triggered by a
rise in [Ca2+]j mobilised from intracellular stores rather than from an influx of
extracellular Ca2+, since release is independent of external Ca2+ (see Fig 4.5).
Such a response has been observed using Ca2+-indicators in bovine chromaffin
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cells when stimulated with muscarinic agents(Cheek and Burgoyne, 1985; 0'
Sullivan and Burgoyne, 1989; and Cheek eta!., 1989b). There is a rise in [Ca2+]j
that is totally independent of extracellular Ca2+. A similar response is seen with
both bradykinin and angiotensin II. These agonists trigger a receptor-mediated
activation of phospholipase C leading to phosphoinositide breakdown and
accumulation of IP3. Generation of IP3 triggers the release of Ca2+ from IP3
sensitive stores. This elevation of [Ca2+]j is limited to distinct sites within the
cell, and digital imaging has shown the rise in [Ca2+]j to be associated with one
pole of the cell.
The muscarinic rise in [Ca2+]j is of a similar magnitude to that seen with
nicotine, but is not associated with catecholamine secretion. It is probable that the
rise in [Ca2+]j occurs at the pole of the cell occupied by the nucleus, endoplasmic
reticulum and Golgi, away from the secretory granules. The IP3-sensitive
component of the endoplasmic reticulum is often found to be localised at one pole of
the cell. A similar pattern is seen with bradykinin and angiotensin II, which
trigger a small secretory response. In support of this, the catecholamine release
in response to angiotensin II was polarised and was associated with the same pole
of the cell as the rise in [Ca2+]| (Cheek etal., 1989b). The magnitude of the
[Ca2+]j elevation in response to bradykinin and angiotensin II was greater than
that seen with muscarine, and this may explain their ability to evoke
catecholamine secretion proportionate to the size of the [Ca2+]j rise. In the case of
bradykinin, stimulation was associated with a secondary influx of Ca2+ through
the plasma membrane which may be the mediator of the secretory response,
rather than the initial release of Ca2+ from internal stores. Catecholamine release
in response to bradykinin, angiotensin II and methacholine is significantly reduced
in the absence of extracellular Ca2+ but the rise in [Ca2+]j remains unchanged (O*
Sullivan and Burgoyne, 1989). Thus while these agents are able to mobilise
internal calcium stores this event alone is not associated with a significant release
of catecholamines. However, in other species, e.g rat and guinea pig, muscarinic
stimulation is able to evoke catecholamine release from adrenal glands and this is
known to occur in the absence of extracellular calcium (Nakazato etal., 1988).
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Ca2+ is also released internally from the mitochondria of hepatocytes under
conditions of anoxia (Nishida et al., 1989), this efflux being induced by a decrease
in intramitochondrial ATP. This Ca2+ efflux is then associated with the subsequent
loss of oxidative phosphorylation capacity and irreversible cell injury seen in
ischaemic myocytes. In chromaffin cells the mitochondria are relatively
metabolically inert in buffering cytosolic Ca2+ levels following a rise in [Ca2+]j
(Kao, 1988). Calcium uptake by the mitochondria in chromaffin cells only
became significant when the calcium concentration was increased above
micromolar levels. The catecholamine release evoked by metabolic inhibitors may
be triggered by Ca2+ efflux from mitochondria induced by ATP rundown which
occurs under these conditions. In the following experiments the calcium indicator
Fura-2 was utilised to investigate the relationship between [Ca2+]j and metabolic
inhibition in chromaffin cells.
7.2 Results
7.2.1 Measurements of fCa2+1j
Fig 7.1 shows the rise in [Ca2+]j in chromaffin cell suspensions in response to
stimulation with nicotine, acetylcholine and high K+, and under conditions of
metabolic inhibition. Cholinergic stimulation and depolarisation with high K+
produced a rapid elevation of [Ca2+]j from resting levels to a maximum of between
200 and 500nM within seconds, which then gradually fell over subsequent
minutes. Similar calcium transients have previously been reported by other
workers (Burgoyne and Cheek, 1985; Cheek and Burgoyne, 1985; and Cobbold et
al., 1987). In the absence of extracellular Ca2+ there was no rise in [Ca2+]j in
response to nicotine or high K+ (Fig 7.2A). Upon readdition of 3mM Ca2+ an
immediate rise in [Ca2+]j was observed, again consistent with previous reports
(Burgoyne and Cheek, 1985). However, [Ca2+]j remained elevated for at least 2
to 3min after the readdition of Ca2+. In the case of K+ depolarisation the
voltage-dependent Ca2+ channels remain open in the presence or absence of
external Ca2+, even though the secretory response has terminated (Burgoyne and
Cheek, 1985). [Ca2+]j also remained elevated following nicotine stimulation (Fig
7.2A) suggesting the transient nature of the secretory response cannot be solely
attributed to receptor desensitisation and closure of voltage-dependent Ca2+
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Fig 7.1 Changes in [Ca2+]j in chromaffin cell suspensions in response to nicotine,
acetylcholine, high K+ and metabolic inhibitors. Basal [Ca2+]j was monitored for
5min then media (all containing 3mM Ca2+) were supplemented with 10pM








































Fig 7.2A Changes in [Ca^i in chromaffin cell suspensions in response to
nicotine, high K* and metabolic inhibitors in the presence and absence
of external Cazt The response to10p.M nicotine (nic); 50mM KCI
(KCI); or metabolic inhibitors (M.I) was monitored in Caz+-free














Fig 7.2B Response of cells to nicotine, high K+ or metabolic inhibitors in the
nominal absence of external Ca^. The figure is an enlargement of
Fig 7.2A over the Ca^-free period.
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channels (Burgoyne and Cheek, 1985).
Treatment of cells with metabolic inhibitors in the presence of extracellular Ca2+
produced a rise in [Ca2+]j comparable in magnitude to that seen with nicotine or
high K+ (Fig 7.1). However, this elevation of [Ca2+]j was slower than that seen
with other secretagogues and [Ca2+]| remained at this elevated level for at least
5min. This response was seen with several cell preparations, [Ca2+]j rising to a
plateau over several minutes.
When Ca2+ is omitted from the external medium metabolic inhibitors evoked a
small but significant rise in [Ca2+]j (Fig 7.2B). Readdition of external Ca2+ (Fig
7.2A) produced a large rise in [Ca2+]j as previously seen (Fig 7.1). The slow and
relatively small rise in [Ca2+]j can only be seen in the absence of external Ca2+. The
latter effect may be the result of mobilisation of intracellular Ca2+ stores
(extracellular Ca2+ being nominally absent). Thus there may be two elements to
the rise in [Ca2+]j, one that results from an influx of external Ca2+, and a much
smaller rise which is the result of released intracellular Ca2+ and which is seen
in the absence of external calcium.
7.2.2 Effect of nicotine pretreatment
Further questions about the nature of catecholamine release evoked by metabolic
inhibition were raised following observation of the effect of nicotine
pretreatment. When cells were treated for 10min with 10jxM nicotine and the
supernatant was then replaced with buffer containing metabolic inhibitors, the
subsequent catecholamine release was significantly greater than that seen with
metabolic inhibitor treatment alone (Fig 7.3A). This potentiated response was not
seen if the cells were pretreated for 10min with Locke's buffer alone or buffer
containing 50mM K+.
The inability of high K+ to potentiate the response evoked by metabolic inhibitors
suggested that it must be some feature of nicotinic treatment that causes this
augmented response. Stimulation of chromaffin cells with nicotine results in
disassembly of the cortical actin network (Cheek and Burgoyne, 1986). The actin
disassembly was not seen with other secretagogues including high K+. Thus it was
conceivable that nicotine pretreatment might 'open' the cytoskeletal network,
allowing more granules access to the plasma membrane upon treatment with
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Fig 7.3A Response of cells to metabolic inhibition following pretreatment with
nicotine. Cells were treated with Locke's buffer plus 10pM nicotine; after 10min
this buffer was replaced with Locke's buffer (Basal); Locke's buffer plus lOpM
nicotine or Locke's buffer plus metabolic inhibitors (M.I.). Catecholamine release
was measured after a further 10min. The figure shows the response in untreated
cells (Normal response) and after 10min nicotine exposure (Nic pretreated).
Results are expressed as percentage catecholamine release of total cell
catecholamine content at the start of the experiment, means ± SE of triplicate
determinations.
Fig 7.3B Release of catecholamines with metabolic inhibitors following
pretreatment with nicotine for various times. Cells were treated with Locke's
buffer plus 10pM nicotine for different lengths of time from 0.5 to 10min. The
buffer was then replaced with Locke's buffer (basal release) or Locke's buffer
plus metabolic inhibitors. Catecholamine release was measured after 10min and
was expressed as a percentage release of total cell catecholamine content at the
start of the experiment in response to metabolic inhibitors after subtraction of
basal release. This is plotted as a function of the time of nicotine pretreatment.






metabolic inhibitors resulting in a second larger release of catecholamines. This
was investigated in more detail by pretreating the cells with 10p.M nicotine for
increasing lengths of time, ranging from 0.5 to 10min, and then measuring the
catecholamine release produced by subsequently replacing the nicotine with
metabolic inhibitors for 10min. Basal release values (10min with Locke's buffer
alone following nicotine pretreatment) were subtracted. The results are shown in
Fig 7.3B.
Treatment of this batch of cells with metabolic inhibitors alone produced a release
of 4.3% above basal levels. Following nicotine pretreatment a release of up to
10% above background was observed. However, no release above that obtained in
the absence of pretreatment was seen until after 1 to 2min pretreatment with
nicotine. Consequently, this potentiation of the response cannot be explained by
actin disassembly, since disassembly is followed by reassembly within the first
60s after nicotine stimulation (Cheek and Burgoyne, 1986). Furthermore, a
recent report has demonstrated that high K+ also elicits a reduction in filamentous
actin at the cell periphery (Burgoyne etai, 1989). Therefore, the
nicotine-evoked potentiation of the response to metabolic inhibitors must either
be due to some event at the nicotinic receptor itself or be due to some event
subsequent to actin disassembly that is not triggered by high K+.
7.3 Discussion
In order to gain further insights into the mechanism of catecholamine release
evoked by metabolic inhibition the role of intracellular cytosolic free Ca2+ was
examined using the fluorescent Ca2+ indicator Fura-2. Both the free and
Ca2+-bound forms fluoresce strongly but their excitation peaks are at different
wavelengths. Thus by measuring the ratio of Ca2+-bound to free dye it is possible
to estimate cytosolic free Ca2+. This method overcomes the problems of dye
concentration and cell thickness encountered with single wavelength
measurements. One problem encountered in measuring the fluorescence of a cell
population in suspension was a gradual increase in apparent basal levels with time
after loading. This is in fact due to some leakage of Fura-2 from intact cells
despite being kept to a minimum by keeping the cells on ice. As the experiments
involved monitoring changes in [Ca2+]j rather than determination of absolute
values, this problem was not considered to be critical to the results obtained.
The secretagogues nicotine, acetylcholine, and high K+ all showed a similar
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transient response that was dependent on extracellular Ca2+, as reported by other
workers (Burgoyne and Cheek, 1985). In contrast, metabolic inhibition caused a
large rise in [Ca2+]j that was retained for at least 5min. The [Ca2+]| rise was
relatively slow compared with the rise evoked by other secretagogues. In single
cells the rise in response to nicotine occurs within 1s and the maximal response
is reached after 27s (O' Sullivan etal., 1989). The rise induced by metabolic
inhibition did not reach a plateau until several minutes after the initial rise was
observed.
As catecholamine release occurred independently of external calcium it was
postulated that this was due to a mobilisation of internal Ca2+. In the absence of
extracellular Ca2+ there was a rise in [Ca2+]j but this was much smaller than
that seen in the presence of Ca2+. Muscarinic secretagogues mobilise an IP3
sensitive Ca2+ store independently of external Ca2+. The subsequent rise in
[Ca2+]| does not, however, evoke catecholamine secretion (0' Sullivan and
Burgoyne, 1989). This lack of secretion has been attributed to the intracellular
localisation of the Ca2+, this being at one pole of the cell away from the secretory
granules (O' Sullivan etal., 1989). Agents such as bradykinin which do evoke a
small secretory response also mobilise calcium release from an IP3 sensitive
store but it now appears to be a secondary influx of Ca2+ at one pole of the cell
rather than the released internal Ca2+ that is the trigger for exocytosis (Cheek et
ai, 1989a).
It is not possible to discern from these results whether or not it is the rise in
[Ca2+]j evoked by metabolic inhibition that causes catecholamine release. Recent
studies on the ability of nicotine stimulation to evoke secretion compared with
muscarinic stimulation suggest that it is the Ca2+ influx rather than mobilisation
of internal Ca2+ that is the trigger for exocytosis. The localisation of Ca2+ also
appears to be a critical factor in exocytosis (Cheek et at., 1989a; Cheek etal.,
1989b; and O' Sullivan etal., 1989).
The small increase in [Ca2+]j caused by metabolic inhibition in the absence of
extracellular Ca2+ may not be sufficient to trigger secretion. However, only a
small rise in [Ca2+]j around the periphery of the cell just beneath the plasma
membrane is sufficient to evoke exocytosis in response to nicotine stimulation (O'
121
Sullivan et al., 1989); the large rise in [Ca2+]j across the whole of the cell
occurs after catecholamine secretion has been initiated. It is conceivable that the
small rise in [Ca2+]j may be localised in the region of the cell close to the
granules and so elicit secretion. It is also plausible that metabolic inhibition may
alter the calcium sensitivity of the secretory mechanism so that exocytosis can be
triggered even at near resting [Ca2+]j and that this rise in [Ca2+]j can be achieved
independently of extracellular Ca2+. Phorbol esters, for example, increase the
affinity of exocytosis for Ca2+ in platelets so that secretion of serotonin takes
place at or near the resting [Ca2+]j of the cell. Phorbol esters are able to
substitute for DAG and activate protein kinase C (Knight, 1987).
Such a mechanism could also explain the potentiation of the response to metabolic
inhibitors induced by nicotine. Following nicotine stimulation protein kinase C is
translocated to the plasma membrane (Terbush and Holz,1986). Nicotine
stimulation produces a reduction in filamentous actin and is able to generate
inositol phosphates and DAG in the presence or absence of external Ca2+
(Burgoyne et al., 1989). Depolarisation with high K+ also results in a reduction
in filamentous actin but only about half that evoked by nicotine. In addition, high
K+ activates phospholipase C to generate inositol phosphates and DAG but both this
response and the reduction of filamentous actin are abolished in the absence of
external Ca2+ (Burgoyne etai, 1989). This is consistent with previous reports
where nicotine but not high K+ caused disassembly of cytoskeletal actin (Cheek and
Burgoyne, 1986). Pretreatment of cells with nicotine would activate
phospholipase C and the ensuing secretory events could leave the cells in a
'primed' state so that the subsequent rise in [Ca2+]j evoked by metabolic
inhibition may be sufficient to trigger exocytosis. Nicotinic stimulation must
activate mechanisms additional to those controlling high K+ stimulated release
since only the former secretagogue potentiates the response to metabolic
inhibition. This may involve elements of the cytoskeletal network.
At present, however, such a mechanism is only hypothetical. The use of specific
inhibitors to identify the internal Ca2+ store responsible for the rise in [Ca2+]j





8.1 Chromaffin cells and anoxia
Isolated bovine adrenal chromaffin cells have been utilised to study catecholamine
release under conditions of anoxia and metabolic inhibition. In the perfused rat
heart such conditions evoke a large overflow of noradrenaline from the
sympathetic nerve terminals by a putative mechanism of carrier-mediated efflux
(Schomig et at., 1984). This overflow only becomes significant in regions of the
heart that are severely ischaemic. In bordering regions where ischaemia is less
severe there may be sufficient glycolytic activity to maintain sympathetic nerve
function and to keep extracellular noradrenaline levels low by active re-uptake,
despite increased sympathetic activity. This heterogeneity of response is in itself
a major factor in triggering the onset of arrhythmias.
Ca2+-independence and inhibition with uptake., blockers were the criteria used to
identify the mechanism of carrier-mediated efflux in isolated perfused rat hearts
(Schomig etal., 1984). Conditions designed to mimic ischaemia in isolated
chromaffin cells (both anoxia and metabolic inhibition) were found to evoke a
release of catecholamines that was independent of external Ca2+. This release,
however, was not inhibited by uptake1 blockers. Furthermore, catecholamines
were co-released with the soluble granule protein chromogranin A and with ATP;
there was no release of the cytosolic protein LDH, indicating that release occurred
by exocytosis. Closer investigation of this catecholamine release revealed that it
was accompanied by a significant uptake of extracellular Na+ and a rise in [Ca2+]j.
The rise in [Ca2+]j was mainly due to in flux of external Ca2+. There was also a small rise in
internal Ca2+ seen in the absence of external Ca2+ and this was attributed to mobilisation of
internal Ca2+ stores. The catecholamine release appeared to be
dependent on extracellular Na+, but the role of this ion in the mechanism of
release remains unclear.
8.2 Chromaffin cells as a model for sympathetic neurons
Chromaffin cells were originally used as a model for sympathetic neurons as they
exhibit many similar biochemical and morphological features and share the same
embryonic origin, deriving from the neural crest (Winkler, 1988). Observations
in this study and by others, however, have illustrated distinct differences between
the two cell types which indicate that they are not directly comparable.
Foetal chromaffin cells in culture will differentiate into sympathetic neurons
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rather than chromaffin cells unless supplied with exogenous glucocorticoids
(Anderson, 1989). Adult chromaffin cells, however, will not revert to
sympathetic neurons unless they are supplemented with nerve growth factor,
which results in neurite outgrowth (Anderson, 1989). Comparative studies on
PC12 cells and chromaffin cells have suggested that PC12 cells may be closer
biochemically and functionally to sympathetic neurons than chromaffin cells. For
instance, sympathetic neurons and PC12 cells both possess MAO type A compared
with chromaffin cells that possess primarily MAO type B (Youdim et at., 1984).
In addition, PC12 cells, like neurons, possess a tyramine releasable pool of
catecholamines unlike chromaffin cells which show no response to prolonged
exposure to tyramine (Youdim etal., 1986; and Chapter 5).
The difference in the response of chromaffin cells to conditions of metabolic
inhibition compared with cardiac sympathetic neurons led to an examination of
carrier-reversible catecholamine release. This mechanism was first identified in
sympathetic neurons from the rat vas deferens (Paton, 1976) and has
subsequently been demonstrated in PC12 cells (Bonisch etal., 1984). It became
apparent, however, that even under artificial conditions designed to elicit and to
demonstrate carrier-reversal, there was no increased efflux of catecholamines
from chromaffin cells (Chapter 5; and Powis etal., 1989). It is therefore
debatable whether the uptake carrier of mature chromaffin cells does in fact
operate in reverse; in contrast to that in neurons it may be 'gated' in some way.
8,3 Catecholamine release in neonates
While the above observations discounted carrier-mediated efflux as a mechanism
of release from chromaffin cells in anoxia, there are indications that the
exocytotic release evoked by metabolic inhibition may be of physiological
importance in neonates.
In human neonates there is a very large surge in circulating catecholamines
during parturition in response to hypoxia (Lagercrantz and Slotkin, 1986).
Studies on animal models have demonstrated that this release is critical in
protecting the neonate against hypoxia and asphyxia; and also in assisting it in
adapting cardiovascular and respiratory function for survival outside the womb.
In many mammalian species, including man, sympathetic innervation is absent or
non-functional at birth. Consequently the surge in catecholamines must be the
result of a direct effect of hypoxia in the adrenal medulla (Slotkin and Seidler,
1988). Neonatal rat adrenal glands in vitro show a full response to direct
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stimulation with nicotine or high K+ even at 2 days old, indicating that the
nicotinic receptors are functional and that the full exocytotic mechanism is
operative even though the chromaffin cells in situ are non-innervated (Slotkin
and Seidler, 1988).
These observations (for discussion see Slotkin and Seidler, 1988) have raised the
question of whether hypoxia causes a loss of catecholamine storage capacity and
subsequent leakage of catecholamines into the cytoplasm and hence out of the cells,
or whether it can directly trigger exocytosis. This was investigated in the neonatal
rat by Seidler and Slotkin (1986). By examining the effects of hypoxia and
nicotine on catecholamine levels and on uptake capabilities they concluded that
hypoxic catecholamine release was proceeded by a mechanism of exocytosis. Hypoxia-
and nicotine-induced depletion of catecholamines were both accompanied by an
equivalent reduction in uptake indicating loss of granule integrity, which is
characteristic of exocytosis. It was postulated that the stimulus for this release
may either be an influx of Ca2+ through voltage-dependent channels or a release of
internal Ca2+ from intracellular stores such as the mitochondria; both responses
being mediated by hypoxia. In addition, similar observations have been described
in chromaffin cells isolated from foetal sheep (Cheung, 1989). Hypoxia elicited a
direct response of isolated cells which did not decrease with maturation; this is in
contrast to the response seen when release elicited by hypoxia declines with age in
parallel with the development of innervation(Slotkin and Seidler, 1988). Upon
denervation, however, the ability of the adrenal gland to respond to hypoxia is
restored.
Consequently, using-isolated chromaffin cells from either an adult or neonate may
give responses analogous to those of neonatal cells in vivo. The catecholamine
release discussed in the present study may thus be comparable to this
non-neurogenic response.
8.4 The role of calcium
The key difference between this anoxia-induced catecholamine release and the
normal exocytotic response to external stimuli is the former's independence of
external Ca2+. This does not, however, imply a total Ca2+-independence. Using the
fluorescent Ca2+-indicator Fura-2 a rise in [ Ca2+]j was identified in the absence
of external Ca2+. This must be induced by the anoxic conditions and is presumably
sufficient in size and cellular location to trigger catecholamine release (Chapter
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7). The source of this Ca2+ is unknown. It could, for example, be mitochondrial,
since anoxic incubation of isolated rat liver mitochondria leads to ATP depletion
and release of Ca2+(Nishida etai, 1989) over a few minutes. This Ca2+ efflux is
associated with uncoupling of the mitochondria through activation of phospholipase
A2 and disruption of the proton impermeability of the inner mitochondrial
membrane.
The question of Ca2+-independent exocytosis has recently been considered in depth
by Knight etal. (1989). They concluded that the mechanism of exocytosis is
Ca2+-dependent. DAG production increases the Ca2+ sensitivity of the secretory
process so in some cases exocytosis can be triggered at or below the basal [Ca2+]j.
In other cases the extent of catecholamine release is increased rather than the
Ca2+ affinity. In chromaffin cells a small rise in [Ca2+]| just beneath the plasma
membrane appears to be sufficient to trigger secretion (O'Sullivan etal., 1989).
In addition, Ca2+-dependent secretion is affected by various modulators which act
either by increasing the Ca2+ affinity of the secretory process or by increasing
the extent of release. For instance, the phorbol ester TPA causes an increase in
Ca2+ affinity so that the Ca2+ threshold for secretion in electropermeabilised
chromaffin cells is lowered (Knight etal., 1989).
The most attractive mechanism of release would thus seem to be one where
conditions of metabolic inhibition increase the Ca2+ sensitivity of the secretory
process so that release is triggered by a small rise in [Ca2+]j. This could be
investigated by examining the effect of metabolic inhibitors on the Ca2+ activation
curve in permeabilised chromaffin cells in experiments similar to those
performed by Knight (1987) with TPA.
In addition, chromaffin granules are translocated to the plasma membrane
independently of external Ca2+ (Burgoyne etal., 1982) and the metabolic changes
caused by anoxia or metabolic inhibition may be sufficient to trigger secretion
from those granules that are close to the plasma membrane. It would thus be
interesting to investigate whether anoxia can lead to slow rearrangements of the
peripheral cytoskeleton, such as can be induced by Ca2+ alone in permeabilised
cells (Burgoyne etal., 1989).
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